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 Phyllodes tumours are uncommon fibroepithelial neoplasms of the 
breast accounting for less than 1% of primary breast tumours, comprising 6.9% 
of breast cancers reported in Singapore. They are classified into benign, 
borderline and malignant tumours by WHO, based on five histological 
parameters – stromal cellularity, stromal atypia, stromal mitoses, presence of 
stromal overgrowth and nature of the tumour border. This diagnostic 
framework remains challenging due to interpretive subjectivity and variable 
combinational permutations of histological criteria, leading to difficulties in 
accurate prediction of biological behaviour.  
 The first section of this work sought to address the combinational 
permutations of the parameters and to improve prediction of clinical 
outcome for phyllodes tumour patients. A total of 605 cases diagnosed in the 
Department of Pathology, Singapore General Hospital from January 1992 to 
December 2010 were examined retrospectively. Multivariate analysis showed 
that stromal atypia, stromal mitosis, stromal overgrowth and surgical margins 
were significant independent predictors for recurrence-free survival. A 
predictive nomogram which was constructed based on these criteria can be 
potentially used for patient counseling and clinical management of women 
diagnosed with phyllodes tumours. 
 Subsequently, 20 cases stratified into prognostically distinct 
categories were subjected to Affymeterix OncoScan™ FFPE microarray 





found that cases which recurred/metastasized had higher chromosomal 
aberrations, with median events of 19 compared to 3.5 in non-recurrent 
cases. Also, high-level amplifications and homozygous deletions were 
detected exclusively in the former group. Regions of high-level amplifications 
included chromosome 1q32.1, 5p13.3, 3p25, and 7p12. Amplification of EGFR 
at chromosome 7p12 was confirmed on FISH and accompanied by intense 
EGFR immunostaining. Regions of homozygous deletion included CDKN2A 
(9p21) and MACROD2 (20p12.1). Loss of protein expression was observed in 
cases with homozygous deletion at chromosome 9p21 involving CDKN2A. No 
mutations were identified in these cases.  
 The KIT gene (also known as CD117) was selected for further 
investigation. Activating mutations of the KIT gene was not observed and 
mutational status was not correlated with protein expression. However, 
CD117 immunoexpression was observed in 10% of 272 cases on tissue 
microarrays, with significant associations with borderline/malignant tumours 
and unfavourable pathological parameters including larger tumour size, 
increased number of mitoses, and permeative tumour margins. Also, patients 
with CD117-positive tumours had a poorer prognosis compared to patients 
with CD117-negative tumours.  
 Prognostic importance of Six1 and Pax3 was evaluated based on 
protein expression by immunohistochemistry on tissue microarrays to 
validate previous findings of increased expression observed at the transcript 





cytoplasmic expression was observed to be associated with higher tumour 
grade and adverse histological parameters. Patients having tumours with 
high Six1 expression experienced a shorter time to recurrence while patients 
having tumours with high Pax3 expression had a worse overall survival.  
 Overall, these findings provide an improved understanding in the 
biology of phyllodes tumours and warrant further investigations to elucidate 
mechanisms and pathways that are exploited by phyllodes tumours for 
malignant progression and aggressive behaviour.     
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1.1 Breast phyllodes tumours 
Breast phyllodes tumours represent an unusual form of breast 
neoplasm. Sketchy reports of phyllodes tumours were documented in the 
literature as early as 1774 [Fiks, 1981  but the tumour was formally 
characteri ed only in      by  ohannes M ller (see Figure 1. for  meline . 
 ohannes M ller, a prominent German anatomist and physiologist, described 
the tumour as ‘Cystosarcoma phyllodes’ in his book “Über den feinern Bau 
und die Formen der krankhaften Geschwülste” (On the Structural Details of 
Pathological Tumours). The gross description is worthy of quote in detail [Lee 
and Pack, 1931]: 
“The tumour forms a large firm mass, with a more or less uneven 
surface. The fibrous substance which constitutes the greater part of it 
is of a greyish white colour, extremely hard, and as firm as fibro-
cartilage. Large portions of the tumour are made up entirely of this 
mass, but in some parts are cavities or clefts not lined with a distinct 
membrane. These cavities contain but little fluid; for either their 
parietes, which are hard like fibro-cartilage, and finely polished, lie in 
close apposition with each other, or a number of firm, irregular 
laminae sprout from the mass, and form the walls of the fissures; or 
excrescences of a foliated or wart-like form sprout from the bottom of 
the cavities and fill up their interior. These excrescences are perfectly 





lie very irregularly, and project into the cavities and fissures like the 
folds of the psalterium in the interior of the third stomach of ruminant 
animals. In one instance the author saw these laminae here and there 
regularly notched or crenated like a cock’s comb. Sometimes the 
laminae are but small, and the warty excrescences from the cysts very 
large, while in other instances both are greatly developed. 
Occasionally these warty excrescences are broad, sessile, and much 
indented; others have a more slender base, and somewhat resemble 
cauliflower condylomata.” 
Since the first detailed gross description by Müller, numerous terms were 
used to describe the same tumour such as intracanalicular fibroma and 
pseudosarcoma. However, the termed ‘cystosarcoma’ was gradually avoided 
as most of these tumours do not possess sarcomatous stroma. It was only in 
1960 that a simpler term was coined by Lomonaco - ‘tumour phyllodes’. 
‘Phyllodes tumour’ has been the preferred term since  9 2, as recommended 
in the second edition of the WHO Histological Classification of Breast 
Tumours and is now classified under the umbrella of fibroepithelial tumours 







Figure 1.1 Timeline of the discovery and development of phyllodes tumours 
 
1.1.1 Epidemiology 
Phyllodes tumour is an uncommon neoplasm, constituting less than 1% 
of primary breast tumours in the United States and the incidence was 
reported to be different among various ethnic groups, with higher rates 
occurring in Asians/Pacific Islanders and Hispanics [Spitaleri et al., 2013]. 
However, the clinical outcome was not significantly different in Hispanic 
patients despite having larger tumours and higher mitotic rates as compared 
to Caucasian and Black patients [Pimiento et al., 2011]. In Singapore, the 
incidence of phyllodes tumour is reported to be 6.9% when compared to the 
frequency of breast cancers, possibly reflecting a true higher occurrence 
among Asian women [Tan et al., 2005a]. However, no significant incidence 
difference was observed between local ethnicities encompassing Chinese, 






1.1.2 Clinical presentation 
Phyllodes tumours present clinically as firm, painless palpable masses. 
In the 1930s Lee and Pack described phyllodes tumour as a rapidly growing 
mass which had a long initial period of quiescent growth. Rapid growth 
corresponded to a sudden in size without adhering to the skin [Lee and Pack, 
1931]. Treves later emphasized that not all phyllodes tumours manifested 
enormous sizes or rapidity of growth. Nonetheless, the skin over large 
tumours may have a bluish discoloration [Pietruszka and Barnes, 1978], with 
some very rare occurrence of nipple retraction, cutaneous ulceration, fixation 
of skin, and nipple discharge [Norris and Taylor, 1967].  
The average size of phyllodes tumours diagnosed is becoming smaller 
with the advent of imaging techniques such as mammography and 
ultrasound. Mammographically, phyllodes tumours typically appear as 
lobulated and benign opacities, with rare occasions of calcification [Stebbing 
and Nash, 1995]. Ultrasound findings usually include smooth contours, 
heterogenous pattern of internal echoes, absence of posterior shadowing 









1.1.3 Clinical management 
1.1.3.1 Surgery 
Surgery is the commonest form of treatment for patients with phyllodes 
tumours and has remained the standard treatment to date. While most have 
moved away from mastectomy to breast conserving surgery, there is no clear 
consensus concerning the type of surgery to be performed. Some authors 
reported a better disease-free survival with mastectomy [Belkacémi et al., 
2008; Pezner et al., 2008; Chen et al., 2005] while some found no impact of 
surgery type on recurrence rate [Asoglu et al., 2004; Macdonald et al., 2006]. 
Nonetheless, establishing a clear surgical margin is important as many 
reports have shown an association of positive margins with recurrence. 
[Asoglu et al., 2004; Tan et al., 2005a; Chen et al., 2005; Kapiris et al., 2001; 
Pandey et al., 2001] 
The current NCCN (National Comprehensive Cancer Network) 
guidelines recommend wide local excision with at least 1cm margin 
regardless of grade [Carlson et al., 2010]. Sampling of lymph nodes is 
generally not advised as phyllodes tumours infrequently spread to lymph 
nodes [Gullett et al., 2009; Guillot et al., 2011]. However, given the suspicious 
histology and large size at clinical presentation especially in higher grade 
tumours, phyllodes tumours are often subjected to aggressive treatment 
including excessive sampling of lymph nodes which usually is a procedure 






1.1.3.2 Adjuvant therapy  
Given the low incidence rate of phyllodes tumours, the effectiveness 
of adjuvant therapy especially for higher grade tumours is unknown. Scant 
literature of small studies has reported mixed results regarding the benefits 
of adjuvant therapy. 
a) Radiotherapy  
Cohn-Cedermark et al reported no improvement in survival and a few 
other authors were reserved in recommending of adjuvant radiotherapy 
[Chen et al., 2005; Chaney et al., 2000]. On the contrary, a few reports 
suggested potential benefits of adjuvant radiotherapy. Pandey et al. found 
slight improvement in disease free survival for patients although this was not 
significant statistically. Belkacémi et al. reported an improved local control 
rate but no impact on survival for borderline and malignant tumours. More 
recently, a relatively larger prospective study with a median follow up of 56 
months concluded that adjuvant radiotherapy is a very effective treatment as 
none of the 46 patients developed local recurrence during the study period. 
A drawback of the study was that no control group was included [Barth et al., 
2009].  
b) Chemotherapy 
 Adjuvant chemotherapy is not well defined in the literature. A 
systematic trial comparing patients with and without chemotherapy revealed 
no significant differences in recurrence-free survival. The regimen was 





[Morales-Vásquez et al., 2007]. Other case reports showed efficacy in some 
women employing cisplatin, etoposide and ifosfamide-based chemotherapy 
[Hawkins et al., 1992; Burton et al., 1989; Turalba et al., 1986]. 
c) Endocrine therapy 
Despite no proven role of endocrine therapy for phyllodes tumours in 
the literature, expression of estrogen and progesterone receptors has been 
previously evaluated in large series of phyllodes tumours in a retrospective 
manner. These hormonal receptors are generally positive in the epithelial 
component but rarely expressed in the stromal component [Tse et al., 2002; 
Sapino et al., 2006]. The limited potential in employing endocrine therapy for 
phyllodes tumours is largely due to the negative expression found in stromal 
cells, the principal neoplastic cell population of phyllodes tumours. 
Nonetheless, there has been documentation of positive ERβ (one of the two 
types of estrogen receptor apart from ERα  being expressed in phyllodes 
tumour stroma [Tse et al., 2002; Sapino et al., 2006]. However, the 
therapeutic potential of ERβ is still at a preliminary stage of research [Gallo et 
al., 2012]. 
1.1.4 Histopathology of breast phyllodes tumours  
Histologically, it is characterized by a double-layered epithelial 
component arranged in cleft-like structures surrounded by a hypercellular 
spindle-cell stromal component (Figure 1.2). The combination of both 
components mimics a leafy architecture, which gives rise to its name 






Figure 1.2 Histology of a phyllodes tumour. (a) Low magnification of a benign 
phyllodes tumour illustrating the cleft-like formation of the epithelial lining. 
Scale bar represents 2mm. (b) High magnification of the tumour showing 
hypercellular spindle-cell stroma. Scale bar represents 200μm. (c) An example 
of a borderline phyllodes tumour with a permeative border. Scale bar: 600μm. 
(d) An example of a malignant phyllodes tumour. Scale bar:  00μm. 
 
Phyllodes tumours were noted as a perfectly benign disease by 
Johannes Müller in 1838. However, this was challenged subsequently by 
other researchers who reported recurrences and metastasis upon follow-up 
of patients with phyllodes tumours [Lee and Pack, 1931; Cooper and 
Ackerman, 1943]. White in 1940 proposed the existence of a malignant 
variant of the tumour after noting a patient who died from the disease with 
recurrences and metastasis prior to death, 19 months after she was first 
diagnosed with the tumour [White, 1940]. The malignant variant of phyllodes 
tumours was well recognized since then. In 1951, when Treves and 





into either benign or malignant categories, and proposed a ‘borderline’ 
category in addition to benign and malignant categories [Treves and 
Sunderland, 1951].  
Over the years, several grading systems have been suggested based 
on histological assessment. The criteria used for assessment were vastly 
similar although there was variation and subjectivity in terms of 
interpretation. Most supported a three-tiered grading scheme (commonly 
termed as benign, borderline, malignant proposed by Treves and Sunderland) 
while some advocated a two-tiered grading method (low grade and high 
grade) [Karim et al., 2009]. The development of molecular techniques has 
also driven researchers to better classify phyllodes tumours in recent years. 
Wang et al. supported a two-tiered grading (low/intermediate and high 
grade), observing no differences between the benign and borderline tumours 
in LOH (loss of heterozygosity) studies [Wang et al., 2006]. Laé et al. 
concurred with a two tiered grading system using CGH (comparative genomic 
hybridization) studies but the authors grouped borderline and malignant 
tumours as one category [Laé et al., 2007]. Jones et al. who performed array-
CGH also agreed with a two-tiered grading based on cluster analysis of array-
CGH data [Jones et al., 2008a]. However, more recently Ang et al. supported 
the three tiered grading based on expression profiles of 21 phyllodes 
tumours [Ang et al., 2011]. Amidst all these molecular classifications is a lack 
of consensus and hence histological assessment remains as the gold standard 





In the 4th edition of the WHO classification of tumours of the breast, 
phyllodes tumours are classified into benign, borderline, and malignant 
groups. The three-tiered grading is preferred because it gives a greater 
certainty at the ends of the spectrums of these tumours [Tan et al., 2012]. 
Grading of the tumours is based on five histological parameters – stromal 
cellularity, stromal atypia, stromal mitosis, presence of stromal overgrowth 
and nature of the tumour border which are described in detail in the next 
page.  
The stromal component is primarily assessed as it is that which 
undergoes malignant progression and drives clinical behaviour. Nonetheless, 
emerging evidence in the literature has shown that the epithelial component 
may play a role in disease progression by interacting with the stroma (Figure 
1.3 . Its innocence as a ‘bystander’ has been challenged with reports of 
abnormality observed in the epithelial component such as harbouring an 
independent set of genetic alterations apart from the stroma [Sawyer et al., 
2000] and an increased frequency of hyperplasia and metaplasia compared 
to normal breast tissue [Karim et al., 2009b]. Besides, the subepithelial 
stromal region demonstrated different changes as compared to stroma 
further away from the epithelium. A higher mitotic activity was observed 
[Treves and Sunderland, 1951; Sawhney et al., 1992] and additional genetic 
changes were noted in peri-epithelial stromal cells [Jones et al., 2008a], 






Figure 1.3 Role of epithelium in phyllodes tumours  
 
The five histological parameters used to grade phyllodes tumours are: 
1) Stromal cellularity (three tiered) - mild, moderate and marked cellularity
 
Figure 1.4 Example of (a) mild cellularity (b) moderate cellularity and (c) 
marked cellularity of the stromal component of phyllodes tumours. All three 







2) Stromal atypia (three tiered) - none/mild, moderate, marked 
 
Figure 1.5 Example of (a) mild stromal atypia (b) moderate stromal atypia 
and (c  marked atypia of phyllodes tumours. Scale bars:  00μm 
 
3) Stromal mitosis – assessing number of mitoses in ten high power fields (x40 
objective and x10 eyepiece, 0.196mm2) 
 
Figure 1.6 Example of mitotic activity (indicated by red arrows). There are 
more than 10 mitoses per one high power field (HPF) in this tumour sample. 










4) Presence of stromal overgrowth – stromal proliferation to the degree 
where the epithelial component is absent in at least one low power field 
(x4 objective and x10 eyepiece, 22.9mm2) 
 
Figure 1.7 Presence of epithelial element in a low power field defines no 
stromal overgrowth (a) while absence of epithelial component defines 
stromal overgrowth (b). Scale bars:  00μm 
 
5) Nature of the microscopic border, whether it is well circumscribed or 
permeative 
 
Figure 1.8 (a) An example of a benign phyllodes tumour illustrates a well-
circumscribed tumour border. Scale bar: 2mm. (b) An example of a 
permeative border where stromal cells creep into the adjacent fat tissue. 








A phyllodes tumour is diagnosed as benign when the following criteria 
were met: mild stromal cellularity, mild or no stromal atypia, occasional 
mitoses of not more than four per 10 high power field (HPF), absence of 
stromal overgrowth, and well-circumscribed margins. Conversely, a 
malignant phyllodes tumour is diagnosed with the combination of marked 
stromal cellularity and atypia, high mitotic activity of usually 10 or more per 
10 HPF, presence of stromal overgrowth and permeative margins. Malignant 
phyllodes tumour is also diagnosed with the finding of a malignant 
heterologous element even without the presence of other histological 
features. A borderline phyllodes tumour shows some, but not all, of the 
characteristics observed in malignant lesions. See Table 1.1 for summarized 
features. 
 
Table 1.1 Histological features of benign, borderline and malignant phyllodes tumours 
Histological Feature Benign Borderline Malignant* 









Stromal Atypia Mild or none Mild or moderate Marked 
Mitotic Activity Usually few 
(<5per 10HPF) 
Usually frequent 
(5-9 per 10HPF) 
Usually abundant 
(≥ 0 per  0HPF  







may be focally 
permeative 
Permeative 
*Presence of malignant heterologous element qualifies designation as a malignant phyllodes 





While the parameters for grading of phyllodes tumours appear well 
defined and clear, there is suboptimal standardization of assessing these 
parameters resulting in inherent observer variability. Also, there are variable 
ways of combining the parameters to derive the grade of phyllodes tumours. 
It is not determined which parameter has higher importance over another, 
and not all criteria could be fulfilled in assigning a grade for phyllodes 
tumours. 
1.1.5 Molecular studies on breast phyllodes tumours 
 Molecular studies have been carried out to elucidate the underlying 
biological mechanisms of progression and behaviour of this unpredictable 
tumour, including copy number assessment, expression profiling, and 
screening for mutations. Copy number assessment is currently the most 
studied in phyllodes tumours while expression profiling and mutational 
analyses are relatively fewer as indicated in the literature review shown in 
Table 1.2.   
A few key areas investigated previously were:  
1.  classification of phyllodes tumours based on molecular differences 
between tumour grades; 
2. identifying distinct changes between epithelium and stroma of 
phyllodes tumours which are biphasic in nature; and 
3. discriminating phyllodes tumours from fibroadenomas which may be 







Table 1.2 Literature review on the molecular studies performed on phyllodes tumours 




Type of Study Key findings 
Noguchi et al.  
(Cancer Res, 
1993) 








using PGK gene 
polymorphism 
1) PT vs FA:  PT consisted of both monoclonal and polyclonal components. FAs were 
polyclonal in origin. 
2) Stroma vs epithelium: Stromal cells were monoclonal. Epithelial cells were 
polyclonal. 
Noguchi et al. 
(Cancer, 1995) 




FFPE Clonal analysis 
using AR gene 
polymorphism 
1) FA vs recurrent PT developed on the same site: All were monoclonal in origin. The 
same allele of AR was inactivated in FA and PT. 
2) Suggested that monoclonal FAs which could progress to PT should be 
differentiated from polyclonal FAs for management.  
Kuijper et al. 









using AR gene 
polymorphism 
1) PT: Mostly, stroma was monoclonal and epithelium polyclonal. However, two 
cases were found to have monoclonal epithelium while three other cases of 
polyclonal stroma. 
2) FA: Normal-appearing and hyperplastic epithelium of FA were polyclonal but 
carcinoma in situ from FA was monoclonal. Stroma of FA was polyclonal too. 
Dietrich et al. 
(Human Pathol, 
1997) 
6 Short term 
cultures from 
excised tumours 
Karyotyping Benign vs malignant PT: Benign PTs had simple chromosomal changes. Malignant PT 
had complex karyotype.  
















Table 1.2 Literature review on the molecular studies performed on phyllodes tumours (continued) 




Type of Study Key findings 








Karyotyping PT vs FA:   
i. PT was hyperdiploid. FA showed diploid or near-diploid modal chromosome 
number. 
ii. FA presented with mostly abnormalities on chr 16, 18 and 21. PT had numerous 
additional abnormalities.  
Lu et al. (Genes, 
Chr & Cancer, 
1997) 
19 Fresh frozen CGH 1) Gain of 1q associated with stromal overgrowth. 
2) Gain of 1q or loss of X chromosome associated with recurrence. 
3) No evidence for gene amplification. 
Sawyer et al. 
(Am J Pathol, 
2000) 










on chr 1q and 
3p 
1) 24% and 30% of PTs showed AI on chr 3p and chr 1 respectively.  
2) Stroma vs epithelium:   
i. AI observed in both epithelium and stroma, sometimes as an independent 
genetic event. 
ii. 6% of PT showed microsatellite instability (MSI) in epithelium but not stroma 
3) No association was observed between epithelial hyperplasia/atypia with epithelial 
AI.  
4) Mapping chr 3p to FHIT (tumour suppressor) gene but no further experiment was 
done. 
Jee et al. (Anal 
Cell Path,2003) 
 
22 FFPE CGH; LOH on 
chr 3p only 
1) Most common abnormality was 1q gain. 
2) No allelic imbalance found for LOH analysis. 







Table 1.2 Literature review on the molecular studies performed on phyllodes tumours (continued) 




Type of Study Key findings 
Wang et al. 
(Breast Cancer 
Res Treat, 2006) 




2 samples with 
epithelial 
microdissection 
- one benign 
epithelial and 
the other a 
carcinoma 
LOH analysis 1) Supported two-tiered (low/intermediate and malignant) grading system : 
i. Allelic loss was significantly higher in high-grade PT vs low- and intermediate-
grade PT (19.2% vs 4.7% and 4.7% respectively). 
ii. Loss of 7p12 was more frequently observed in high-grade PT while LOH at 
3p24 was more frequently observed in low-/intermediate-grade PTs.  
2) Primary vs matched recurrent: shared similar LOH with additional regions of LOH 
observed in recurrent cases.   
3) Epithelial vs stromal: Epithelial component had lower allelic loss. Shared LOH 
regions include 4p15, 13p12, 13q32 and 17p. Stromal had additional LOH on chr 9 
while epithelial had LOH on 17q, 18 and 22.  
4) PT vs FA: FA had either lacked LOH or very low allelic loss rate (average 0.4%) vs PT 
(average 9.4%). 
5) Mapping 7p12 (more observed in high-grade) to HUS1, a checkpoint homolog 
involved in DNA repair. No further experiment was carried out. 
 
Laé et al. (Mod 
Pathology 2007) 
30 Fresh frozen CGH and FISH 1) Genetically segregate PT into two groups (benign, and borderline/malignant) 
2) 1q gain and 13q loss were significantly associated with the borderline/malignant 
group. 








Table 1.2 Literature review on the molecular studies performed on phyllodes tumours (continued) 




Type of Study Key findings 
Lv et al. (Breast 
Cancer Res 
Treat, 2008) 
36 FFPE stromal 
microdissection 
CGH 1) Genetically segregate PT into two groups (benign, and borderline/malignant) 
2) Benign PTs have increased number of chromosomal gains especially 4q12  
3) Mapping 4q12 to KIT, VEGFR and AFP (alpha-fetoprotein) but no further 
experiment was carried out. 
Jones et al.  
(J Pathol, 2008) 
















1) Supported two-tiered grading system (benign/borderline and malignant) based on 
cluster analysis of array-CGH data: malignant group was characterized by regions 
of gains on chr 7. 
2) Commonest change was +1q. In addition, +5p, +7, +8, -6, -9p (9p21 involving 
p16INK4a), -10p, -13 were associated with borderline/malignant PTs.  
3) Mapping homozygous deletions of 9p21.3 to p16INK4a :  
i. methylation observed in 2 malignant cases 
ii. Mutation (exons 1-3): A single missense P48L found in a malignant PT  
iii. IHC: loss of p16 protein expression associated with 9p deletion 
4) mRNA expression profiling: Six gene sets (at 1q25, 2q36, 18q22, 5q23, 5q31 and 
7p11) were associated with borderline/malignant group. 1q25 had most significant 
association with over-expression of genes of that region.  
5) With vs without sub-epithelial stroma condensation: additional genetic changes 
were found, including deletion in 17p and 8p12. 
6) PT vs FA: FA showed no chromosomal-scale changes. 
7) Mapping 17p to p53: mutation not found, but protein expression was found in 
stroma of only 3/24 borderline/malignant tumours  








Table 1.2 Literature review on the molecular studies performed on phyllodes tumours (continued) 




Type of Study Key findings 
Kuijper et al. 
(Cell Oncol, 
2009) 
11 PTs;  
3 FAs 
Fresh frozen CGH 1) PT vs FA: 91% of PTs showed chromosomal changes with mean number of 5.5 per 
case. No copy number change is detected in FA. 
2) Copy number changes not correlated with tumour grade - copy number changes 
found in all PTs. 
3) Loss of 16q most frequently found. Mapping loss of 16q to members of cadherin 
family (E-cadherin, M cadherin) 
4) Amplifications (log2 ratio ≥    were seen infrequently - only on chromosome 5q 
and 22q. Mapping amplification regions (5q and 22q) to MAP3K1, MAPK1, PIK3R1, 
and PIK4CA. 
Ang et al. 
(Breast Cancer 
Res Treat, 2010) 






1) Supported three-tiered pathology grading with a 29 gene list: mean chromosomal 
changes was 2.7, 4.2, and 9 for benign, borderline and malignant respectively.    
2) 1q gain most commonly associated with borderline and malignant tumours.   
3) HOXB13 was upregulated in malignant PTs compared with borderline and benign 
groups (~2.8-fold change) 




1 mal PT FFPE Oligo-array CGH Found gain of 1q, loss of 1p36 and 17q11.2. Mapping the region of 1p36 to SDHB 











Table 1.2 Literature review on the molecular studies performed on phyllodes tumours (continued) 




Type of Study Key findings 
Kim et al. 
(Virchows 
Archiv, 2009) 
87 FFPE Methylation  
analysis of 5 
genes and IHC 
on GSTP1 
1) Supported two-tiered (benign, borderline/malignant) grading system: mean 
number of methylated genes were 1.63 for benign, 3.13 and 3.70 respectively for 
borderline and malignant PT   
2) Increasing methylation frequency observed with increasing grade of PTs. 
 (5 genes - RASSF1A, Twist, RARβ, GSTP1 and HIN-1) 
Huang et al. 
(Breast Cancer 
Res Treat, 2010) 
86 PTs;  
26 FAs 
FFPE Methylation 
profiling on  11 
genes  
1) PT vs FA: Elevated RASSF1A and TWIST1 were significantly associated with PT vs 
FA.  
2) TWIST1 significantly associated with increasing malignancy of PTs. 
3) Using RASSF1A (involved in cell cycle control and apoptotic signalling) and TWIST1 
(transcription factor involved in cell differentiation and survival) methylation to 
distinguish PT from FA. High positive predictive value of 0.83. 
 (11 genes - RASSF1A, TWIST1, RARβ, APC, WIF1, MGMT, MAL, CDKN2A, CDH1, TP73 
and MLH1) 
 
Sawyer et al.  
(J Pathol, 2002) 
119 FFPE Mutational 
analysis on APC 
and β-catenin; 




1) IHC: β-catenin nuclear staining was observed in stroma but not in epithelial. Its 
expression was also associated with stromal cyclin D1 staining. 
2) Mutational analysis:  
i. only one benign PT showed LOH (inference to mutation) on APC gene. 
ii. no β-catenin mutations (exon 3) were found. 
3) ISH: Epithelial Wnt5a mRNA expression was associated with strong nuclear 








Table 1.2 Literature review on the molecular studies performed on phyllodes tumours (continued) 




Type of Study Key findings 
Jones et al.  
(J Pathol, 2008) 
23 Fresh frozen, 


















1) A group of 162 genes were over-expressed in borderline/malignant group, with a 
fold change of >2 
2) Observation of over-expression of PAX3, SIX1, TGFB2 and HMGA2 in 
borderline/malignant group 
i. ISH: Overexpression of PAX3, SIX1 and TGFB2 observed in 
borderline/malignant PTs but not in benign PTs. 
ii. Amplification: No amplification of all four genes. 
iii. Mutations: No activating mutations found in PAX3, SIX1 and TGFB2. HMGA2 
was not screened. 
iv. M-FISH on cell culture: PAX3 translocation (of unclear significance) found in 
borderline/malignant vs benign. No translocation of HMGA2 was observed. 
v. IHC: Nuclear staining of HMGA2 was associated with borderline/malignant PTs. 
vi. Functional studies: Knockdown of SIX1 and HMGA2 had significant decreased 
proliferation and increased apoptosis observed in malignant but not borderline 
cell cultures.  Conversely, such trend was observed in borderline but not 
malignant cell cultures with knockdown of TGFB2. Decreased cell proliferation 
was observed in both borderline and malignant cell cultures with PAX3 
knockdown.  
Sawyer et al. 
(J Pathol, 2003) 
30 FFPE ISH, FISH, 
mutational 
analysis, IHC on 
c-myc and c-kit 
1) c-myc expression was observed in both stroma and epithelium on IHC. 
Amplification of myc gene on FISH was observed in one malignant tumour which 
had weak immunostaining. 
2) c-kit IHC staining was associated with malignant PTs. However, no activating 







Table 1.2 Literature review on the molecular studies performed on phyllodes tumours (continued) 




Type of Study Key findings 
Bose et al. 
(Anticancer Res, 
2010) 
17 FFPE Mutational 
analysis and IHC 
on c-kit 
1) c-kit IHC staining was not associated with tumour grade. 
2) No activating mutations were found for exons 9, 11, 13 and 17. 
3) A germline mutation was found at exon 17, codon 798 – IHC negative 
Chen et al. (J 
Surg Res, 2000) 
19 FFPE IHC and 
mutational 
analysis of e11 
on c-kit on 2 
mal cases 
1) Q556X (nonsense mutation) found in one sample and N564S (missense mutation) 
in another – strongly stained on IHC. 
2) CD117 IHC expression was associated with increasing grade of PT. 
Carvalho et al. (J 
Clin Pathol, 
2004) 
19 FFPE IHC and 
mutational 
analysis of c-kit 
and PDGFRA 
1) IHC:  
i. c-kit stromal positivity was associated with malignant PT. 
ii. No association was observed between PDGFRA stromal staining and tumour 
grade. 
2) Mutational analysis:  
i. c-kit: A silent mutation at codon 798 was observed in 2 benign cases 
ii. PDGFRA: Intronic insertion IVS17-50insT and G956X (nonsense mutation) 










Table 1.2 Literature review on the molecular studies performed on phyllodes tumours (continued) 




Type of Study Key findings 







EGFR using FISH, 
ISH and IHC 
1) Amplification of a CA repeat within intron 1 of EGFR was observed in 41.8% with 
average copy number of 5.2 and was associated positively with IHC expression. 
2) EGFR whole gene amplification (>4 copies per nucleus) was observed in 15.8% of 
all cases, two of which were high-level amplification (>10 copies per nucleus) and 
associated positively with IHC expression.  
3) PT vs FA: None of the FAs showed EGFR expression on IHC and only 2.3% of FAs 





10 PTs  Fresh frozen Expression 
profiling and IHC 
on PTs with 
known status of 
EGFR CA-SSR 
ampliﬁcation 
1) EGFR CA-SSR amplified vs non-amplified cases: Presence of EGFR CA-SSR 
amplification was associated with 230 differentially expressed genes. Many of 
these genes were involved in nucleic acid metabolism, signal transduction and 
receptor tyrosine kinase signalling pathway. 
2) EGFR CA-SSR amplification was associated with caveolin-1 and esp15 protein 
expression on IHC.  
  
Tse et al. 
(Breast Cancer 
Res Treat, 2009) 
453 FFPE FISH and IHC 
analysis of EGFR 
1) 24% of PTs expressed stromal EGFR on IHC. Staining was associated with tumour 
grade. 
2)  EGFR gene amplification (>4 copies per nucleus) was present in 8% of 12 strong 









Table 1.2 Literature review on the molecular studies performed on phyllodes tumours (continued) 














1) Identified a S8R substitution in FBX4 gene present in 11.5% of tumours. 
2) No other mutations were found in a panel of 321 mutations across 30 genes, 
including EGFR, KIT, KRAS and TP53. 
Do et al.  
(Tumor Biol, 
2012) 




TWIST1 promoter methylation was associated with tumour grade but not associated 
with protein expression on IHC.  
Kuenen-
Boumeester et 
al. (J Pathol, 
1999) 
19 Fresh frozen Mutational 
analysis and IHC 
on TP53 
P128S and R273C missense mutation was observed in one case each. Only R273C 
mutation was associated with overexpression of p53 protein on IHC.  
Woolley et al. 
(Mol Diagn, 
2000)  
1 mal PT Cell culture 
from tumour 
Mutational 
analysis on TP53 
No mutation was found in exons 5-8 of TP53.   
Gatalica et al.  
(Pathol Res 
Pract, 2001) 
1 mal PT FFPE Mutational 
analysis on TP53 
p53 protein expression was correlated with malignant PT.  R248W mutation in exon 
7 was found in one sample.  
Abbreviations: 
PT - phyllodes tumour; FA – fibroadenoma; FFPE - formalin-fixed, paraffin-embedded tissue; mal – malignant; chr – chromosome; CGH - comparative 






 Four main molecular study types could be identified from Table 1.2 - 
chromosomal investigations, methylation, expression profiling and 
mutational analysis.  Largely, there are no common observations of recurrent 
aberrations except for gain of chromosome 1q reported by a few groups [Jee 
et al., 2003; Lu et al., 1997; Jones et al., 2008; Laé et al., 2007; Lee et al., 2010; 
Ang et al., 2010]. Although it is widely agreed that higher grade tumours 
harbour increased molecular aberrations such as chromosomal changes and 
methylation events, none of the studies has correlated their findings with 







1.2 Prognostic factors 
   1.2.1 Prognosis of phyllodes tumours 
The majority of phyllodes tumours behave in a benign fashion, with 
reported overall local recurrence rates of about 19% ranging from 0% to 67% 
in a review of retrospective series from 1951 to 2012 [Spitaleri et al., 2013]. 
Deaths from phyllodes tumours are rare, often preceded by distant 
metastases [Tan et al., 2005a]. The common sites for metastasis include lung 
and bone. The rates of recurrences and deaths of large series previously 
published are shown in Table 1.3. 
Grade is a good indicator of biological behaviour of the tumour. 
Majority of those in the benign grade have a good prognosis while the course 
of malignant grade tumours is usually unfavourable. However, recurrences 
could occur regardless of grade, even in benign ones. While local recurrences 
are more commonly reported in the benign grades and distant metastases 
occurring almost exclusively in the malignant group, some benign tumours 
could recur with increased grade and advance with an aggressive behaviour. 
Such unpredictable behaviour of phyllodes tumours drives the search for 
prognostic factor(s) and/or marker(s) which could identify tumours with 
potential aggressive behaviour at an early stage so that they could be 
managed accordingly. 
1.2.2 Clinical and histological prognostic factors 
Age does not seem to be an important factor [Pietruszka and Barnes, 





than sporadic reports of age being a significant factor for survival [Macdonald 
et al., 2006; Pezner et al., 2008]. The role of tumour size is not clear with 
some reporting larger tumour size having unfavourable outcomes [Belkacémi 
et al., 2008; Chaney et al., 2000; Roa et al., 2006] while others found no 
impact of tumour size on outcome [Pietruszka and Barnes, 1978; Tan et al., 
2005a, Chen et al., 2005].  
 Although many histological prognostic factors have been investigated, 
findings between studies are not always consistent. Tan et al. reported that 
stromal atypia, cellularity and tumour borders were associated with local 
recurrence on univariate analysis [Tan et al., 2005a]. Multivariate analysis 
revealed surgical margin status and pseudoangiomatous stromal hyperplasia 
to be independent predictors for recurrence. Cohn-Cedermark et al. reported 
tumour necrosis and presence of heterologous stromal elements were 
independent prognostic factors on multivariate analysis [Cohn-Cedermark et 
al., 1991]. Chaney reported stromal overgrowth to be the only independent 
predictor of distance metastasis in a study of 101 patients [Chaney et al., 
2000]. Nonetheless, surgical margins appear to be a rather consistent 
determinant for local recurrences [Pandey et al., 2001; Asoglu et al., 2004; 
Kapiris et al., 2001; Belkacémi et al., 2008] and distant metastasis [Pandey et 





Table 1.3 Descriptive data of past large retrospective series conducted for phyllodes tumours 
Author Journal Year Period N Country Age Size 
Grade (%) Prognosis (%) 
Ben Bor Mal LR DR Death 
Treves Cancer 1951 1930–1949 77 USA 41a 10 54 23 23 67 11.6 10.4 
Norris Cancer 1967 Before1967 94 USA 45 6.4 Not graded 35 NR 17 
Hajdu Cancer 1976 1932–1976 199 USA NR 4 75 NG 25 16 1.5 2 
Chua Aust N Z J Surg 1988 1978–1984 106 Singapore 30 a 5 91 6 3 19 0.9 1 
Cohn-
Cedermark 
Cancer 1991 1958–1986 77 Sweden 50 5 55b NG 45c 19 21 21 
Zurrida Eur J Cancer 1992 1970–1989 216 Italy NR NR 65 14 21 12.5 NR NR 
Reinfuss Cancer 1996 1952–1988 170 Poland 52 a 7 54 11 35 8 16 16 
Zissis 
Breast Cancer Res 
Treat 
1998 1981–1995 84 Greece NR 6 65 17 18 2.3 1 1 
Chaney Cancer 2000 1944–1998 101 USA 41 6 58 12 30 4 8 16 
Niezabitowski 
Breast Cancer Res 
Treat 
2001 1952–1998 118 Poland 49 NR 44 20 36 8 9 11 
Chen J Surg Oncol 2005 1985–2003 172 Taiwan 37 a 5.8 76 7 17 11 1.7 2 
 





             Table 1.3 Descriptive data of past large retrospective series conducted for phyllodes tumours (continued) 
Author Journal Year Period N Country Age Size 
Grade (%) Prognosis (%) 
Ben Bor Mal LR DR Death 
Tan Am J Clin Pathol 2005 1992–2002 335 Singapore 42 5.4 75 16 9 12.8 2 2 
Abdalla 
J Egypt Natl Canc 
Inst 
2006 1988–2003 79 Egypt 42 11 39 34 27 20 14 13 
Ben hassouna Am J Surg 2006 1986–2001 106 Tunisia 40a 8.3 59 25 26 12.2 7.5 8 
Barrio Am Surg Oncol 2007 1954–2005 293 USA 42 6 69 NG 31 8.5 1.7 2 
Belkacémi 
Int J Radiat Oncol 
Biol Phys 
2008 1971-2003 443 France 40 4.6 64 18 18 19 3.4 NR 
Guillot Breast J 2011 1994–2008 165 France 44 3 69 22 9 10 1.2 1 
Pimiento J Am Coll Surg 2011 1999–2010 124 USA 45 4.5 49 35 16 6.5 1.6 NR 




2013 1999-2010 172 Italy 44 NR 40 24 36 10.5 1.2 2 
Kim 
Breast Cancer Res 
Treat 
2013 2000-2010 193 Korea 41a 4 75 17 8 9.3 4.1 2.1 
amean age, otherwise median; bbenign and borderline; cprobably or clearly malignant;  





1.2.3 Biological markers as prognostic factors 
The increasingly important role of immunohistochemistry as an adjunct tool 
in diagnostic surgical pathology has directed the attention of researchers 
from histological parameters to biological markers over the years. Extensive 
studies have been performed over the last decade in search of suitable 
biological markers to predict the behaviour of phyllodes tumours. An 
excellent review performed by Karim et al. which was published in Journal of 
Clinical Pathology in two separate articles detailed the summary of the 
findings for these studies [Karim et al., 2009b; Karim et al., 2013].  
However, studies focusing on the prognostic impact of biomarkers are 
limited by the events of recurrences and deaths in each series. Table 1.4 
shows the biological markers studied in relation to clinical outcome in terms 
of local recurrence, distant recurrence and/or deaths. Broadly, these markers 
can be categorized into cell cycle markers, angiogenesis markers, epithelial-
mesenchymal transition (EMT) markers and receptor tyrosine kinases (Figure 
1.9). Many recurring biological markers were investigated but consistent 
findings were scanty. For example, some authors reported p53 to be 
correlated with disease free recurrence [Niezabitowski et al., 2001; Kuijper et 
al., 2005a; Yonemori et al., 2006] but some observed no correlation [Kleer et 
al., 2001; Tan et al., 2005b; Esposito et al., 2006]. Ki67 and CD117 are other 
examples of well studied markers in phyllodes tumours but with mixed 





While immunohistochemistry is an excellent supplement to classic 
morphology [Ramos-Vara and Miller, 2014], many aspects of the technique 
are applied differently between laboratories. These include types and 
duration of fixation used, methods of antigen retrieval, staining protocol, and 
evaluation of staining results. Without standardization of these aspects, it is 
unlikely that the results are comparable between laboratories.  
 
 






Table 1.4 Studies on biological markers of prognostic importance 
First Author, 
Journal 
Year Number of cases Prognosis Test Marker Summary 
Kleer 
Mod Pathol 
2001 20  
  7 benign (35%) 
  13 malignant (65%) 





2001 118  
  52 benign (44%) 
  24 borderline (20%) 
  42 malignant (36%) 
17 recur (14.4%)  
 -6 LR, 7 DR, 4 LR+DR 







-SPF and p53 independent prognostic 
marker for DFS 
-Ki67 independently influenced OS. 
Shpitz B 
J Surg Oncol 
2002 23  
16 benign (70%) 
4 borderline (17%) 
3 malignant (13%) 
4/22 LR (17%) 
1/22 death (4.5%) 
IHC HER2, Ki67, p53 No correlation with recurrence 
Tse 
Mod Pathol 
2003 186  
106 benign (57%) 
51 borderline (27%) 
29 malignant (16%) 
24/180 recur (13%) 
 -21 LR, 3 DR 
 
IHC CD31, p53 No correlation with recurrence 
Tse 
Mod Pathol 
2004 179   
101 benign (56%) 
50 borderline (28%) 
28 malignant (16%) 
9 recur (5%) 
 -7 LR, 2 DR 
IHC CD117 No relationship with recurrence 
Kuijper  
Am J Clin Path 
2005a 40  
  21 benign (53%) 
8 borderline (20%) 
11 malignant (27%) 
10/37 recur (27%) IHC bcl-2, Cyclin A, 
Cyclin D1, Ki-67, 
Rb, p53, p16, and 
p21 
Inverse relation between DFS and 





Table 1.4 Studies on biological markers of prognostic importance (continued) 
First Author, 
Journal 




2005b 37  
  18 benign (49%) 
  8 borderline (21%) 
  11 malignant (30%) 
10/30 recur (33%) 
 -9 LR,1 DR 
IHC CAIX, CD31, HIF- α, 
Ki67, p53, VEGF 
HIF- α predictive of DFS 
Tan PH 
Mod Pathol 
2005 335  
250 benign (75%) 
54 borderline (16%) 
31 malignant (9%) 
43 recur (13%)  
7 deaths (2%) 
IHC CD117, p53 CD117 predicted recurrence 
Esposito  
Arch Pathol Lab 
Med 
2006 30  
16 benign (53%) 
8 borderline (27%) 
6 malignant (20%) 
4/25 recur (16%) 
1 death 
IHC CD117, Endothelin-
1, Ki67 p16, p21, 
p53 
No correlation with recurrence 
Yonemori  
Pathol Res Prac 
2006 41  
20 benign (49%) 
5 borderline (12%) 
16 malignant (39%) 
11 recur (27%) 
-2 LR, 7 DR, 2 LR+DR 
Deaths not 
mentioned  
IHC CD117, EGFR, 
HER2, Ki67 
Ki67 and p53 significantly correlated 
with DFS and OS.  
Karim 
J Clin Path 
2009 65 
34 benign (52%) 
23 borderline (35%) 
8 malignant (12%) 







DFS significantly decreased with 
positive epithelial E-cadherin staining 
Karim 
Histopathology 
2010 65  
34 benign (52%) 
23 borderline (35%) 
8 malignant (12%) 
9/62 recur (15%) IHC Cyclin D1, Ki67, 
p16, Rb  
High epithelial expression of Rb 





Table 1.4 Studies on biological markers of prognostic importance (continued) 
First Author, 
Journal 
Year Number of cases Prognosis Test Marker Summary 
Jung 
J Breast Cancer 
2010 67 
39 benign (58%) 
16 borderline (24%) 
12 malignant (18%) 
11 recur (16.4%) 




CD117, PDGFRA Stromal CD117, PDGFRA and Ki67 
expression is predictive of recurrence 
Al-Masri 
Ann Surg Oncol 
2012 43 
16 benign (37%) 
10 borderline (23%) 
17 malignant (40%) 
6 DR (14%) IHC CD10 CD10 significantly correlated with the 
occurrence of distant metastasis. 
Tsang 
Histopathology 
2012a 158  
92 benign (58%) 
43 borderline (27%) 
23 malignant (15%)  
22 recur (14%) IHC α-catenin, β-
catenin, E-cadherin 
α-catenin showed a 
significant correlation with recurrence 
Tsang 
Hum Pathol 
2012b 155  
  92 benign (59%) 
  42 borderline (27%) 
  21 malignant (14%) 




2012 207  
  157 benign (76%) 
  34 borderline (16%) 
  16 malignant (8%)  
26 recur (13%) 
 -18 LR, 8 DR 
8 deaths (4%) 





High Twist expression correlated with 







Table 1.4 Studies on biological markers of prognostic importance (continued) 
First Author, 
Journal 
Year Number of cases Prognosis Test Marker Summary 
Do 
Tumor Biol 
2012 179  
  103 benign (58%) 
  38 borderline (21%) 
  38 malignant (21%) 
29 recur (16%) 
-24 LR, 5 DR 





NF-κB, SIP , Snail, 
Slug (IHC only) 




  120 benign (65%) 
  48 borderline (26%) 
  17 malignant (9%) 
11 recur (6%) 
3 deaths (2%) 
IHC β-catenin ,CD34, 
VEGF 





80 benign (57%) 
30 borderline (21.5%) 
30 malignant (21.5%) 
30 recur (21%) 








Axl and ST6GalNAcII was significantly 
correlated with 
distance metastasis by IHC 
Abbreviations: LR- local recurrences; DR- distant recurrences; IHC- immunohistochemistry; PCR – polymerase chain reaction; OS- overall survival; DFS – 





1.2.3.1 CD117 as a prognostic marker in phyllodes tumours 
 CD117, or known as c-kit, is a type III transmembrane receptor 
tyrosine kinase encoded by the KIT gene located at chromosome 4q12. The 
receptor is characterized by an extracellular domain comprising five 
immunoglobulin-like repeats (encoded by exons 2-9), a transmembrane 
domain (exon 10), a juxtamembrane domain (exon 11), and two intracellular 
tyrosine kinase domains (exons 12-20) as shown in Figure 1.10. The 
extracellular domain binds to ligands for receptor activation. The 
juxtamembrane domain has an autoinhibitory mechanism maintaining the 
dormant state of an inactive receptor and tyrosine kinase domains act as 
docking sites for signalling molecules.  
 
Figure 1.10 Schematic illustration of a CD117 receptor, made up of an 
extracellular domain comprising five immunoglobulin-like repeats, a 
juxtamembrane domain encoded by exon 11, and tyrosine kinase domains I 





 CD117 exists as monomer in its inactive state. Upon binding of stem 
cell factor (KIT ligand), the extracellular domain undergoes conformational 
changes and allows two monomers to form a dimer, facilitating activation of 
the receptors via transphosphorylation (Figure 1.11). Activation of CD117 
initiates various downstream signalling pathways such as the 
phosphatidylinositol  ’-kinase (PI ’-kinase), Src family kinases, mitogen-
activated protein kinase (MAP kinase) signalling pathways, mediating cell 




Figure 1.11 Activation of CD117. CD117 receptors exist as monomers in the 
inactive state. Upon binding of the stem cell factor (SCF), the extracellular 
domain undergoes conformational changes, allowing two monomers to be in 
close proximity, thereby forming a dimer which facilitates activation of the 
receptors via transphosphorylation, starting from the juxtamembrane 









CD117 has been implicated in various malignancies, including 
gastrointestinal stromal tumours (GISTs) [Corless et al., 2002], colon cancer 
[Gavert et al., 2013] and small cell lung carcinoma [Fischer et al., 2007]. 
Mutations of CD117 are commonly seen in these tumours especially those at 
exons 11 (juxtamembrane domain), 13 and 17 (kinase domains) and to a 
lesser extent in exon 9 (extracellular domain). Patients with GISTs harbouring 
overexpression or mutation of CD117 are responsive to tyrosine kinase 
inhibitors which can block the activity of an activated CD117 receptor. There 
has been previous suggestion that the stromal component of phyllodes 
tumours bear some similarities with GIST such as the spindled nature and 
spectrum of behaviour from benign to malignant [Carvalho et al., 2004].  
Investigation of CD117 mutational status in phyllodes tumours started 
in year 2000 by Chen et al. where the authors found two point mutations 
Q556X and N564S at exon 11 [Chen et al., 2000]. Mutations in this domain 
release the autoinhibitory mechanism of the receptor, enabling the receptor 
to be activated even without the binding of a ligand. Following this, many 
other researchers have performed similar investigations, assessing both 
mutational status and protein expression of CD117 in phyllodes tumours 
(Table 1.5). However, reports vary across studies and data on prognosis of 







Table 1.5 Summary of investigations of CD117 expression and mutation status in phyllodes tumours 
Authors, 
year 
N Antibody and 
dilution 
Scoring Criteria CD117 expression Mutation Status Follow-up 
Chen et al. 
2000 
19 Chemicon clone 
K69 
1:100 
≥ 0% Associated with 
malignant grade 
Q556X (exon 11) and 
N564S (exon 11) in one 
case each 
NA 




Intensity≥  Associated with 
malignant grade  
L510M (exon 10) in one 
case 
NA 










NA Not correlated 
with recurrence 




≥25% Associated with 
malignant grade 
Silent mutation Isoleucine 
798 (exon 17) in two cases 
NA 
Tan et al. 
2005b 










Esposito et al. 
2006 




score ≥  
Associated with 
tumour grade 










Table 1.5 Summary of investigations of CD117 expression and mutation status in phyllodes tumours 
Authors, 
year 
N Antibody and 
dilution 




41 Dako A4502 
Dilution not 
specified 
>10% of at least 
moderate 
intensity  
None of the cases 
were positive 










>0% No correlation Not detected in two 
CD117 positive tumours 
NA 




≥5% No correlation Silent mutation Isoleucine 
798 (exon 17) in one case 
NA 
Jung et al. 
2010 
67 Dako polyclonal 
1:300 
>10% Correlated with 
increasing grade 
None detected in subset 




Noronha et al. 
2011 













1.2.3.2 Homeobox proteins as prognostic markers in phyllodes tumours 
 Homeoproteins are transcribed from homeobox genes which 
constitute a large group of developmental regulators for embryogenesis. 
Homeobox was first identified as a sequence motif in the fruit fly Drosophila 
and is well conserved across species. It encodes a signature homeodomain 
which forms a helix-turn helix three dimensional structure that binds to 
specific DNA elements, primarily those that contain a TAAT core motif 
[Samuel and Naora, 2005], enabling them to act as transcriptional regulators, 
triggering activation or suppression of downstream target genes including 
those involved in cell growth and differentiation.  
 The process of development shares common critical pathways as 
neoplasia [Kelleher et al., 2006], and aberrant expression of homeoproteins 
has been implicated in many solid tumours [Samuel and Naora, 2005] 
including colorectal cancers, breast cancers and sarcomas. Six1 and Pax3 are 
among these homeoproteins which are reportedly deregulated in tumours. 
Overexpression of Six1 was associated with higher tumour stage in cervical 
cancer and hepatocellular carcinoma [Zheng et al., 2010; Ng et al., 2006] 
while aberrant expression of Pax3 was demonstrated in Ewing sarcoma and 
glioma.  
 We previously found that Six1 and Pax3 were overexpressed in 
borderline/malignant phyllodes tumours at the transcript level in a 
collaborative project [Jones et al., 2008b].  The comprehensive expression 





benign and borderline/malignant tumours among 162 differentially 
expressed genes. Moreover, knockdown of Six1 and Pax3 resulted in 
significantly decreased cell proliferation in short term cultures established 
from borderline and malignant phyllodes tumours. However, protein 
expression of both Six1 and Pax3 was not investigated and their prognostic 
significance in clinical samples was not addressed. It would be of interest to 
expand the study in a larger cohort to corroborate these findings with 







1.3 Scope of study 
The hypothesis of this study is that there are distinct subgroups within 
phyllodes tumours, having different course of disease which harbours unique 
characteristics that set them apart from each other.   
This study aims to investigate and evaluate the prognostic importance 
of clinical and molecular parameters of phyllodes tumours, to understand the 
biology of phyllodes tumours from these perspectives, of which the eventual 
desired outcome is to improve management of patients with phyllodes 
tumours, with a more accurate ability to predict biological behaviour.  
 










The scope of this study encompasses specific aims as follow: 
1) To evaluate individual clinicopathological parameters in predicting 
recurrences in patients with phyllodes tumours and to propose a 
predictive model with these parameters 
2) To screen for genetic aberrations in prognostically distinct groups of 
phyllodes tumours to understand the biological differences between 
tumours with good course of disease and tumours with poor course of 
disease 
3) To investigate and validate the prognostic importance of receptor 
tyrosine kinase CD117, and homeobox proteins Six1 and Pax3 in 
phyllodes tumours 





2.0 MATERIALS AND METHODS 
 













2.1 Proposal of a predictive clinical model 
2.1.1 Study population and data collation 
This study received approval from the SingHealth Centralized 
Institutional Review Board. Cases of breast phyllodes tumours diagnosed in 
the Department of Pathology, Singapore General Hospital between January 
1992 and December 2010 were included in this study. Patient details and 
case information such as age, ethnicity, type of surgery performed, surgical 
margins of tumours, and follow-up data were retrieved from the information 
database.      
Haematoxylin and eosin-stained (H&E) slides for all cases were 
retrieved from the archive room. Old slides were subjected to restaining and 
missing slides were replaced by re-sectioning of tissue from archival formalin-
fixed, paraffin embedded (FFPE) tissue blocks.  
2.1.2 Sample criteria 
Slides were reviewed by a pathologist. The five histological 
parameters were reviewed and noted - stromal cellularity, stromal atypia, 
stromal mitotic activity, presence or absence of stromal overgrowth, and 
nature of microscopic margins. 
Stromal cellularity and atypia were categorized as mild, moderate and 
marked. Stromal mitotic activity was quantified per 10 high-power 
microscopic fields (x40 objective and x10 eyepiece) over the most mitotically 
active stromal areas. Stromal overgrowth was defined as a low-power field 
(x4 objective and x10 eyepiece) that consisted of stroma only without 





epithelial elements. Microscopic margins were classified as circumscribed or 
permeative if the margin between the tumour and surrounding breast tissue 
was well defined or permeative, respectively.  
A phyllodes tumour was diagnosed as benign when the following 
criteria were fulfilled: mild stromal cellularity and atypia, occasional mitoses 
of not more than four per 10 high-power fields, no stromal overgrowth, and 
with circumscribed margins. Conversely, a malignant phyllodes tumour was 
diagnosed when the following features were present: marked stromal 
hypercellularity and atypia, brisk mitotic activity (10 or more per 10 high-
power fields), presence of stromal overgrowth, and permeative margins. A 
borderline phyllodes tumour showed some, but not all of the characteristics 
observed in malignant phyllodes tumours.     
2.1.3 Histology processing 
2.1.3.1 Sectioning 
Tissue was sectioned from the archival FFPE tissue block or a tissue 
microarray block using a manual rotary microtome (Leica RM2135, Leica 
Biosystems, Germany). Sections were placed on a floatation bath at room 
temperature and flattened using a pair of forceps. Sections were then 
transferred to a warm water bath with temperature at approximately 50°C 
using a glass slide before placing  onto a glass slide, charged slide 
(Microsystems Plus Slides, Leica Biosystems, Germany), or membrane slides 
(1.0 mm PEN, Carl Zeiss, Germany) depending on downstream procedures. 





To ensure tissue adherence, tissue on glass slides were left on a hot 
plate at 80°C for 3 minutes while charged slides were incubated in an oven 
overnight at 80°C. Membrane slides were left to air-dry at room temperature.  
2.1.3.2 Haematoxylin and eosin (H&E) staining 
Old slides were first incubated in xylene for ≥ 2 hours to remove cover 
slips and associated depex before being subjected to H&E re-staining. New 
slides of tissue sections dried on a hotplate were loaded directly into an 
automated H&E staining system on ST5010 Autostainer XL (Leica Biosystems, 
Germany). Briefly, tissues were dipped in two changes of xylene for 2 minutes 
each and rehydrated through graded alcohol. Subsequently, slides were 
washed in running water, incubated in two changes of haematoxylin and 
washed under running water again. Upon staining with eosin, tissues were 
dehydrated through graded alcohol and dipped in xylene before mounted 
with DPX mounting media and cover slips.  
 
2.1.4 Model and nomogram building 
 All analyses were done using R V.2.13.0 (http://www.R-project.org), 
STATA version 11, and PASW Statistics for Windows version 18.0. Differences 
between benign, borderline and malignant phyllodes tumours were assessed 
with χ2 test and Fisher’s exact test.  
 Kaplan Meier survival curves were employed to estimate recurrence-
free survival (RFS) and overall survival (OS), defined as time from date of 
surgery to date of first relapse and death, respectively, or to the date of last 





follow-up for censored cases. Log-rank test was used to compare survival 
between groups. Univariate and multivariate Cox regression analyses were 
performed to evaluate the effect of potential features in predicting 
recurrences.  
A backward elimination method was used applying in the Akaike 
information criterion (AIC) to select best performing features. Assumptions 
for proportional hazards were verified systematically. Multivariate Cox 
regression coefficients of the model were used to generate the nomogram. 
The nomogram performance was validated using 200 bootstrap set of 
resamples. Calibration plots were constructed to evaluate the ability of the 
nomogram in predicting RFS of individual patients at 1, 3, 5 and 10 years after 
surgery.  
2.1.5 Comparison of models 
 A total histological score model was derived on the assumption that 
the potential features had a linear additive effect. Scores were assigned 
based on the criteria as listed in Table 2.1 for each category. The total 
histological score model was defined as the sum of the scores of the five 










Table 2.1 Scores assigned for each category. Total score were derived by 
summing up the score from each criterion 
              Score 
Criteria 
1 2 3 
Hypercellularity Mild Moderate Marked 
Atypia Mild Moderate Marked 
Mitotic rate 0-4 5-9 ≥ 0 
Overgrowth Absent Present NA 
Microscopic margin Pushing/Circumscribed Permeative NA 
 NA: not applicable 
 The performance of the nomogram and the total histological score 
model was compared using Harrell’s c-index and likelihood ratio. Harrell’s c-
index measures the predictive power of each model by evaluating 
concordance between predicted and observed response of the individual 
subject separately. For assessment using likelihood ratio test, the nomogram 
and total histological score model were first combined to give rise to a full 
model. Then the performance of a nested model comprising only the 
nomogram and total histological score respectively were evaluated with 
likelihood ratio test. Adequacy index was calculated to measure the 
percentage of variation explained by the respective nested model as 
compared to the full model.  





2.2 Genetic aberrations study 
2.2.1 Selection of cases for molecular investigation 
 Twenty cases were further selected from the cohort for molecular 
investigation based on clinical outcome. Cases were stratified into two 
prognostically distinct groups:  
 a) cases with recurrence, metastasis and/or death 
 b) cases without recurrence with a follow-up period of no less than 
two years, a duration supported by our own data of a median time to 
recurrence of 24.6 months.  
2.2.2 Tissue dissection 
2.2.2.1 Macrodissection 
 5-10 sections of tissue of  0μm thick on glass slides were 
deparaffinized with 3 changes of xylene for 2 minutes each and 2 changes of 
absolute alcohol for one minute each.  Corresponding desired areas 
containing >95% lesional tissue pre-marked on a H&E slide by a 
histopathologist were macrodissected using a sterile scalpel blade for each 









2.2.2.2 Laser capture microdissection 
 10-15 sections of 5µm thick tissues were sectioned on UV-screened 
membrane slides (1.0 mm PEN, Carl Zeiss, Germany) and stained with 
haematoxylin. The PALM® Microbeam system (Carl Zeiss, Germany) was 
employed. A tissue section was viewed through the imaging software of the 
system under the microscope and the desired tissue area was drawn. Then, a 
laser beam was used to cut and isolate the desired area onto the PALM® 
AdhesiveCaps (Carl Zeiss, Germany) for downstream analysis (Figure 2.2). 
Figure 2.2 Procedure of laser capture microdissection. (a) Epithelium was 
drawn and highlighted before laser dissection. (b) After laser dissection, the 
epithelial component was isolated and captured for DNA extraction.  
 
2.2.3 DNA extraction 
 DNA extraction from tissue dissected was performed using the 
Ambion® RecoverAll™ Total Nucleic Acid Isolation Kit (Life Technologies, USA) 
according to the manufacturer’s instruction. Briefly, digestion buffer and 
protease were added to the tissue and incubated for 48 hours at 50°C. After 
the temperature had settled at room temperature, isolation additive and 





ethanol mixture was added to the samples and mixed thoroughly. The 
mixture was then passed through a filter cartridge and washed several times. 
Nuclease digestion was performed with RNase mix prior to elution of DNA in 
nuclease-free water.   
2.2.4 Genome wide molecular inversion probe array 
Purified DNA was sent for processing via the utility of the OncoScan™ 
FFPE Express 2.0 Service (Affymetrix, Inc, CA). Samples were quantified with 
the PicoGreen® assay. Only samples with at least 75ng of DNA were passed 
and normalized. The OncoScan™ assay interrogates ~333,000 markers for 
copy number (CN) changes, and 541 somatic mutations from 59 genes 
specific for cancer (Supplementary Table 2).  Technicalities and the design of 
probes were as previously described [Wang et al., 2012b]. Pre-processed data 
analysed using Nexus 6 Copy Number™ (Biodiscovery, CA) was delivered. The 
fraction of genome altered (FGA) for each tumour was calculated [Schiffman 
et al., 2010] as total lengths of gains and losses divided by the total genome 
length (3224.46Mb, Genome Reference Consortium Human Build 37).  
Mutation score, a measurement of differences between the normal 
wild-type cluster and test sample, was provided for each mutation assay. A 
higher score denotes a larger difference from the wild-type cluster and hence 
a higher likelihood for the mutation to be real. A score of 4 was 
recommended for BRAF V600E assay to be valid while other mutation assays 
were recommended at a score of 9. 






2.2.5.1 Sanger sequencing 
Polymerase chain reaction (PCR) was performed for samples which 
harboured potential mutations detected on the OncoScan™ mutation panel. 
Primer sequences as shown in Table 2.3 were designed with Primer-BLAST. 
PCR was set up using Taq PCR Core Kit (Qiagen, Germany) in accordance with 
the manufacturer's protocol in a total volume of 50µl. The PCR cycling 
program was as follows: (1) 94°C for 5 minutes (1 cycle), (2) 94°C for 1 minute, 
57°C for 1 minute, 72°C for 1 minute (40 cycles) and (3) 72°C for 10 minutes 
(1 cycle). Negative controls (non-template) were included in every PCR run. 
PCR products were analysed with 2% gel electrophoresis stained with 
GelRed™ and purified using QIAquick PCR Purification Kit (Qiagen, Germany .  
Purified PCR amplicons were sequenced by 1st BASE Pte Ltd (Singapore). DNA 
sequences were analysed using the NCBI database and BLAST software. 
  
 









Forward Sequence Reverse Sequence 
Size 
(bp) 
ATM_p.T2666A_c.7996A<G NM_000051.3  ATTCCAGCAGACCAGCCAAT AGGGCTTGGGCAAAGGAAAT 237 
BRCA1_c.134plus1G<T* NG_005905.2 TGTCTCCACAAAGTGTGACCA GGTGTTTCCTGGGTTATGAAGG 103 
CDKN2A_p.W110X_c.329G<A NM_000077.4 CCCTGGCTCTGACCATTCTG ATGGTTACTGCCTCTGGTGC 309 
CDKN2A_c.151minus1G<A* NG_007485.1 CCCTGGCTCTGACCATTCTG ATGGTTACTGCCTCTGGTGC 309 
EGFR_p.G598V_c.1793G<T NM_005228.3  TGTGCCCACTACATTGACGG GTGCAGTTTGGATGGCACAG 131 
EGFR_p.L858R_c.2573T<G NM_005228.3  AGCAGGGTCTTCTCTGTTTCA  TGACCTAAAGCCACCTCCTT 200 
KIT_p.V654A_c.1961T<C NM_000222.2 GTTCCTGTATGGTACTGCATGCG  CAGTTTATAATCTAGCATTGCC 282 
MEN1_c.654plus3A<G* NG_008929.1 ATGCCTGGGTAGTGTTTGGG ATGACAGCCAGGAAAAGGGG 263 
NF2_p.V219M_c.655G<A NM_000268.3  CAGTGTCTTCCGTTCTCCCC TTTAGCAGTCTGGCCCTCAC 167 
NOTCH1_p.Q2460X_c.7378C<T NM_017617.3 CTGGCGGTGCACACTATTCT TGTCCACAGGCGAGGAGTAG 136 
NPM _p.W2   frame shift_c. 6 insCCTG† NM_002520.6 TCTCTGGCAGTGGAGGAAGT CCATGTCTGACCACCGCTAC 289 
RB1_p.E440X_c.1318G<T NM_000321.2 TGCTAAAGCTGTGGGACAGG ACGAACTGGAAAGATGCTGC 114 
RET_p.A664D_c.1991C<A NM_020630.4 TCTGCCTTCTGCATCCACTG GAGGAGTAGCTGACCGGGAA 110 
SMAD4_p.K507Q_c.1519A<C NM_005359.5 GTCAGCTGCTGCTGGAATTG GTTAAGGGCCCCAACGGTAA 234 
TGFBR2_p.R497X_c.1489C<T NM_001024847.2 CCCTGTGTTTGCTGGCTTTC GTCGCCCTCGATCTCTCAAC 123 
TP53_p.H179R_c.536A<G NM_000546.5 CACTTGTGCCCTGACTTTCA GGGCCAGACCTAAGAGCAAT 320 
TP53_p.C124R_c.370T<C NM_000546.5 TGAAGCTCCCAGAATGCCAG AAGTCTCATGGAAGCCAGCC 229 
Note: Mutations written in such format: Gene_p. amino acid position_c. DNA coding sequence position. 
* Mutations at intronic regions 
† Insertion of four bases (CCTG  between coding sequence position  6  and  64  





2.2.5.2 Fluorescence in situ hybridization (FISH) 
Tissue sections of 4μm thick on charged slide were deparaffini ed and 
left to air-dry. Sections were treated in 0.2M hydrogen chloride for 20 
minutes at room temperature, followed by washes in purified water and 2X 
saline-sodium citrate (SSC) buffer. The slides were then incubated in 
Pretreatment Solution (Abbott Molecular, USA) for 30 minutes at 80°C. Tissue 
was digested with Protease I Solution (Abbott Molecular), washed in 2X SSC 
buffer and dehydrated in graded alcohol.  
Dual colour LSI EGFR SpectrumOrange™/ CEP 7 SpectrumGreen™ 
probes (Abbott Molecular) were applied and co-denatured. Probes were 
hybridized overnight at 37°C. Slide was washed in 2X SSC/0.3% Igepal® CA-
630 (Sigma-Aldrich, USA) at 75°C then at room temperature for 2 minutes 
and 1 minute respectively. The tissue was counterstained with 4', 6-
diamidino-2-phenylindole (DAPI) antifade solution (Vectashield, USA) and 
analyzed under an epifluorescence microscope. Signals from 60 non-
overlapping nuclei were enumerated for copy numbers of EGFR and CEP 7. 
EGFR amplification was defined with the ratio of EGFR to CEP7 of 2 and above.  
2.2.5.3 Immunohistochemistry 
Immunohistochemistry was performed using CDK18, MDM4, RAF1, 
EGFR and p16 primary antibodies. Please refer to section 2.3.3 for further 
details. 
 





2.3 Prognostic importance of CD117, Six1 and Pax3 
2.3.1 Selection of cases 
 A subset of cases was used for this part of the study. All cases 
diagnosed from January 2003 to December 2010 were included. 
2.3.2 Tissue microarrays (TMAs) 
Tissue microarrays (TMAs) were constructed using the Manual Tissue 
Arrayer MTA-1 (Beecher Instruments Inc., Sun Prairie, USA). A brief summary 
is illustrated in Figure 2.3. First, three representative areas comprising high 
stromal cells density were marked on selected H&E slides for each case by a 
histopathologist. Then, the marked areas were identified on the 
corresponding FFPE blocks and punched with a 2.0mm diameter core. Before 
each core was transferred to the recipient block, a core wax from the 
recipient block was removed with the recipient puncher. The three cores 
were arrayed to three recipient blocks respectively. A maximum of 40 cores 
were arrayed in a single block, with a tonsil core as an orientation marker. 
 






Figure 2.3 Construction of a tissue microarray. First, representative areas are 
marked by a histopathologist. Then the areas are identified on the 
corresponding green FFPE tissue block (donor block). The donor block is 
punched with a 2.0mm core (blue-coded puncher), and then transferred to a 
recipient wax block (purple as shown in figure) where a paraffin cylinder was  
previously removed by the recipient puncher (red-coded puncher). A 
maximum of 40 cores are arrayed in a single block with a tonsil core as an 














2.3.3.1 Immunohistochemical staining 
The procedure of immunohistochemistry was optimized on three 
automated platforms for respective antibodies (please see Table 2.3). 
Antibody was diluted with ‘Antibody Diluent with Background Reducing 
Components’ (Dako, Glostrup, Denmark) to the optimized dilution. The three 
platforms used in this study are Autostainer Plus (Dako, Glostrup, Denmark), 
BenchMark ULTRA (Ventana Medical Systems, Arizona, USA), and BOND-
MAX™ (Leica Biosystems, Germany .  
The fundamental procedures for all three platforms are similar (Figure 
2.4 . First, 4μm thick tissue section on charged slides (Microsystems Plus 
Slides, Leica Biosystems, Germany) were deparaffinized and underwent pre-
treatment for antigen retrieval. Endogenous peroxidase activity was blocked 
with hydrogen peroxide. Then primary antibody was added and incubated 
according to the optimized protocol. Secondary antibody conjugated with 
horse radish peroxidase (HRP) was applied after which 3, 3'-diaminobenzidine 
(DAB) was added. Counter-staining with haematoxylin was subsequently 
performed before sections were dehydrated and mounted with DPX and 
cover slips. All runs were performed together with controls as listed in Table 
2.4. 
 






Figure 2.4 Procedure of immunohistochemistry staining 




Table 2.3 Antibody details and optimized protocol for immunohistochemistry staining 
Antibody Source Catalogue 
No. 
Dilution Time Pre-treatment Automation system Secondary antibody and 
visualization 
CD117 Dako  A4502 1:400 20 min ER2 at 100°C 20min Leica BOND-MAX™ Bond™ Polymer Refine 
Detection 
CDK18 Sigma  HPA045429 1:100 60 min Ct at 120°C 5 min Dako Autostainer 
Plus 
Dako EnVision® kit 





Universal DAB Detection 
Kit 
MDM4 Abcam  ab84393 1:100 30 min Ct at 120°C 5 min Dako Autostainer 
Plus 
Dako EnVision® kit 
p16 Santa 
Cruz  
sc-56330 1:100 20 min ER2 at 100°C 20 min Leica BOND-MAX™ Bond™ Polymer Refine 
Detection 
Pax3 Abcam  ab15717 1:150 30 min TE at 98°C 15 min Dako Autostainer 
Plus 
Abcam anti-goat IgG 1:100 
30min and DAB 
Raf1 Sigma  HPA002640 1:50 30 min Ct at 98°C 15 min Dako Autostainer 
Plus 
Dako EnVision® kit 
Six 1 Sigma  HPA001893 1:100 60 min Ct at 98°C 15 min Dako Autostainer 
Plus 
Dako EnVision® kit 
Sigma: Sigma-Alrich; min: minutes; ER2: epitope retrieval solution 2 (pH9.0) ; TE: Tris-EDTA buffer (pH9.0); Ct: Citrate buffer (pH6.0); RT: room 
temperature; DAB: 3, 3'-diaminobenzidine 
 
 




Table 2.4 Positive and negative controls used for each antibody and the cellular localization for the antibody expression 







Positive: at least 1% or more stroma 
cells reactive 

























High: Mean H-score of 14 
Raf1 Normal kidney tissue 
Omitting primary 
antibody 
Nucleus or cytoplasm Nil 
Six 1 














2.3.3.2 Evaluation of staining 
Slides were scanned using the ScanScope System (Aperio 
Technologies, Inc., USA) and viewed using the ImageScope software (Aperio). 
Staining was evaluated by eye-balling and scored by two blinded observers 
independently. Disagreements were reviewed jointly and resolved by 
consensus [Pinder et al., 2013].  
Cellular localization of each stain evaluated is as listed in Table 2.4. 
Reactivity in each localization was assessed separately except for CD117, 
where cytoplasm and membrane were assessed together. Triplicates of cores 
were scored separately and the core with the highest expression was used 
for statistical analysis. Staining was evaluated in two aspects where 
appropriate – intensity of staining and percentage of tumour cells stained.  
Staining intensity was graded 0, 1+, 2+ and 3+ for nil, weak, moderate and 
strong intensity respectively. Percentage of tumour cells stained was 
estimated numerically. Semi-quantitative H-score [McCarty et al., 1985] 
ranging from 0 to 300 points was calculated as follows: 
 
                                           
                                        
                                         




2.3.3.3 Toluidine blue staining 
 To further confirm that the CD117-positive cases were not 
confounded by mast cells, the sections were subjected to toluidine blue stain. 
Briefly, tissue sections of 4μm thick on glass slides were obtained. After 
deparaffinization with xylene and graded alcohols, tissue sections were 
incubated in 0.5% toluidine blue working solution for 6 minutes. 
Subsequently, slides were rinsed in changes of 95% alcohol immediately and 
dipped in 100% alcohol for one minute. Sections were then cleared with 
xylene and mounted with DPX mounting media. Bone marrow tissue 
containing mast cells were used as positive control. Presence of mast cells 
was identified by their metachromatic appearance (red-purple coloured) of 
the cytoplasm amidst the toluidine blue-stained background.   
2.3.4 Statistical Analysis 
 Statistical analysis was performed with SPSS for Windows, version 18. 
Chi-square and Fisher’s exact tests were used to analyze associations 
between categorical data. Means between groups were compared using 
analysis of variance (ANOVA). Kaplan-Meier survival curves were used to 
estimate recurrence-free survival and overall survival, defined as the time 
from date of surgery to date of first relapse and death from phyllodes tumour, 
respectively, or to the last follow-up date for censored cases. Log-rank test 
was performed to compare survival between groups. A p-value of less than 








3.1 Proposal of a predictive clinical model  
3.1.1 Characteristics of the study population 
A total of 605 cases of phyllodes tumours were diagnosed from 
January 1992 to December 2010 - 440 (72.7%) benign, 111 (18.4%) borderline 
and 54 (8.9%) malignant tumours. Patient ages ranged from 15 to 79, with a 
median age of 43 years.  Clinicopathological characteristics stratified 
according to tumours are as shown in Table 3.1.1. Older patients and larger 
tumour sizes were observed more frequently with borderline and malignant 
grade tumours. Significant associations were observed with the five 
histological parameters and tumour grade, suggesting a good concordance 
with the grade classification. No significant association was observed with 
ethnicity and surgical margins with tumour grade.  
 Recurrences were documented in 80 (13.2%) cases. There was an 
increasing trend of recurrences observed with increasing grade - 48 (10.9%) 
benign grade tumours, 16 (14.4%) borderline grade tumours, and 16 (29.6%) 
malignant grade tumours. Mean and median times to recurrence were 29.8 
and 24.6 months respectively. Of the 80 cases, 68 were local recurrences, 7 
were distant recurrences, and 5 were local preceding distant recurrences 
(Table 3.1.1). Sites of distant recurrence which were histologically confirmed 
or radiologically detected include lung and pleura, liver, vertebra and soft 






phyllodes tumours and the remaining seven from non-phyllodes tumour 
related causes. 














Age (years) (mean 42, median 43, range 15–79) 
 
<0.001* 
 <mean age 227 (51.6) 36 (32.4) 16 (29.6) 
  ≥mean age 213 (48.4) 75 (67.6) 38 (70.4) 
 Ethnicity 
   
0.724 
 Chinese 307 (69.8) 81 (73.0) 37 (68.5) 
  Malay  66 (15.0) 19 (17.1) 10 (18.5) 
  Indian 31 (7.0) 3 (2.7)          0 (0) 
  Others 36 (8.2)  8 (7.2) 7 (13.0) 
 Size (mm) (mean 52, median 40, range 3–250) 
 
<0.001* 
 <mean size 343 (78.0) 54 (48.6) 16 (29.6) 
  ≥mean si e   97 (22.0) 57 (51.4) 38 (69.4) 
 Stromal hypercellularity 
  
<0.001* 
 Mild 302 (68.6) 21 (18.9)  3 (5.6) 
  Moderate 131 (29.8) 75 (67.6) 25 (46.3) 
  Marked    7 (1.6) 15 (13.5) 26 (48.1) 
 Stromal atypia 
   
<0.001a 
 Mild 412 (93.6) 54 (48.7) 0 (0) 
  Moderate 28 (6.4) 54 (48.7) 30 (55.6) 
  Marked 0 (0)  3 (2.6) 24 (44.4) 
 Stromal overgrowth 
  
<0.001a 
 Absent 440 (100) 86 (77.5) 14 (25.9) 
  Present  0 (0) 25 (22.5) 40 (74.1) 
 Stromal mitotic activity/10 hpfb 
  
<0.001a 
 0–4 402 (91.4) 31 (27.9) 5 (9.2) 
  5–9 34 (7.7) 51 (46.0) 15 (27.8) 
  ≥ 0   4 (0.9) 29 (26.1) 34 (63.0) 
 Microscopic borders 
  
<0.001a 
 Circumscribed 283 (64.3) 49 (44.1) 20 (37.0) 







Table 3.1.1 Clinicopathological features of 605 cases stratified according to 














   
0.511 
 Complete  257 (58.4) 58 (52.3) 34 (63.0) 
  Focal involvement 168 (38.2) 44 (39.6) 16 (29.6) 
  Diffuse involvement 15 (3.4)  9 (8.1) 4 (7.4) 
 Recurrences 
   
<0.001a 
  No 392 (89.1) 95 (85.6) 38 (70.4) 
   Yes  48 (10.9) 16 (14.4) 16 (29.6) 
      Local 48 16 4 
      Distant 0 0 7 
      Local and distant 0 0 5 










3.1.2 Factors affecting recurrences 
3.1.2.1 Univariate analysis  
 A total of 552 patients were included in this analysis after discounting 
19 non-local residents where follow-up data was not available and cases with 
follow-up period less than 3 months. Results of unadjusted univariate Cox 
analysis are shown in Table 3.1.2. Patients with borderline and malignant 
tumours had an increased risk of recurrence as compared to patients with 
benign tumours, with a hazard ratio of 1.67 and 3.83 respectively. Cases of 
involved surgical margins were more likely to encounter a recurrence as 
compared to cases without surgical margins involved, with a hazard ratio of 
7.14. Stromal hypercellularity, stromal atypia, stromal overgrowth and nature 
of microscopic borders were also significantly associated with recurrence-


















events Hazard ratio (95% CI)c p-value 
All 552 85 
  Age 552 85 1.00 (0.98 to 1.02) 0.7006 
Ethnicity 
   
0.2095 
 Chinese 394 60 Reference 
  Malay 89 17 1.29 (0.75 to 2.22) 
  Indian 34 1 0.19 (0.03 to 1.39) 
  Others 35 4 1.04 (0.38 to 2.87) 
 Size 552 85 1.00 (1.00 to 1.01) 0.1725 
Mitoses per 10 hpfb 552 85 1.05 (1.03 to 1.07) <0.0001a 
Grade 
   
<0.0001a 
 Benign 399 46 Reference 
  Borderline 103 17 1.67 (0.96 to 2.92) 
  Malignant 50 19 3.83 (2.24 to 6.53) 
 Stromal hypercellularity 
  
0.0005a 
 Mild 302 31 Reference 
  Moderate 208 41 2.22 (1.39 to 3.54) 
  Marked 42 10 2.83 (1.39 to 5.78) 
 Stromal atypia 
   
<0.0001a 
 Mild 424 48 Reference 
  Moderate 101 23 2.16 (1.316 to 3.55) 
  Marked 27 11 4.42 (2.29 to 8.50) 
 Stromal overgrowth 
  
0.0003a 
 Absent 482 63 Reference 
  Present 70 19 2.49 (1.49 to 4.15) 
 Microscopic borders 
  
0.0047a 
Circumscribed 314 33 Reference 
  Permeative 238 49 1.87 (1.20 to 2.91) 
 Surgical margin 
   
<0.0001a 
 Negative 314 15 Reference 
  Positive 228 70 7.14 (4.07 to 12.52) 









3.1.2.2 Multivariate analysis  
 All features significantly associated with recurrence-free survival were 
incorporated for multivariate analysis (Table 3.1.3) except tumour grade due 
to issue of multicollinearity as tumour grade was derived from histological 
parameters. The multivariate analysis showed that stromal atypia, 
overgrowth and surgical margins affected recurrence-free survival 
significantly upon adjustment for interaction while stromal mitotic activity 
was close to statistical significance (p=0.058).  Stromal hypercellularity and 
nature of microscopic borders were excluded in the final model as they did 
not affect recurrence-free survival significantly upon adjustment for 
interaction. Further, log-likelihood ratio test showed that adding the 
respective features into the model did not significantly improve the model 
(p=0.065 and p=0.329 respectively). 









Mitoses per 10 hpfb 552 82 1.03 (1.00 to 1.06) 0.0580 
Surgical margin 
 Negative 314 15 Reference 
  Positive 238 67 8.37 (4.71 to 14.90) <0.0001a 
Stromal atypia 
 Mild 424 48 Reference 
  Moderate 101 23 1.79 (1.01 to 3.16) 0.0446a 
 Marked 27 11 3.28 (1.48 to 7.23) 0.0033a 
Stromal overgrowth 
 Absent 482 63 Reference 
  Present 70 19 2.28 (1.19 to 4.36) 0.0126a 









3.1.3.1 Constructing the nomogram 
 The multivariate Cox regression coefficients were used to derive the 
nomogram as shown in Figure 3.1.1a. Each feature corresponded to a 
weighted contribution in terms of points. For example, moderate atypia 
corresponds to 11 points, 10 mitoses/10hpf corresponds to 3 points, absent 
of overgrowth corresponds to zero point and positive surgical margin 
corresponds to 40 points. The sum of these points (Figure 3.1.1b) determined 
the likelihood of recurrence-free survival at 1 year, 3 years, 5 years, and 10 
years.  A case with accumulated total points of 54 will have a probability of 
recurrence-free survival of just above 0.9 at 1 year, 0.7 at 3 years, 0.58 at 5 
years, and 0.5 at 10 years. The calculations can be automated through 











Figure 3.1.1a Nomogram for predicting recurrence-free survival of patients 
with phyllodes tumours. Each feature (atypia, mitoses per 10hpf, overgrowth 
and surgical margins) corresponds to a weighted contribution in terms of 
points (yellow bar). To use the nomogram, a line is drawn to the points bar 
for each feature and total points are calculated to be used for Figure 3.1.1b. 
For example, moderate atypia corresponds to 11 points, 10 mitoses/10hpf 
corresponds to 3 points, absence of overgrowth corresponds to zero point 
and positive surgical margin corresponds to 40 points. The total points from 




















Figure 3.1.1b The total points accumulated from Figure 3.1.1a corresponds to 
the likelihood of recurrence-free survival at 1 year, 3 years, 5 years and 10 
years. Draw a line from the total points bar (yellow) down for the respectively 
likelihood. For example the case which had total points of 54 will have a 
probability of recurrence-free survival of just above 0.9 at 1 year, 0.7 at 3 
years, 0.58 at 5 years, and 0.5 at 10 years. 
 
 
3.1.3.2 Validation of the nomogram 
The nomogram’s performance was evaluated through bootstrapping 
and the calibration plots of 200 bootstrap resamples are as shown in Figure 
3.1.2. The mean and maximum deviations between observed and corrected 
outcomes are 0.03 and 0.02 at 1 year, 0.04 and 0.05 at 3 years, 0.04 and 0.07 
at 5 years, and 0.04 and 0.08 at 10 years. The predictive accuracy of the 








Figure 3.1.2 Calibration plots for the nomogram at 1 year (A), 3 years (B), 5 
years (C), and 10 years (D). The ideal outcome, observed outcome, and the 
optimism corrected outcome are depicted as grey, black and blue lines. Mean 
and maximum deviations between observed and corrected outcomes are 0.03 
and 0.02 at 1 year, 0.04 and 0.05 at 3 years, 0.04 and 0.07 at 5 years, and 0.04 











3.1.3.3 Comparison of nomogram with total histological score model 
 Both the nomogram and the total histological score model were 
significant as predictors of recurrence-free survival with hazard ratios of 1.05 
(95% CI 1.04 to 1.06) and 1.27 (95% CI 1.15 to 1.40) respectively (Table 3.1.4). 
This means that for every point increase in the nomogram and total 
histological score model, there is an increase of risk of recurrence by 5% and 
27% respectively. However, the nomogram has a range of scores between 0 
and 100 while the total histological score model has a range of score 
between 5 and 13, accounting for the apparent higher hazard ratio in the 
total histological score model.  
 
Table 3.1.4 Comparison of nomogram and histological score by hazard ratio 
and concordance index 
 
Hazard ratioa 




Nomogram  1.05 (1.04 to 1.06) <0.001 0.79 
Total histological score 1.27 (1.15 to 1.40) <0.001 0.65 
aFor every unit increase in score. It should be noted that the nomogram has a score 
range between 0 and 100, but the total histological score has a narrower range 











The Harrell’s c-index of the nomogram was 0.79 while that of the total 
histological score model was 0.65, indicating a higher prediction accuracy of 
the nomogram as compared to the total histological score model. The 
likelihood ratio test also demonstrated a superior performance of the 
nomogram as compared to the total histological score model (Table 3.1.5). 
The individual nested nomogram and total histological score model, when 
compared to the full model, had an adequacy index of 99.9% and 22.7% 
respectively (Figure 3.1.3). Moreover, inclusion of the nomogram to the total 
histological score model significantly (p<0.001) improved the accuracy 
prediction but inclusion of the total histological score model to the 



















Table 3.1.5 Comparison of nomogram and histological score by likelihood 






















aInclusion of nomogram significantly improves the prediction accuracy compared to 
a nested model of total score only 
bInclusion of the total score does not significantly improve the prediction accuracy 
compared to a nested model of nomogram only 
cPercentage of variation explained by nomogram compared to the full model 




Figure 3.1.3 Comparison of the nomogram and the total histological score 
model. The predictive value of each model is represented by the likelihood 
ratio value (y-axis) and the adequacy index (%). 99.9% of the full model is 
attributable to the nomogram while only 22.7% of the full model is 









3.2 Genome-wide copy number and mutational analysis 
 
 3.2.1 Characteristics of the study population 
 Details of sample selected are as shown in Table 3.2.1. Tumour grade 
was significantly associated with recurrence/death. However, no significant 
differences were observed between the two groups in terms of pathological 
features except for mitotic activity (Table 3.2.2).   
19 (95%) passed the quality control with median absolute pairwise 
difference (MAPD  ≤0.6 [Wang et al., 2007] and were further analysed for 
copy number changes and mutations. None of the microdissected tumours 















Table 3.2.1 Features of 20 samples selected for genome-wide copy number 




Ethnicity Diagnosis Prognosis 
1 23 55 Chinese Benign No recurrence 
2 50 100 Chinese Benign No recurrence 
3 26 55 Malay Benign No recurrence 
4 18 35 Malay Benign No recurrence 
5 24 35 Indian Benign No recurrence 
6 15 55 Chinese Borderline No recurrence 
7 34 190 Chinese Borderline No recurrence 
8 37 24 Chinese Borderline No recurrence 
9 45 60 Malay Borderline No recurrence 
10 55 250 Malay Borderline No recurrence 
11 58 150 Chinese Malignant No recurrence 
12 43 112 Chinese Benign Local Recurrencea 
13 46 55 Chinese Benign Local Recurrencea 
14 40 35 Chinese Borderline Local Recurrenceb 
15 44 210 Malay Borderline Metastasis preceded death 
16 40 190 Chinese Malignant Metastasis preceded death 
17 54 60 Chinese Malignant Death without recurrence 
18 49 100 Others Malignant Lung metastasis 
19 20 65 Others Malignant Lung metastasis 
20 57 95 Malay Malignant Lung metastasis 
a Recurred with grade progressed to borderline  













Table 3.2.2 Clinicopathological characteristics of 19 phyllodes tumours 









Age (mean 38 years, median 40 years, range 15-58 years)  
  ≤median age 7 (70%) 3 (33.3%)  
  >median age 3 (30%) 6 (66.7%) 0.179 
Size (mean 94mm, median 60mm, range 24mm-250mm)  
  ≤median si e 7 (70%) 3 (33.3%)  
  >median size 3 (30%) 6 (66.7%) 0.179 
Tumour grade    
  Benign 5 (50%) 2 (22.2%)  
  Borderline 5 (50%) 2 (22.2%)  
  Malignant 0 (0%) 5 (55.6%) 0.023* 
Stromal Hypercellularity   
  Mild 4 (40%) 1 (11.1%)  
  Moderate 5 (50%) 6 (66.7%)  
  Marked 1 (10%) 2 (22.2%) 0.337 
Stromal Atypia    
  Mild 8 (80%) 4 (44.5%)  
  Moderate 2 (20%) 3 (33.3%)  
  Marked 0 (0%) 2 (22.2%) 0.175 
Stromal Overgrowth    
  Absent 9 (90%) 4 (44.4%)  
  Present 1 (10%) 5 (55.6%) 0.057 
Stromal Mitotic Activity/10 hpf   
  0-4 8 (80%) 2 (22.2%)  
  5-9 2 (20%) 4 (44.5%)  
  ≥ 0 0 (0%) 3 (33.3%) 0.027* 
Microscopic Border    
  Circumscribed 8 (80%) 3 (33.3%)  
  Permeative 2 (20%) 6 (66.6%) 0.070 
Haemorrhage    
  Absent 6 (60%) 2 (22.2%)  
  Present 4 (40%) 7 (77.8%) 0.170 
Necrosis    
  Absent 9 (90%) 5 (55.6%)  
  Present 1 (10%) 4 (44.4%) 0.141 
Surgical Margin    
  Negative 6 (60%) 3 (33.3%)  
  Positive 4 (40%) 6 (66.7%) 0.370 






3.2.2 Copy number analysis 
 Copy number changes were noted in all samples ranging from 1 to 83 
events across tumours. An event was defined with two or more copy gains, or 
loss of single or both copies. Cases with recurrence and death harboured 
more aberrations with median events of 19 (range 0 – 72) compared to 3.5 
(range 0 – 49) in the recurrence-free group. Fraction of genome altered (FGA) 
was also higher in the former group with median FGA of 6% as compared to 
1.35% in the latter group. A summary of the alterations is shown in Table 
3.2.3 and the details of aberrations for each sample are listed in 
Supplemental Table 1.  
The most frequently observed loci of aberrations were 1q21.1, 2p11.1, 
7q21.3, 7q33, 8p22, and 15q11.1 (Table 3.2.4). Gain of 1q21.1 and loss of 
2p11.1 were more frequently observed in cases with recurrences/deaths. The 
function of genes within the 1q21.1 and 2p11.1 regions is largely unknown. 
However, 1q21.1 copy number variation was associated with neuroblastoma 
[Diskin et al., 2009] and hepatocellular carcinoma [Chen et al., 2010]. On the 
contrary, 7q21.3 gain was more frequently observed in the non-recurrent 
tumours. Though genes are also largely unknown in this region, a recent 
study revealed SGCE (sarcoglycan, epsilon) and DYNC1I1 (dynein, cytoplasmic 
1, intermediate chain 1) as a probable target gene at the 7q21.3 locus [Dong 




Table 3.2.3 Summary of patient cohort and genomic alterations observed in 20 phyllodes tumours 
No. Diagnosis  Details FGAa 
Events Amplification/Homozygous deletion 
(Candidate Gene) Gain Loss 
Cases without recurrence                                            Med: 0.0135        Med: 3.5 
1 Benign No recurrence 0.046 3 40 None 
2 Benign No recurrence 0.046 1 2 None 
3 Benign No recurrence 0.000 0 1 None 
4 Benign No recurrence 0.000 0 1 None 
5 Benign No recurrence 0.055 19 49 None 
6 Borderline No recurrence 0.007 2 1 None 
7 Borderline No recurrence 0.000 0 1 None 
8 Borderline No recurrence 0.000 2 2 None 
9 Borderline No recurrence 0.106 25 37 None 
10 Borderline No recurrence 0.020 0 4 None 
11 Malignant No recurrence Failed quality control 
Cases with recurrence/metastasis/death              Med: 0.06            Med: 19 
12 Benign Local Recurrenceb 0.013 14 14 [A] 5p13.3 (PDZD2) 
13 Benign Local Recurrenceb 0.021 0 4 [HD] 9p21 (CDKN2A) 
14 Borderline Local Recurrencec 0.077 0 2 None 
15 Borderline Metastasis preceded death 0.032 0 1 None 
16 Malignant Metastasis preceded death 0.320 22 24 [A] 7p12 (EGFR) 
17 Malignant Death without recurrence 0.240 11 72 [A] 3p25 (RAF1) 
18 Malignant Lung metastasis 0.060 15 4 [A] 1q32.1 (MDM4); [HD] 9p21 (CDKN2A) 





Table 3.2.3 Summary of patient cohort and genomic alterations observed in 20 phyllodes tumours (continued) 
No. Diagnosis  Details FGAa 
Events Amplification/Homozygous deletion 
(Candidate Gene) Gain Loss 
Cases with recurrence/metastasis/death              Med: 0.06            Med: 19 
19 Malignant Lung metastasis 0.138 5 39 [HD] 20p12.1 (MACROD2) 
20 Malignant Lung metastasis 0.003 1 2 None 
a Fraction of Genome Altered (FGA) calculated as total lengths of gains and losses divided by the total genome length (3224.46Mb)  
b Recurred with grade progressed to borderline cRecurred with increased size   
 [A] High-level amplification(>10copies gain);  [HD] Homozygous deletion 
   
 











1q21.1 gain 5 (50.0%) 8 (88.9%) 13 (68.4%) 
2p11.1 loss 3 (30.0%) 7 (77.8%) 10 (52.6%) 
7q21.3 gain 7 (70.0%) 4 (44.4%) 11 (57.9%) 
7q33 gain 5 (50.0%) 4 (44.4%)    9 (47.4%) 
8p22 gain 5 (50.0%) 5 (55.6%) 10 (52.6%) 





3.2.2.1 High-level amplifications and candidate genes 
 High-level amplifications, defined as presence of more than 10 copies, 
were observed only in cases which recurred/died. Regions of amplification 
included chromosome 1q32.1, 3p25, 5p13.3, and 7p12 in four separate 
samples (Figure 3.2.1).  
 Amplification of chromosome 1q32.1 was observed in tumour sample 
#18, a malignant grade tumour which subsequently metastasized. A total of 
71 genes were covered under the amplified region (Table 3.2.5), of which 
MDM4 (MDM4, p53 regulator) and CDK18 (cyclin-dependent kinase 18) were 
selected for further testing on immunohistochemistry (Figure 3.2.2). 
However, no overexpression of MDM4 and CDK18 on immunohistochemistry 
was observed, suggesting these genes were not overexpressed at the protein 
level.
 
Figure 3.2.1 Manhattan plots showing copy number mapped to chromosomal 
location on the x-axis for four different samples. Each colour represents a 
chromosome on x-axis. Region of high level amplifications with candidate 






Figure 3.2.2 (A) Amplification of chromosome 1q32.1 was observed in sample 
#18 which subsequently metastasized. No overexpression of protein levels by 
candidate genes CDK18 (B) and MDM4 (C) were observed on 
immunohistochemistry, suggesting these genes were not amplified in this 
sample. Positive and negative controls are shown as insets. Scale bars: 50μm 
 
 Chromosome 3p25 was amplified in a case which the patient passed 
away without tumour recurrence. RAF1 (Raf-1 proto-oncogene, 
serine/threonine kinase) was selected among the 53 candidate genes within 
the amplified region of 3p25 (Table 3.2.6) for immunohistochemical 
assessment. Patchy staining was observed on immunohistochemistry, 







Figure 3.2.3 Amplification of chromosome 3p25 (top panel) was observed in 
sample #17 of which the patient died from the disease. Candidate gene RAF1 
was however, patchy in this sample (bottom panel) and has a much weaker 
expression as compared to the positive control. Negative control is as shown 





Table 3.2.5 Candidate genes covered under the region of chromosome 1q32.1 for sample #18 
No. Gene Symbol Start position End position Length Name 
1 MIR5191 201688635 201688755 121 microRNA 5191 
2 NAV1 201617449 201796102 178654 neuron navigator 1 
3 RNU6-79 201736888 201767778 30891 RNA, U6 small nuclear 79 
4 MIR1231 201777738 201777830 93 microRNA 1231 
5 IPO9 201798287 201853422 55136 importin 9 
6 SHISA4 201857796 201861715 3920 shisa homolog 4 (Xenopus laevis) 
7 LMOD1 201865583 201915716 50134 leiomodin 1 (smooth muscle) 
8 TIMM17A 201924618 201939789 15172 
translocase of inner mitochondrial membrane 17 homolog A 
(yeast) 
9 RNPEP 201951765 201975275 23511 arginyl aminopeptidase (aminopeptidase B) 
10 ELF3 201979689 201986315 6627 
E74-like factor 3 (ets domain transcription factor, epithelial-
specific) 
11 GPR37L1 202092028 202098634 6607 G-protein coupled receptor 37 like 1 
12 ARL8A 202102531 202113871 11341 ADP-ribosylation factor-like 8A 
13 PTPN7 202116140 202130716 14577 protein tyrosine phosphatase, non-receptor type 7 
14 PTPRVP 202137178 202158577 21400 protein tyrosine phosphatase, receptor type, V, pseudogene 
15 LGR6 202163117 202288889 125773 leucine-rich repeat containing G protein-coupled receptor 6 
16 UBE2T 202300784 202311094 10311 ubiquitin-conjugating enzyme E2T (putative) 
17 PPP1R12B 202317829 202557697 239869 protein phosphatase 1, regulatory subunit 12B 
18 SYT2 202559724 202679551 119828 synaptotagmin II 
19 KDM5B 202696531 202777549 81019 lysine (K)-specific demethylase 5B 




Table 3.2.5 Candidate genes covered under the region of chromosome 1q32.1 for sample #18 (continued) 
No. Gene Symbol Start position End position Length Name 
21 LOC641515 202794328 202795421 1094 uncharacterized LOC641515 
22 LOC148709 202830881 202844369 13489 actin pseudogene 
23 RABIF 202847409 202858385 10977 RAB interacting factor 
24 KLHL12 202860229 202896371 36143 kelch-like 12 (Drosophila) 
25 ADIPOR1 202909959 202927700 17742 adiponectin receptor 1 
26 CYB5R1 202931000 202936404 5405 cytochrome b5 reductase 1 
27 LOC401980 202955579 202976393 20815 4933406M09Rik pseudogene 
28 TMEM183B 202976535 202992668 16134 transmembrane protein 183B 
29 TMEM183A 202976533 202993197 16665 transmembrane protein 183A 
30 PPFIA4 203020310 203047864 27555 
protein tyrosine phosphatase, receptor type, f polypeptide 
(PTPRF), interacting protein (liprin), alpha 4 
31 MYOG 203052256 203055166 2911 myogenin (myogenic factor 4) 
32 ADORA1 203096835 203136533 39699 adenosine A1 receptor 
33 MYBPH 203136938 203144942 8005 myosin binding protein H 
34 CHI3L1 203148058 203155922 7865 chitinase 3-like 1 (cartilage glycoprotein-39) 
35 CHIT1 203185206 203198860 13655 chitinase 1 (chitotriosidase) 
36 LOC730227 203267885 203274453 6569 uncharacterized LOC730227 
37 BTG2 203274663 203278729 4067 BTG family, member 2 
38 FMOD 203309751 203320289 10539 fibromodulin 
39 PRELP 203444882 203460479 15598 proline/arginine-rich end leucine-rich repeat protein 
40 OPTC 203463270 203478077 14808 opticin 




Table 3.2.5 Candidate genes covered under the region of chromosome 1q32.1 for sample #18 (continued) 
No. Gene Symbol Start position End position Length Name 
42 SNORA77 203698708 203698833 126 small nucleolar RNA, H/ACA box 77 
43 LINC00260 203699704 203700979 1276 long intergenic non-protein coding RNA 260 
44 LAX1 203734283 203745480 11198 lymphocyte transmembrane adaptor 1 
45 ZBED6 203766650 203769590 2941 zinc finger, BED-type containing 6 
46 ZC3H11A 203764750 203823256 58507 zinc finger CCCH-type containing 11A 
47 SNRPE 203830739 203840280 9542 small nuclear ribonucleoprotein polypeptide E 
48 LINC00303 204001574 204010392 8819 long intergenic non-protein coding RNA 303 
49 SOX13 204042245 204096871 54627 SRY (sex determining region Y)-box 13 
50 ETNK2 204100189 204121307 21119 ethanolamine kinase 2 
51 REN 204123943 204135465 11523 renin 
52 KISS1 204159468 204165619 6152 KiSS-1 metastasis-suppressor 
53 GOLT1A 204167287 204183220 15934 golgi transport 1A 
54 PLEKHA6 204187978 204329057 141080 pleckstrin homology domain containing, family A member 6 
55 LINC00628 204337557 204338847 1291 long intergenic non-protein coding RNA 628 
56 PPP1R15B 204372491 204380944 8454 protein phosphatase 1, regulatory subunit 15B 
57 PIK3C2B 204391757 204459474 67718 
phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 
2 beta 
58 MDM4 204485506 204527248 41743 Mdm4 p53 binding protein homolog (mouse) 
59 LRRN2 204586302 204654597 68296 leucine rich repeat neuronal 2 
60 NFASC 204797781 204991950 194170 neurofascin 
61 CNTN2 205012339 205047171 34833 contactin 2 (axonal) 




Table 3.2.5 Candidate genes covered under the region of chromosome 1q32.1 for sample #18 (continued) 
No. Gene Symbol Start position End position Length Name 
63 RBBP5 205055269 205091150 35882 retinoblastoma binding protein 5 
64 DSTYK 205111630 205180727 69098 dual serine/threonine and tyrosine protein kinase 
65 TMCC2 205197037 205242471 45435 transmembrane and coiled-coil domain family 2 
66 NUAK2 205271190 205290883 19694 NUAK family, SNF1-like kinase, 2 
67 KLHDC8A 205305647 205326039 20393 kelch domain containing 8A 
68 LEMD1-AS1 205342379 205356568 14190 LEMD1 antisense RNA 1 
69 LEMD1 205350505 205391214 40710 LEM domain containing 1 
70 MIR135B 205417429 205417526 98 microRNA 135b 











Table 3.2.6 Candidate genes covered under the region of chromosome 3p25 for sample #17 
No. Gene Symbol Start position End position Length Name 
1 FGD5 14860468 14976072 115605 FYVE, RhoGEF and PH domain containing 5 
2 FGD5-AS1 14984285 14989948 5664 FGD5 antisense RNA 1 
3 NR2C2 14989235 15090780 101546 nuclear receptor subfamily 2, group C, member 2 
4 MRPS25 15090018 15106816 16799 mitochondrial ribosomal protein S25 
5 ZFYVE20 15111579 15140655 29077 zinc finger, FYVE domain containing 20 
6 COL6A4P1 15206868 15247466 40599 collagen, type VI, alpha 4 pseudogene 1 
7 CAPN7 15247732 15294423 46692 calpain 7 
8 LOC100505696 15295690 15306005 10316 uncharacterized LOC100505696 
9 SH3BP5 15295862 15382901 87040 SH3-domain binding protein 5 (BTK-associated) 
10 IRAK2 10206562 10285427 78866 interleukin-1 receptor-associated kinase 2 
11 TATDN2 10290176 10322906 32731 TatD DNase domain containing 2 
12 GHRLOS2 10326102 10327430 1329 ghrelin opposite strand RNA 2 (non-protein coding) 
13 GHRL 10327433 10334631 7199 ghrelin/obestatin prepropeptide 
14 GHRLOS 10327437 10335133 7697 ghrelin opposite strand/antisense RNA 
15 SEC13 10342614 10362858 20245 SEC13 homolog (S. cerevisiae) 
16 MIR885 10436172 10436246 75 microRNA 885 
17 ATP2B2 10365706 10547268 181563 ATPase, Ca++ transporting, plasma membrane 2 
18 LINC00606 10801168 10805877 4710 long intergenic non-protein coding RNA 606 
19 SLC6A11 10857916 10980146 122231 
solute carrier family 6 (neurotransmitter transporter, GABA), 
member 11 
20 SLC6A1-AS1 11047783 11060910 13128 SLC6A1 antisense RNA 1 
 




Table 3.2.6 Candidate genes covered under the region of chromosome 3p25 for sample #17 (continued) 
No. Gene Symbol Start position End position Length Name 
21 SLC6A1 11034419 11080935 46517 
solute carrier family 6 (neurotransmitter transporter, GABA), 
member 1 
22 HRH1 11178778 11304939 126162 histamine receptor H1 
23 ATG7 11314009 11599139 285131 autophagy related 7 
24 VGLL4 11597543 11762220 164678 vestigial like 4 (Drosophila) 
25 TAMM41 11831918 11888352 56435 
TAM41, mitochondrial translocator assembly and maintenance 
protein, homolog (S. cerevisiae) 
26 SYN2 12045861 12233532 187672 synapsin II 
27 TIMP4 12194567 12200851 6285 TIMP metallopeptidase inhibitor 4 
28 PPARG 12329348 12475855 146508 peroxisome proliferator-activated receptor gamma 
29 TSEN2 12525930 12574820 48891 tRNA splicing endonuclease 2 homolog (S. cerevisiae) 
30 LOC100129480 12581279 12586963 5685 uncharacterized LOC100129480 
31 MKRN2 12598593 12625210 26618 makorin ring finger protein 2 
32 RAF1 12625099 12705700 80602 v-raf-1 murine leukemia viral oncogene homolog 1 
33 THUMPD3 9404716 9428475 23760 THUMP domain containing 3 
34 LOC440944 9430536 9439174 8639 uncharacterized LOC440944 
35 SETD5 9439402 9519838 80437 SET domain containing 5 
36 LHFPL4 9540044 9595486 55443 lipoma HMGIC fusion partner-like 4 
37 MTMR14 9691116 9744078 52963 myotubularin related protein 14 
38 CPNE9 9745509 9771592 26084 copine family member IX 
39 BRPF1 9773433 9789699 16267 bromodomain and PHD finger containing, 1 




Table 3.2.6 Candidate genes covered under the region of chromosome 3p25 for sample #17 (continued) 
No. Gene Symbol Start position End position Length Name 
41 CAMK1 9799028 9811668 12641 calcium/calmodulin-dependent protein kinase I 
42 TADA3 9821653 9834420 12768 transcriptional adaptor 3 
43 ARPC4 9834178 9848789 14612 actin related protein 2/3 complex, subunit 4, 20kDa 
44 ARPC4-TTLL3 9834231 9878040 43810 ARPC4-TTLL3 readthrough 
45 TTLL3 9851643 9878040 26398 tubulin tyrosine ligase-like family, member 3 
46 RPUSD3 9879532 9885702 6171 RNA pseudouridylate synthase domain containing 3 
47 CIDEC 9908393 9921938 13546 cell death-inducing DFFA-like effector c 
48 JAGN1 9932270 9936031 3762 jagunal homolog 1 (Drosophila) 
49 IL17RE 9944295 9958084 13790 interleukin 17 receptor E 
50 IL17RC 9958757 9975305 16549 interleukin 17 receptor C 
51 CRELD1 9975523 9987097 11575 cysteine-rich with EGF-like domains 1 
52 PRRT3 9987225 9994078 6854 proline-rich transmembrane protein 3 








 Sample #12 which recurred twice and progressed to a borderline 
grade harboured an amplification of chromosome 5p13.3. There were 19 
candidate genes within the amplified region of 5p13.3 (Table 3.2.7). None 
were selected for further experimentation as no satisfactory antibody was 
available commercially. 
 Lastly, chromosome 7p12 was amplified in a sample of a patient who 
experienced metastasis and subsequently died from disease (sample #16). 
Nine genes were within the amplified region (Table 3.2.8) and EGFR 
(epidermal growth factor receptor) was selected for further testing on 
fluorescence in situ hybridization (FISH) and immunohistochemistry. EGFR 
amplification was confirmed on FISH with mean copy number of 25 per 
nucleus. The ratio of EGFR/CEP 7 signals enumerated from 60 nuclei was 8.3 
(Figure 3.2.4). The sample exhibited strong EGFR staining on 







Figure 3.2.4 (A) Amplification of chromosome 7p12 was among other 
amplifications observed in sample #16 where the patient died from disease. 
(B) EGFR was overexpressed on immunohistochemistry with strong intensity 
as compared to an example of a positive case (inset). Scale bar: 200μm.  (C  
Fluorescence image showing amplification of EGFR with ratio of EGFR (red 












Table 3.2.7 Candidate genes covered under the region of chromosome 5p13.3 for sample #12 
No. Gene Symbol Start position End position Length Name 
1 CDH6 31193761 31329253 135493 cadherin 6, type 2, K-cadherin (fetal kidney) 
2 DROSHA 31400601 31532282 131682 drosha, ribonuclease type III 
3 C5orf22 31532372 31555165 22794 chromosome 5 open reading frame 22 
4 MIR4279 31936207 31936265 59 microRNA 4279 
5 PDZD2 31799030 32111038 312009 PDZ domain containing 2 
6 GOLPH3 32124823 32174425 49603 golgi phosphoprotein 3 (coat-protein) 
7 MTMR12 32227110 32313114 86005 myotubularin related protein 12 
8 ZFR 32354455 32444844 90390 zinc finger RNA binding protein 
9 SUB1 32585604 32604185 18582 SUB1 homolog (S. cerevisiae) 
10 NPR3 32710742 32791830 81089 
natriuretic peptide receptor C/guanylate cyclase C 
(atrionatriuretic peptide receptor C) 
11 LOC340113 32947548 32962573 15026 uncharacterized LOC340113 
12 TARS 33440801 33468196 27396 threonyl-tRNA synthetase 
13 ADAMTS12 33527286 33892124 364839 ADAM metallopeptidase with thrombospondin type 1 motif, 12 
14 RXFP3 33936490 33939023 2534 relaxin/insulin-like family peptide receptor 3 
15 SLC45A2 33944720 33984780 40061 solute carrier family 45, member 2 
16 AMACR 33987090 34008220 21131 alpha-methylacyl-CoA racemase 




33987090 34124633 137544 C1QTNF3-AMACR readthrough 





Table 3.2.8 Candidate genes covered under the region of chromosome 7p12 for sample #16 
No. Gene Symbol Start position End position Length Name 
1 POM121L12 53103348 53104618 1271 POM121 transmembrane nucleoporin-like 12 
2 FLJ45974 53723201 53879624 156424 uncharacterized LOC401337 
3 HPVC1 54268916 54270114 1199 human papillomavirus (type 18) E5 central sequence-like 1 
4 VSTM2A 54610018 54636948 26931 V-set and transmembrane domain containing 2A 
5 LOC285878 54624662 54639419 14758 uncharacterized LOC285878 
6 SEC61G 54819939 54826939 7001 Sec61 gamma subunit 
7 EGFR 55086724 55275031 188308 epidermal growth factor receptor 
8 LOC100507500 55247442 55256642 9201 uncharacterized LOC100507500 


















 The 152 candidate genes under the amplified regions were classified 
into different functional groups using the DAVID functional annotation 
bioinformatics tool and were found to be highly involved in regulation of 
enzymatic activity, neurological processes and circulatory system (Figure 
3.2.5).   
3.2.2.2 Homozygous deletion 
Two regions of homozygous deletions were observed – chromosome 
9p21 involving CDKN2A (cyclin-dependent kinase inhibitor 2A) and 
chromosome 20p12.1. Chromosome 9p21 deletion was observed in two 
samples - one with a local recurrence of an increased grade and the other 
with metastasis. Both samples were negative when tested with CDKN2A (or 
more commonly known as p16) antibody on immunohistochemistry (Figure 
3.2.6).  
Homozygous deletion at chromosome 20p12.1 was observed in a case 
which had lung metastasis. Deletion at this region was frequently reported 
even in non-cancer patients and could be a result of genome instability 





Figure 3.2.6 Homozygous deletion of chromosome 9p21 covering CDKN2A gene was observed in tumour #18 (A) and tumour #13 (C). 
Corresponding protein staining showed loss of expression in both tumours (B, D) Positive and negative controls as shown in between 





3.2.3 Mutations and validation with Sanger Sequencing 
None of the 541 mutation assays (Supplemental Table 2) for the 19 
samples scored above 9 points, the recommended threshold for a mutation 
to be valid. However, the threshold for BRAF V600E assay was recommended 
at 4 points. Hence, to validate the absence of mutations in other assays, 
Sanger sequencing was performed on selected assays which had score 5 and 
above (Table 3.2.9). Results from Sanger sequencing corroborated the 
negative findings on OncoScanTM mutation assay. No mutations were 





Table 3.2.9 Mutation score (threshold>5) of each mutation detected on the OncoScan™ mutation panel 
                  Tumour ID, prognosis                            
 
Mutations 






recurrence Died Metastasis Metastasis Metastasis 
 ABL1_p.M351T_c.1052T<C - - - - - -  5.29c 1 
APC_p.S1341R_c.4023T<G - - - - - -  6.11c 1 
ATM_p.Q2442P_c.7325A<C - - - - - -  5.95c 1 
ATM_p.T2666A_c7996A_G - - - 5.74 - - - 1 
BRCA1_c.134plus1G<Ta - - - - - 5.22 5.38 2 
CDKN2A_pW110X_c329G_A - - - - 6.26 5.33 - 2 
CDKN2A_c.151minus1G<Aa - - - - - 5.51 - 1 
CTNNB1_p.G34E_c.101G<A - - - - - -   5.53c 1 
EGFR_p.G598V_c.1793G<T 5.02 - - - - - 6.52 2 
EGFR_p.L858R_c.2573T<G - - - - - - 6.09 1 
FGFR3_p.K650Q_c.1948A<C - - - - - -  5.52c 1 
KIT_p.V654A_c.1961T<C  - - - - - - 6.13 1 
MEN1_c.654plus3A<G - - 5.71 - - - - 1 
NF2_p.V219M_c.655G<A - 5.49 - - - - - 1 
NOTCH1_p.Q2460X_c.7378C<T 5.23 5.30 - - - - - 2 
NPM1_p.W288 frame 
shift12_c.863insCCTGb - - - 5.67 - - - 1 
PTEN_p.I101T_c.302T<C - - - - - -  5.66c 1 
PTEN_c.1027minus2A<Ga - - - - - -  5.12c 1 




Table 3.2.9 Mutation score (threshold>5) of each mutation detected on the OncoScan™ mutation panel (continued) 
                  Tumour ID, prognosis                            
 
Mutations 






recurrence Died Metastasis Metastasis Metastasis 
 RET_p.A664D_c.1991C<A 5.59 - - - - - - 1 
SMAD4_p.E330A_c.989A<C - - - - - -  6.13c 1 
SMAD4_p.K507Q_c.1519A<C - - - - - - 7.50 1 
TGFBR2_p.R497X_c.1489C<T - 5.83 - - - - - 1 
TP53_p.H179R_c.536A<G - - 5.33 - - - 5.19 2 
TP53_p.C124R_c.370T<C - - - - - - 5.47 1 
Total mutations 3 3 2 3 1 3 15 30 
a Mutations at intronic regions 
b Insertion of four bases (CCTG) between coding sequence position 863 and 864. No good sequencing data was obtained. 













Figure 3.2.7 Polymerase chain reaction (PCR) was designed targeting the 
specific mutation region. Amplified products were sequenced and screened 
for presence of mutation. (A) Gel electrophoresis for the PCR products. (B) 
Examples of two assays with chromatograms showing targeted regions in red 









3.3 CD117 protein expression and mutation status in phyllodes tumours 
3.3.1 Characteristic of the study population 
 A total of 272 cases were screened for protein expression of CD117 on 
immunohistochemistry using tissue microarray sections. These cases 
constituted a series of consecutive cases diagnosed in the Department of 
Pathology, Singapore General Hospital from January 2003 to December 2010. 
Of the 272 cases, 189 (69.5%) were benign, 60 (22.1%) were borderline, and 
23 (8.4%) were malignant. Median age of this cohort was 43 years, ranging 
from 15 to 79 years. Tumour size range was 8-250mm with a median of 
38mm. Ethnic distribution of patients comprised 187 (68.8%) Chinese, 42 
(15.4%) Malay, 15 (5.5%) Indian and 28 (10.3%) of other ethnic origins.  
 Data from 248 patients were available for follow-up analysis, after 
discounting cases of loss to follow-up and those in whom follow-up was less 
than three months. There were 24 (10%) recurrences in this series, of which 
18 cases were local recurrences and 6 were distant recurrences. Five deaths 
were documented- one benign, two borderline, and two malignant cases. The 
benign case recurred with progression to borderline grade tumour and 
metastasis to the lung before death. One patient with borderline tumour 
died from acute pancolitis and the other patient with borderline tumour had 
lung metastasis leading to death. One malignant case had a lung metastasis 






3.3.2 Immunohistochemistry results 
 Among the 272 cases, 28 cases (10%) were positive for CD117 of 
which 9 were benign, 14 were borderline and 5 were malignant tumours. 
Example of a positive case is shown in Figure 3.3.1c. As mast cells are also 
positively indicated by CD117 (Figure 3.3.1e), toluidine blue was performed 
to identify these cells which could be a confounding factor in assessing the 
staining status of stromal cells. The percentage of positively stained stromal 
cells ranged from 1% to 5% with a mean and median percentage of 1.4% and 
1% respectively.   
 CD117 positivity was significantly associated with 
borderline/malignant tumours (p<0.001). Also, a significant association was 
observed with larger tumour size, increased cellularity, atypia, number of 
mitoses, permeative tumour margins, and presence of haemorrhage (Table 
3.3.1). A trend of shorter time to recurrence was observed in tumours which 
expressed CD117 compared to tumours which did not express CD117 (Figure 
3.3.2). In addition, patients with CD117-positive tumours had a worse overall 






Figure 3.3.1 CD117 immunostaining and toluidine blue staining. (a) CD117 
positive control. (b) CD117 negative control. (c, d) Example of a CD117-
positive phyllodes tumour with the corresponding negative toluidine blue 
staining. Positive control with a purple metachromatic appearance of a mast 
cell is shown on the top right inset. (e, f) Mast cells which are positive for 
both CD117 and toluidine blue staining are excluded from the assessment in 





Table 3.3.1 Clinicopathological characteristics of phyllodes tumours in 








Age (mean 43 years, median 43 years,  range 15‒79) 
  ≤4  years 124 (90.5) 13 (9.5)  
  > 43 years 120 (88.9) 15 (11.1) 0.694 
Tumour Size (mean 51mm, median 38mm, range 8‒250mm) 
  ≤51 mm 175 (93.1) 13 (6.9)  
  >51 mm   69 (82.1) 15 (17.9) 0.009a 
Tumour grade    
  Benign 180 (95.2)   9 (4.8)  
  Borderline   46 (76.7) 14 (23.3)  
  Malignant   18 (78.3)   5 (21.7) <0.001a 
Stromal Hypercellularity    
  Mild 142 (95.3)   7 (4.7)  
  Moderate   87 (82.1) 19 (17.9)  
  Marked   15 (88.2)   2 (11.8) 0.003a 
Stromal Atypia    
  Mild 207 (92.0) 18 (8.0)  
  Moderate    31 (81.6)   7 (18.4)  
  Marked      6 (66.7)   3 (33.3) 0.01a 
Stromal Mitosis    
  0-4 181 (94.8) 10 (5.2)  
  5-9   39 (84.8)   7 (15.2)   
  >9   24 (68.6) 11 (31.4) <0.001a 
Stromal Overgrowth    
  No 218 (91.2) 21 (8.8) 0.059 
  Yes    26 (78.8)   7 (21.2)  
Microscopic Margin    
  Circumscribed 192 (93.2) 14 (6.8)  
  Permeative   52 (78.8) 14 (21.2) 0.002a 
Necrosis    
  Absent 217 (91.2) 21 (8.8)  
  Present   27 (79.4)   7 (20.6) 0.062 
Haemorrhage    
  Absent 152 (95.0)   8 (5.0)  
  Present   92 (82.1) 20 (17.9) 0.001a 












Figure 3.3.3 Patients with CD117-positive tumours had a worse overall 





3.3.3 Mutational analysis for CD117/KIT 
 Results from section 3.2.3 were analyzed further with a focus on the 
KIT gene. A total of 17 commonly reported mutations including the tyrosine 
kinase domains of exons 11, 13 and 17 were found in the panel of 
OncoScan™ FFPE assay (Table  . .2 . The corresponding 
immunohistochemistry statuses of the 19 cases which did not harbour these 
mutations are shown in Table 3.3.3.  
 
Table 3.3.2 17 commonly reported KIT mutations included in the OncoScan™ 
assay 
No. KIT mutations Exon number 
1 D52N 2 
2 Y503_F504ins 9 
3 W557R 11 
4 V559A 11 
5 V560D 11 
6 L576P 11 
7 F584S 11 
8 P585P 11 
9 K642E 13 
10 V654A 13 
11 T670I 13 
12 I798I 13 
13 D816Y 17 
14 N822K 17 
15 Y823D 17 
16 V825A 17 






Table 3.3.3 Staining status of KIT protein in the 19 cases interrogated on the 






1 Benign 40-60 Negative 
2 Benign 15-85 Positive 
3 Benign 35-75 Negative 
4 Benign 40-60 Negative 
5 Benign 30-70 Negative 
6 Borderline 15-85 Positive 
7 Borderline 20-80 Negative 
8 Borderline 50-50 Positive 
9 Borderline 30-70 Positive 
10 Borderline 10-90 Negative 
12 Benign 20-80 Negative 
13 Benign 20-80 Positive 
14 Borderline 20-80 Negative 
15 Borderline 10-90 Positive 
16 Malignant 0-100 Negative 
17 Malignant 1-99 Positive 
18 Malignant 5-95 Negative 
19 Malignant 0-100 Negative 





3.4 Immunohistochemical expression of homeoproteins Six1 and Pax3 in           
phyllodes tumours 
 
 The rationale for investigating protein expression of Six1 and Pax3 in 
phyllodes tumours was to extend the findings of a collaborative project which 
found that Six1 and Pax3 was overexpressed in borderline/malignant 
phyllodes tumours at the transcript level [Jones et al., 2008b]. It is of interest 
to corroborate the findings with expression at the protein level. The study 
population as described in Section 3.3 and the corresponding tissue 
microarrays were employed for this study to investigate protein expression of 
Six1 and Pax3 by immunohistochemistry. As these are transcription factors, 
expression in both nucleus and cytoplasm was assessed. Also, epithelial and 
stromal expression was determined separately to identify distinct expression 
between the two components. 
 
3.4.1 Six1 expression  
 Analysis was available in 270 cases after discounting loss of cores due 
to processing. Nine cases were without epithelial component and excluded 
from the epithelial analysis. Mean expression quantified as H-score stratified 
according to tumour grades and localization are shown in Figure 3.4.1. In the 
stromal component, Six1 expression was significantly associated with 
increasing tumour grade but this trend was observed only with cytoplasmic 
expression as illustrated in Figure 3.4.1. Conversely in the epithelial 





was associated with increasing tumour grade and this was exhibited in the 
nucleus instead of cytoplasm as seen in the stromal component. 
 For analysis with clinicopathological parameters, H-score was 
classified into low and high expression using the overall mean, 63 points, as 
threshold. High expression was defined as H-score exceeding 63 points while 
low expression was defined with 63 points and below. In the stromal 
component, high cytoplasmic expression was associated with larger tumour 
size, higher cellularity, atypia and mitoses, stromal overgrowth, permeative 
microscopic margins and haemorrhage (Table 3.4.1). Stromal nuclear 














Table 3.4.1 Associations between clinicopathological parameters and stromal 
expression of Six1 
Clinicopathological 
parameters 
Six1 expression in stromal 
nuclei 
















Age (mean 43 years, median 43 years,  range 15‒79)   
  ≤4  years 75 (50.3) 62 (51.2)   62 (48.1) 62 (44.0)  
  >43 years 74 (49.7) 59 (48.8) 0.903  67 (51.9) 79 (56.0) 0.542 
Tumour Size (mean 51mm, median 38mm, range 8‒250mm)   
  ≤5  mm 100 (67.1) 87 (71.9)   98 (76.0) 89 (63.1)  
  >51 mm   49 (32.9) 34 (28.1) 0.428  31 (24.0) 52 (36.9) 0.025a 
Tumour Grade        
  Benign 103 (69.1) 85 (70.2)   104 (80.6) 84 (59.6)  
  Borderline   29 (19.5) 30 (24.8)     22 (17.1) 37 (26.2)  
  Malignant   17 (11.4)   6 (5.0) 0.126    2  (2.3) 20 (14.2) <0.001a 
Stromal Hypercellularity       
  Mild 84 (56.4) 65 (53.7)   83 (64.3) 66 (46.8)  
  Moderate 55 (36.9) 50 (41.3)   39 (30.2) 66 (46.8)  
  Marked 10 (6.7)   6 (5.0) 0.682  7 (5.4) 9 (6.4) 0.013a 
Stromal Atypia        
  Mild 121 (81.2) 102 (84.3)   118 (91.5) 105 (74.5)  
  Moderate   20 (13.4)   18 (14.9)   8  (6.2)   30 (21.3)  
  Marked     8 (5.4)     1 (0.8) 0.116  3  (2.3)     6  (4.3) 0.001a 
Stromal Mitosis        
  0-4 103 (69.1) 87 (71.9)   105 (81.4) 85 (60.3)  
  5-9   25 (16.8) 20 (16.5)   16 (12.4) 29 (20.6)  
  >9   21 (14.1) 14 (11.6) 0.817  8  (6.2) 27 (19.1) <0.001a 
Stromal Overgrowth       
  Absent 129 (86.6 108 (89.3)   123 (95.3) 114 (80.9)  
  Present   20 (13.4)   13 (10.7) 0.577  6  (4.7)   27 (19.1) <0.001a 
Microscopic Margins       
  Circumscribed 113 (75.8) 92 (76.0)   109 (84.5) 96 (68.1)  
  Permeative   36 (24.2) 29 (24.0) 1.000  20 (15.5) 45 (31.9) 0.002a 
Necrosis        
  Absent 127 (85.2) 109 (90.1)   117 (90.7)  119 (84.4)   
  Present   22 (14.8)   12 (9.9) 0.271     12 (9.3)    22 (15.6)  0.143 
Haemorrhage        
  Absent 88 (59.1) 72 (59.5)     87 (67.4)    73 (51.8)   
  Present  61 (40.9) 49 (40.5) 1.000    42 (32.6)    68 (48.2)  0.009a 





Figure 3.4.1 Six1 expression in the stroma and epithelium of phyllodes tumours. (A) Expression of Six1 in the stromal cytoplasm 
increases with tumour grade. Scale bar:  00μm. (B  Bar charts of mean H-score stratified according to localization of staining. Error 








  In the epithelial component, high nuclear expression was associated 
with smaller tumour size and circumscribed tumour margin while high 
cytoplasmic expression was associated with circumscribed tumour margin 
only (Table 3.4.2).  
Table 3.4.2 Associations between clinicopathological parameters and epithelial 
expression of Six1 
Clinicopathological 
parameters 
Six1 expression in epithelial 
nuclei 














Age (mean 43 years, median 43 years,  range 
15‒79) 
    
  ≤4  years 87 (47.3) 34 (44.2)   69 (53.9) 65 (48.9)  
  >43 years 97 (52.7) 43 (55.8) 0.684  59 (46.1) 68 (51.1) 0.458 
Tumour Size (mean 51mm, median 38mm, range 8‒250mm)   
  ≤5 mm 120 (65.2) 65 (84.4)   89 (69.5) 96 (72.2)  
  >51mm   64 (34.8) 12 (15.6) 0.002a  39 (30.5) 37 (27.8) 0.684 
Tumour Grade        
  Benign 125 (67.9) 63 (81.8)   85 (66.4) 103 (77.4)  
  Borderline   45 (24.5) 13 (16.9)   34 (26.6) 24 (18.0)  
  Malignant 14  (7.6) 1  (1.3) 0.037a      9 (7.0)     6 (4.5) 0.139 
Stromal Hypercellularity       
  Mild 101 (54.9) 48 (62.3)   71 (55.5) 78 (58.6)  
  Moderate   72 (39.1) 27 (35.1)   52 (40.6) 47 (35.3)  
  Marked 11  (6.0) 2 (2.6) 0.366    5 (3.9)   8 (6.0) 0.555 
Stromal Atypia        
  Mild 152 (82.6)   69 (89.6)   104 (81.3) 117 (88.0)  
  Moderate   28 (15.2)     8 (10.4)     22 (17.2)   14 (10.5)  
  Marked    4  (2.2) 0  (0) 0.234      2 (1.6)     2 (1.5) 0.294 
Stromal Mitosis        
  0-4 130 (70.7) 60 (77.9)   87 (68.0) 103 (77.4)  
  5-9   35 (19.0) 10 (13.0)   26 (20.3)   19 (14.3)  
  >9   19 (10.3)   7 (9.1) 0.444  15 (11.7)   11 (8.3) 0.228 
Stromal Overgrowth       
  Absent 166 (90.2) 71 (92.2)   115 (89.8) 122 (91.7)  
  Present 18  (9.8)   6 (7.8) 0.815    13 (10.2)   11 (8.3) 0.671 
Microscopic Margins       
  Circumscribed 136 (73.9) 68 (88.3)   93 (72.7) 111 (83.5)  
  Permeative   48 (26.1)   9 (11.7) 0.013a  35 (27.3)   22 (16.5) 0.037a 
Necrosis        
  Absent 162 (88.0)    71 (92.2)    110 (85.9) 123 (92.5)  
  Present   22 (12.0)     6  (7.8)  0.386     18 (14.1)   10 (7.5) 0.110 
Haemorrhage        
  Absent 105 (57.1)    54 (70.1)    77 (60.2) 82 (61.7)  
  Present    79 (42.9)    23 (29.9)  0.053  51 (39.8) 51 (38.3) 0.899 





 Among the 18 cases with local recurrences, 11 (61.1%) expressed high 
Six1 stromal cytoplasmic expression. All 6 cases with distant recurrences also 
expressed high Six1 stromal cytoplasmic expression. Patients with tumours 
expressing high stromal cytoplasmic Six1 or low epithelial nuclear Six1 
expression was found to have a shorter time to recurrence with Kaplan Meier 
survival analysis, although only the latter was significant statistically (Figure 
3.4.2). However, tumours with both high stromal and low epithelial 
expression did not exhibit significant differences in recurrence-free survival 
as compared with those which had either high stromal expression or low 
epithelial expression (p=0.136, results not shown). Analysis of overall survival 
returned no significant differences in prognoses between patients with high 
Six1 versus low Six1 expressing tumours.  
 
3.4.2 Pax3 expression 
 Analysis was available for 271 cases with 268 cases containing an 
epithelial component. Overall mean and median H-scores were 14 and 10 
respectively, ranging from 0 to 80 points. Similar to what was observed for 
Six1 expression, tumour grade was positively associated with expression of 
Pax3 in the stromal cytoplasm but not in the stromal nucleus as illustrated in 
Figure 3.4.3. Also, the expression in the epithelial nucleus was inversely 
correlated with tumour grade, a similar trend observed in Six1 expression. 
 For analysis of Pax3 expression in association with clinicopathological 
parameters, mean H-score of 14 was employed as a threshold to define low 






Figure 3.4.2 Kaplan Meier survival curves demonstrating differences in 
recurrence-free survival between tumours expressing high Six1 and low Six1 in 
(A) stromal nucleus; (B) stromal cytoplasm; (C) epithelial nucleus; (D) 
epithelial cytoplasm. A trend of shorter recurrence-free survival was observed 









Figure 3.4.3 Pax3 expression in the stroma and epithelium of phyllodes tumours. (A) Expression of Pax3 in the stromal cytoplasm increases 
across tumour grade but the trend is not seen in the stromal nucleus. Scale bar:  00μm. (B  Bar charts of mean H-score stratified according to 
localization of staining for Pax3 expression. Error bars represent 95% confidence interval. Expression in stromal cytoplasm and epithelial nuclei 






 In the stromal component, high cytoplasmic expression was 
associated with stromal overgrowth, permeative microscopic margins, 
presence of necrosis and haemorrhage. Expression in the nucleus was not 
significantly associated with any clinicopathological parameters (Table 3.4.3).  
 In the epithelium, nuclear expression of Pax3 was significantly 
associated with stromal overgrowth only (Table 3.4.4). However, when H-
score was analyzed as a continuous variable using ANOVA test, higher 
epithelial nuclear expression was associated with mild stromal atypia 
(p=0.008), lower stromal mitoses (p=0.03), absence of necrosis (p=0.011) and 
haemorrhage (p=0.025). No significant association was observed with 
epithelial cytoplasmic expression. 
 Pax3 expression was not associated with recurrence-free survival 
regardless of localization. Nonetheless, patients with tumours exhibiting high 












Table 3.4.3 Associations between clinicopathological parameters and stromal 
expression of Pax3 
Clinicopathological 
parameters 
Pax3 expression in stromal 
nucleus 













Age (mean 43 years, median 43 years,  range 15‒79)     
  ≤4  years 43 (46.2) 94 (52.8)   85 (47.2) 39 (42.9)  
  >43 years 50 (53.8) 84 (47.2) 0.310  95 (52.8) 52 (57.1) 0.521 
Tumour Size (mean 51mm, median 38mm, range 8‒250mm)   
  ≤5  mm 61 (65.6) 127 (71.3)   130 (72.2) 58 (63.7)  
  >51 mm 32 (34.4)   51 (28.7) 0.335  50 (27.8) 33 (36.3) 0.165 
Tumour Grade        
  Benign 65 (69.9) 124 (69.7)   136 (75.6) 53 (58.2)  
  Borderline 20 (21.5)   39 (21.9)     33 (18.3) 26 (28.6)  
  Malignant   8 (8.6)   12 (8.4) 0.996  11  (6.1) 12 (13.2) 0.011a 
Stromal Hypercellularity       
  Mild 51 (54.8) 98 (55.1)   101 (56.1) 48 (52.7)  
  Moderate 34 (36.6) 72 (40.4)   69 (38.3) 37 (40.7)  
  Marked   8 (8.6)   8 (4.5) 0.371  10  (5.6) 6  (6.6) 0.853 
Stromal Atypia        
  Mild 79 (84.9) 145 (81.5)   151(91.5) 73 (80.2)  
  Moderate 10 (10.8)   28 (15.7)   24 (13.3) 14 (15.4)  
  Marked   4 (4.3)     5 (2.8) 0.454  5  (2.8) 4  (4.4) 0.685 
Stromal Mitosis        
  0-4 67 (72.0) 124 (69.7)   132 (73.3) 59 (64.8)  
  5-9 16 (17.2)   29 (16.3)   28 (15.6) 17 (18.7)  
  >9 10 (10.8)   25 (14.0) 0.744  20 (11.1) 15 (16.5) 0.313 
Stromal Overgrowth       
  Absent 82 (88.2) 156 (87.6)   168 (93.3) 70 (76.9)  
  Present 11 (11.8)   22 (12.4) 1.000  12  (6.7) 21 (23.1) <0.001a 
Microscopic Margins       
  Circumscribed 70 (75.3) 136 (76.4)   146 (81.1) 60 (65.9)  
  Permeative 23 (24.7)   42 (23.6) 1.000  34 (18.9) 31 (34.1) 0.007a 
Necrosis        
  Absent 79 (84.9) 158 (88.8)   164 (91.1)    73 (80.2)   
  Present 14 (15.1)   20 (11.2) 0.440    16  (8.9)    18 (19.8)  0.018a  
Haemorrhage        
  Absent 56 (60.2) 104 (58.4)   114 (63.3)    46 (50.5)   
  Present  37 (39.8)   74 (41.6) 0.796    66 (36.7)    45 (49.5)  0.05a  




Table 3.4.4 Associations between clinicopathological parameters and epithelial expression 
of Pax3 localized to nuclei and cytoplasm respectively 
Clinicopathological 
parameters 
Pax3 expression in epithelial nuclei 














Age (mean 43 years, median 43 years,  range 15‒79)     
  ≤4  years 60 (42.6) 63 (49.6)   109 (49.3) 27 (57.4)  
  >43 years 81 (57.4) 64 (50.4) 0.270  112 (50.7) 20 (42.6) 0.338 
Tumour Size (mean 51mm, median 38mm, range 8‒250mm)   
  ≤5 mm   97 (68.8) 91 (71.7)   157 (71.0) 31 (66.0)  
  >51mm   44 (31.2) 36 (28.3) 0.689    64 (29.0) 16 (34.0) 0.487 
Tumour Grade        
  Benign 91 (64.5) 98 (77.2)   155 (70.1) 34 (72.3)  
  Borderline 37 (26.2) 22 (17.3)     49 (22.2) 10 (21.3)  
  Malignant 13   (9.2)   7 (5.5) 0.076    17 (7.7)   3 (6.4) 0.937 
Stromal Hypercellularity       
  Mild   73 (51.8) 76 (59.8)   122 (55.2) 27 (57.4)  
  Moderate   59 (41.8) 46 (36.2)     89 (40.3) 16 (34.0)  
  Marked    9  (6.4)  5  (3.9) 0.352    10 (4.5)   4 (8.5) 0.450 
Stromal Atypia        
  Mild 111 (78.7) 113 (89.0)   182 (82.4) 42 (89.4)  
  Moderate   25 (17.7)  12  (9.4)     33 (14.9)   4 (8.5)  
  Marked    5  (3.5)    2  (1.6) 0.076      6 (2.7)   1 (2.1) 0.488 
Stromal Mitosis        
  0-4   93 (66.0) 98 (77.2)   156 (70.6) 35 (74.5)  
  5-9   29 (20.6) 16 (12.6)     36 (16.3)   9 (19.1)  
  >9  19 (13.5) 13 (10.2) 0.117    29 (13.1)   3 (6.4) 0.418 
Stromal Overgrowth       
  Absent 119 (84.4) 119 (93.7)   195 (88.2) 43 (91.5)  
  Present    22 (15.6)     8  (6.3) 0.019a    26 (11.8)   4 (8.5) 0.620 
Microscopic Margins       
  Circumscribed 107 (75.9) 99 (78.0)   172 (77.8) 34 (72.3)  
  Permeative   34 (24.1) 28 (22.0) 0.772    49 (22.2) 13 (27.7) 0.448 
Necrosis        
  Absent 120 (85.1)  117 (92.1)    196 (88.7) 41 (87.2)  
  Present    21 (14.9)    10 (7.9)  0.086     25 (11.3)   6 (12.8) 0.802 
Haemorrhage        
  Absent 107 (75.9)    99 (78.0)    131 (59.3) 29 (61.7)  
  Present    34 (24.1)    28 (22.0)  0.772     90 (40.7) 18 (38.3) 0.870 









Figure 3.4.4 Kaplan Meier survival analysis showing patients with tumours 
expressing high stromal cytoplasmic Pax3 had a poorer overall survival. 
3.4.3 Combinational analysis of Six1 and Pax3 
 For this purpose, only the expression in the stromal cytoplasm was 
analyzed as it associated significantly with tumour grade and 
clinicopathological parameters among all other localizations. Six1 expression 
was found to be associated positively with Pax  (Spearman’s ρ= 0.45 , p-
value<0.001), whereby a high Six1 stromal expression was observed with high 
stromal Pax3 expression (Figure 3.4.5) 
 When the two markers were analyzed in combination, tumours with 
low expression of both Six1 and Pax3 were found to have a better 
recurrence-free survival compared to tumours exhibiting either high 






Figure 3.4.5 Scatterplot illustrating a positive correlation (Spearman’s ρ= 
0.458, p-value<0.001) between Six1 stromal cytoplasmic expression and Pax3 
stromal cytoplasmic expression measured in H-score.  
 
 
Figure 3.4.6 Kaplan Meier survival analysis illustrating patients with tumours 
exhibiting low expression of both Six1 and Pax3 had a better recurrence-free 
survival than patients with tumours exhibiting high expression of either 






4.1  Nomogram as a prognostic and predictive tool for phyllodes tumour 
patients 
 
 A nomogram is fundamentally a graphical calculation instrument 
which can be based on any type of statistical function such as linear 
regression or Cox regression models [Shariat et al., 2009]. In medicine, 
nomograms are typically used as clinical prognostic and predictive models. 
They currently represent the most accurate tool for predicting outcomes in 
cancer patients with reported superior performance over other predictive 
tools such as risk-grouping, look-up tables, tree analysis and artificial neural 
network [Shariat et al., 2009]. Nomograms are gaining popularity among 
clinicians especially those made available with a user-friendly interface and 
accessible via internet such as the MSKCC (Memorial Sloan Kettering Cancer 
Center) prostate cancer nomogram and the Karakiewicz nomogram for 
predicting survival in patients with renal cell carcinoma.  
 While many studies have described important prognostic factors in 
phyllodes tumour, none have translated the findings into such an application. 
As phyllodes tumours are uncommon, the lack of sufficient events and a 
small study cohort might have impeded the success of such a statistical 
modelling method. The large cohort size of this study made modelling viable 
with adequate events and long follow-up data. Moreover, the relatively 
homogenous patient cohort is managed in a uniform manner within a single 





institutional medical records and information from the National Registry of 
Births and Deaths reduces possible inaccuracy.  
 The development of this nomogram for patients with phyllodes 
tumours allows discussions of management strategies for the individual 
patient, eliminating generalization based solely on histological grade. The 
permutations of integrating the assessment of stromal atypia, mitoses, 
cellularity, overgrowth and nature of microscopic margins to derive a grade 
render variability, leading to difficulties in accurately predicting behaviour. 
Nonetheless, it is not advocated that the grading of phyllodes tumours should 
be replaced as histological grade reflects the biology of the tumour, as 
evidenced by its significant association with recurrence free survival. 
Moreover, utility of grade enables comparison across studies as it is the most 
widely used form of diagnostic assessment [Spitaleri, 2013].  
  The final nomogram incorporated three histological criteria (stromal 
atypia, mitoses and overgrowth) and surgical margins, simply referred to as 
the AMOS criteria. Stromal cellularity and nature of microscopic margins are 
excluded in the model because they are not independently associated with 
recurrence in the multivariate analysis. Even in cases with negative surgical 
margins, the nature of microscopic borders was not predictive of recurrence 
free survival. Surgical margins are frequently reported to be significantly 
associated with recurrence in previous studies [Pandey et al., 2001; Asoglu et 





findings which showed that having a positive surgical margin greatly 
increases the risk of recurrence. 
 The performance of the nomogram is superior to that of the total 
histological score derived arbitrarily based on a linear additive effect. This 
reflects the complexity of the biological impact of each parameter affecting 
tumour behaviour, which could not be simplified with a linear additive scale. 
Each parameter has a certain weight as to how much it affects recurrence 
free survival and is accounted for in the nomogram. The nomogram has a 
good discriminating ability with a concordance index of 0.79 and high 
calibration accuracy with small deviation at 1 year, 3 years, 5 years and 10 
years. However, a similar issue faced by all nomograms is whether the 
performance of the nomogram could be extrapolated to be applied in an 
external cohort and in a different population. Recently, a Japanese group 
validated the utility of this nomogram by demonstrating the ability of the 
nomogram in predicting recurrence-free survival for patients with phyllodes 
tumours albeit in a small cohort of 43 patients [Nishimura et al., 2014].    
 Compared to other nomograms developed, the relatively small 
number of events is a limitation of the study. The rare occurrence coupled 
with the innate biology of the tumour is a common challenge faced by many 
researchers investigating phyllodes tumours. Nonetheless, the recurrence 
rate of this series (13.2%) corroborates the reported rates of recurrence in 
the literature, largely ranging from 10% to 20% [Spitaleri et al., 2013]. 





point of the disease, previous reports have shown that local recurrences 
precede distant metastases which could cause demise except tumours which 
are primarily diagnosed as malignant grade tumours as they can metastasize 
or lead to death without local recurrence [Tan et al., 2005a]. Besides, 
recurrence often leads to subsequent treatment that could instil 
psychological distress and affect quality of life. Hence, probability of 
recurrences would be a valuable piece of information for patients to know 
even if it does not reflect the endpoint of the disease [Kattan, 2008].  
4.2 Genome-wide copy number and mutational analysis 
 The aims and design of this study differed slightly from those 
investigated previously. Instead of identifying differences between tumour 
grades, this study aims to elucidate differences between prognostically 
distinct tumours. Hence, tumours were stratified according to clinical 
outcome instead of traditional tumour grade (benign, borderline and 
malignant) as recurrences could occur regardless of grade. Although such 
stratification leads to an imbalance in representation of histological grades in 
the two groups, as it was within expectation to find more benign tumours in 
the non-recurrent group and malignant tumours in the recurrent/metastasis 
group, it is not the aim of this present study to perform a molecular profile of 
tumours according to grade, but to identify apparent candidate gene(s) which 
could possibly drive malignant clinical behaviour. The other aspect of this 
study was to identify distinct changes between the epithelium and stroma of 





was unsuccessful due to insufficient yield of genomic DNA from the 
microdissected samples. The whole section samples nonetheless, had 95% 
success rate (19/20 tumours) of being analyzed. High throughput screening 
on FFPE materials are challenging as the quality of DNA is often compromised. 
Hence, the high success rate of this technology is advantageous particularly 
for rare tumours such as the phyllodes tumours as fresh frozen tissues are 
difficult to obtain. 
 Local recurrences were grouped together with those experiencing 
metastasis and death in this study. Again, some may argue that local 
recurrences may not truly reflect the disease endpoint and may be 
confounded by inadequate surgical margins. However, local recurrences are 
clinically relevant as tumours which recur locally may progress in grade. 
Moreover, local recurrences usually precede distant metastases that 
eventually lead to demise [Tan et al., 2005a]. It is further exemplified in this 
study that the exclusive presence of high-level amplification and homozygous 
deletions in cases which recurred, including those that recurred locally, 
showed that these aberrations were not limited only to cases which 
metastasized but can also be discovered in benign tumours that recur locally. 
Although it is true that surgical margin involvement is a key factor for 
recurrences as shown in the previous section of this study, it is believed that 
the underlying biology also plays an important role, since there are many 
benign tumours do not recur locally despite involvement of surgical margins. 
In the 19 cases which were interrogated successfully in this study, surgical 





distinct groups. It may be argued that it is uncertain if recurrence-free 
tumours will truly be free from recurrence given a longer follow-up, but the 
results from the previous section indicated that recurrences in breast 
phyllodes tumours occurred at a median duration of 24.6 months, a period 
encompassed in the follow-up of the cases evaluated.  
 One recurrent molecular aberration in phyllodes tumours is gain of 
chromosome 1q.  Gain of 1q was reported to be associated with 
borderline/malignant grade [Laé et al., 2007; Jones et al., 2008a; Ang et al., 
2011] and recurrence [Lu et al., 1997]. However, chromosome 1q is a large 
region encompassing numerous known and unknown genes. Jones et al. 
correlated findings of the 1q gain with expression data and found that genes 
set at region 1q25 showed the most significant association with copy number 
data [Jones et al., 2008a]. Also reported by the authors is the gain of 1q21.1, 
a similar region found in this study to be the most frequent aberration found 
among the 19 tumours. The function of the genes located within this region is 
largely unknown. However, it was previously reported that the chromosome 
region of 1q21.1 encompasses many of the NBPF (neuroblastoma breakpoint 
family) genes and its gain was associated with neuroblastoma [Diskin et al., 
2009]. 
  While chromosomal aberrations are important in giving an aerial view 
of alterations harboured by tumours, it is difficult to identify specific target 
gene(s) which confer(s) growth and survival advantage to the tumours within 





case of amplifications, homozygous deletions and chromosome translocation 
[Vogelstein et al., 2013]. Such findings reported in phyllodes tumours 
hitherto are limited. Some of the few specific target genes previously 
identified in phyllodes tumours include EGFR, MYC, MDM2 and CDKN2A [Laé 
et al., 2007; Sawyer et al., 2003; Kersting et al., 2006; Tse et al., 2009]. In this 
present study, four regions of amplifications (1q32.1, 3p25, 5p13.3, 7p12) 
were identified as shown in section 3.2.2.1 with one specific target gene 
(EGFR) isolated and confirmed on FISH and immunohistochemistry. EGFR 
amplification was previously reported by Kersting et al. and Tse et al. in 
isolated cases. Agelopoulos et al. further demonstrated that EGFR 
amplification in phyllodes tumours is associated with 230 differentially 
expressed genes [Agelopoulos et al., 2007], notably with CAV1 (Caveolin 1) 
and EPS15 (epidermal growth factor receptor pathway substrate 15). Three 
other amplified regions in this study have no target genes isolated, however 
the functional annotation analysis revealed that genes covered within the 
amplified region are highly involved in regulation of enzymatic activity, 
suggesting the exploitation of such pathways for tumour survival and 
migration.  
Two regions of homozygous deletions were observed in this study - 
chromosome 9p21 involving CDKN2A (cyclin-dependent kinase inhibitor 2A) 
and chromosome 20p12.1. Cases with homozygous deletion at 9p21 
concurred with loss of protein expression of CDKN2A (better known as p16). 





expression was associated with interstitial deletion of 9p21 involving the 
CDKN2A region in malignant tumours. Interestingly, even in malignant 
tumours which did not harbour this deletion, CDKN2A methylation was 
observed, suggesting the importance of its downregulation in malignant 
progression [Jones et al., 2008a]. On the contrary, Karim et al. observed that 
p16 protein expression was elevated with increasing tumour grade with no 
molecular information available [Karim et al., 2010]. The homozygous 
deletion at chromosome 20p12.1 was reported to be one of the hotspots of 
large rare deletions in human genome [Bradley et al., 2010]. It is found in 
non-cancer patients and could arise due to genome instability. It is however 
unclear whether this will result in susceptibility towards cancer as deletions 
at this region are also noted in colorectal cancer [Davison et al., 2005] and 
gastric cancer cell lines [Tada et al., 2010].    
 Yet another key genomic alteration in tumours is represented by 
somatic mutations, acquired and accumulated over the lifetime of the cancer 
patient [Stratton et al., 2009]. It is important to identify somatic mutations as 
they confer selective growth advantage to cancer cells, enabling them to 
outgrow normal cells and evade cell death. From a clinical point of view, 
knowing the specific mutations allows targeted therapy to be administered 
such as imatinib and gefitinib targeting selective c-kit [Heinrich et al., 2003] 
and EGFR-mutant cells respectively [Paez et al., 2004]. Mutational analyses 
previously performed in phyllodes tumours have presented with inconsistent 





FBX4 (an E3 ubiquitin ligase) gene to be present in 11.5% of tumours after 
screening 321 mutations across 30 genes [Korcheva et al., 2011]. Jones et al. 
found a missense mutation P48L in the CDKN2A gene in a malignant 
phyllodes tumour after screening 35 tumours [Jones et al., 2008a]. Some 
authors have reported the presence of TP53 mutations in isolated cases of 
malignant tumours [Kuenen-Boumeester et al., 1999; Gatalica et al., 2001] 
but others have found none [Woolley et al., 2000; Korcheva et al., 2011]. In 
this current study, no mutation was found after screening for 541 mutation 
hotspots of 59 genes including oncogenes and tumour suppressor genes such 
as ABL1, BRAF, BRCA1, CDKN2A, EGFR, ERBB2, KIT, KRAS, PTEN, RB1 and TP53. 
This implies that the genomic landscape of the phyllodes tumours may differ 
from that of the common carcinoma which usually harbours these mutations 
and need to be explored as such.  
 In summary for this section of the study, higher chromosomal 
aberrations were observed in phyllodes tumours which 
recurred/metastasized with amplifications and homozygous deletions 
identified exclusively in this group. Regions of amplifications at 1q32.1, 
5p13.3, 3p25 and homozygous deletions at 20p12.1 were previously not 
reported in phyllodes tumours. Moreover, no mutation has been identified. 
Limitations of this study are the small sample size and its retrospective nature. 
Nonetheless, the findings warrant expansion to future investigations to 
identify driver genes which would be useful to elucidate possible pathways 





4.3 CD117 protein expression and mutation status in phyllodes tumours 
The mutation panel in this study included frequently reported CD117 
mutations of exons 9, 11, 13 and 17. As described in the previous section, no 
mutation was observed in these hotspots. This concurs with findings reported 
by Jung et al. who found no mutations in exons 9, 11, 13 and 17 in a subset of 
28 samples [Jung et al., 2010]. Djordjevic and Hanna also found no mutations 
in two cases of CD117 positive tumours [Djordjevic and Hanna, 2008]. Other 
reports found no activating mutations but discovered a silent mutation of 
isoleucine 798 (exon 17) [Carvalho et al., 2004; Bose et al., 2010] and a point 
mutation of L510M (exon 10) of unknown significance [Sawyer et al., 2003]. It 
was also observed in this study that CD117 protein expression did not 
correlate with mutation status. Although none of the cases had mutations, 37% 
of the 19 tumours expressed CD117 at the protein level. The high percentage 
of CD117-positive tumours prompted further investigation on a larger series 
of 272 cases, of which the percentage of CD117-positive tumours reduces to 
10%. This was rationalized when the findings of the larger series showed that 
the CD117 expression was associated with borderline/malignant tumours. 
The percentage of borderline/malignant tumours was relatively higher in the 
smaller series of 19 tumours (63%) compared to the larger series (30%). 
 In addition to association with borderline/malignant grade, CD117 
expression was also associated with unfavourable outcome. Patients with 
CD117-positive tumours had a significantly poorer survival outcome. A trend 





despite not significant statistically. This concurs with observations reported 
by Tan et al. and Jung et al. where CD117 expression was correlated with 
recurrence [Tan et al., 2008b; Jung et al., 2010]. On the contrary, Tse et al. 
and Esposito et al. observed no associations in their study of 179 and 16 
cases respectively [Tse et al., 2004; Esposito et al., 2006]. In other CD117-
expressing tumours, multivariate analyses showed that CD117 expression 
was an independent prognostic marker for oesophageal squamous cell 
carcinoma patients [Fan et al., 2013]. Multivariate analysis for this section of 
study is not feasible due to the low number of events documented. With the 
low number of events, the accuracy, precision and significance of the 
coefficients estimated by the analysis will become unreliable [Peduzzi et al., 
1995].  Nonetheless, it is worthwhile to note the implication of a poorer 
clinical outcome of CD117 expressing tumours despite the limitation of a 
small number of events documented, suggesting an underlying aggressive 
nature of these tumours.   
 The inconsistent findings of CD117 protein expression from various 
groups could be attributed to usage of different antibodies, staining protocols 
and scoring criteria. Standardization of protocols between laboratories is 
challenging and there is no universal consensus as to which staining protocol 
and scoring criteria are the best. Hence, these protocols need to be 
optimized and validated accordingly in respective laboratories [Loughrey et 
al., 2006]. The antibody Dako A4502 employed in this study is validated for 





sensitivity and specificity across different tumours [Went, 2004; Lucas et al., 
2003]. Furthermore, the staining protocol was complemented with toluidine 
blue staining to exclude possibly confounding contribution of mast cells, as 
previously suggested by Djodjervic and Hanna that the expression of CD117 
in phyllodes tumours observed by other authors might have just been a mast 
cell phenomenon [Djordjevic and Hanna, 2008]. All cases initially defined to 
be CD117 positive were negative on toluidine blue, reinforcing the initial 
observation that these were not mast cells but stromal cells instead. A 1% 
cutoff for scoring criteria was used here in view that CD117 is not normally 
expressed in breast stromal cells [Kondi-Pafiti et al., 2010]. Hence, presence 
of the protein even in a low percentage could indicate an abnormal state. 
Although the low percentage could be partly contributed by the use of tissue 
microarrays which represent a small proportion of the entire tumour, it has 
been previously shown that tissue microarrays provide a reliable replication 
of phyllodes tumours in terms of biomarker expression [Ho et al., 2013].  
 Patients with GISTs harbouring overexpression or mutation of CD117 
are responsive to tyrosine kinase inhibitors which can block the activity of an 
activated CD117 receptor. This largely motivates the investigation of CD117 
expression and mutation status in phyllodes tumours as there has been 
previous suggestion that the stromal component of phyllodes tumours bear 
some similarities with GIST such as the spindled nature and spectrum of 
behaviour from benign to malignant [Carvalho et al., 2004]. However, recent 





different types of CD117 expressing tumours. CD117-expressing tumours are 
broadly classified into two groups [Pittoni et al., 2011]. The first group is 
usually characterized by gain-of-function (activating) CD117 mutations which 
play a central pathogenetic role in neoplasm initiation. These tumours are 
made up of cells that normally express CD117, such as GIST which arise from 
the oncogenic transformation of interstitial cells of Cajal that normally 
express high levels of CD117. On the contrary, the second group of tumours 
has rare occurrence of CD117 mutations and are composed of cells that do 
not normally express CD117. In this case, CD117 has a passive role and its 
expression is acquired during tumour progression. This may explain the lack 
of mutations found in phyllodes tumours as compared to GISTs. The stromal 
component of phyllodes tumour, which likely arises from breast 
mesenchymal tissue, does not usually express CD117 under normal 
circumstances. 
 The lack of activating mutations in phyllodes tumours suggests that 
the therapeutic option of using a tyrosine kinase inhibitor such as imatinib in 
patients with phyllodes tumours is unlikely to be effective. Nonetheless, the 
associations of CD117 protein expression with borderline/malignant 
phyllodes tumours, worse pathologic parameters and poorer prognosis are 
real phenomena that suggest a role of CD117 in the biological behaviour of 





4.4  Immunohistochemical expression of homeoproteins Six1 and Pax3 in 
phyllodes tumours 
 
 In a comprehensive expression profiling performed by Jones et al. 
which employed 23 fresh frozen phyllodes tumours, Six1 and Pax3 was found 
to have the highest fold change (5-fold difference) among 162 differentially 
expressed genes comparing borderline/malignant tumours to benign 
phyllodes tumours [Jones et al., 2008b]. The difference was predominantly 
observed in the stromal component. To validate the findings from the 
microarray data, the authors performed mRNA in situ hybridization in a 
separate set of 49 formalin-fixed paraffin embedded tissue and observed a 
similar association. These findings indicate that Six1 and Pax3 were highly 
transcribed but whether the protein was translated was not investigated. 
Results from this section filled in the gap, where protein expression of Six1 
and Pax3 was assessed in phyllodes tumours by immunohistochemistry. A 
significant association of Six1 and Pax3 immunohistochemical expression was 
observed with tumour grade, corroborating what was reported by Jones et al. 
However, such a trend was only observed in the cytoplasm, but not in the 
nucleus, of the stromal cells.  The findings of cytoplasmic expression 
associating with increasing tumour grade suggest a possible non-
transcriptional effect of these homeoproteins in the cytoplasm, indicating 
that its role is not solely dependent on its DNA-binding activity which occurs 
in the nucleus. Cytoplasmic function of transcription factors playing a role in 





to promote cell migration by binding to stathmin, thus stabilizing microtubule 
formation in the cytoplasm [Ng et al., 2006].   
 In contrast to the observations in the stroma, a negative association 
of homeoprotein expression with tumour grade was observed instead in the 
epithelial component. This resonates with previous reports that the epithelial 
component has its own distinct set of molecular changes as compared to the 
stromal component [Sawyer et al., 2000]. The significance and mechanism of 
elevated expression of homeoproteins in the epithelium of lower grade 
phyllodes tumours were unclear. However, Six1 expression was shown to 
stimulate cellular proliferation through induction of cyclin A1 in mammary 
cancer cell lines [Coletta et al., 2004]. This corroborates the previous reports 
of noting an actively proliferating epithelium in benign phyllodes tumours, 
and an inverse correlation of epithelial hyperplasia with tumour grade [Tan et 
al., 2005a; Pietruszka and Barnes, 1978]. It could be possible that reactivation 
of homeoprotein expression was used in the early stages of the 
tumourigenesis to trigger cellular proliferation in the epithelium, thus 
keeping the epithelial-stromal architecture in balance in lower grade tumours.  
 Despite a small number of distant recurrences documented in this 
series, it is nonetheless interesting to note that all tumours which 
subsequently metastasized exhibited high expression of Six1 in the primary 
tumours. Jones et al. also noted that metastatic phyllodes tumours had a 
particularly high Six1 overexpression among the Six1-overexpressed 





limited to phyllodes tumours but also observed in breast cancer, where 
patients with Six1 overexpressed tumours had a shortened time to relapse, 
metastasis and death [Micalizzi et al., 2009]. Six1 was demonstrated to 
mediate breast tumour cell metastasis by multiple means such activating 
TGF-β signalling through miR-106b-25 microRNA cluster [Smith et al., 2012], 
promoting VEGF-C production and lymphangiogenesis [Wang et al., 2012a], 
and inducing epithelial-mesenchymal transition [McCoy et al., 2009]. Further, 
association of Six1 overexpression with metastasis was also implicated in 
other solid tumours. Ng et al. found that increased Six1 protein expression in 
hepatocellular carcinoma patients was significantly correlated with 
pathologic tumour-node-metastasis stage and venous infiltration [Ng et al., 
2006]. Yu et al. demonstrated using mouse model that pulmonary metastasis 
of rhabdomyosarcoma was inhibited when Six1 expression was reduced [Yu 
et al., 2004], suggesting a functional role of Six1 in tumour dissemination.   
 A high expression of stromal Pax3 was significantly associated with 
reduced overall survival despite the limitation of a small number of 
mortalities documented. Studies on Pax3 with follow-up clinical data are 
scant in the literature with a study reporting a high expression of Pax3 was 
associated with higher grade gliomas and poorer survival [Chen et al., 2012]. 
Aberrant Pax3 expression was often associated with rhabdomyosarcoma, 
where chromosomal rearrangement producing oncogenic fusion protein 
Pax3-Foxo1 (forkhead box O1) was observed. Jones et al. did not find any 





activating mutations and amplifications of Pax3 in their series of phyllodes 
tumours. However, the authors identified a hybrid transcript of unknown 
significance between Pax3 and FARSB, a phenylalanyl-tRNA synthetase [Jones 
et al., 2008b]. In this study, the Pax3 antibody employed targets against the 
N-terminal amino acids 2-12 of Pax3, enabling expression of most isoforms of 
Pax3 protein to be detected, including possible fusion proteins which consist 
of Pax3 at its N-terminal.  
 The crosstalk between Six1 and Pax3 has been investigated in 
developmental studies, with some reporting regulation of one molecule by 
the other. Ridgeway and Skerjanc demonstrated that Pax3 expression was 
able to induce Six1 in skeletal myogenesis of mouse embryonic cell lines 
[Ridgeway and Skerjanc, 2001]. On the contrary, Grifone et al. reported that 
Six1 homeoprotein regulated Pax3 expression instead, during myogenesis in 
mouse embryos [Grifone et al., 2005]. Jones et al. demonstrated that 
knockdown of Pax3 resulted in downregulation of Six1 in phyllodes tumour 
cell lines, suggesting that Pax3 may be the upstream molecular of Six1 in 
phyllodes tumours [Jones et al., 2008a]. A positive association was observed 
in this study between Six1 and Pax3 stromal expression. However, an 
investigation into the potential regulation of Six 1 by Pax3 is out of the scope 
of the present study as this is a retrospective series on FFPE materials. 
Nonetheless, a combinatorial panel of the two markers showed that low 
expression of both augured a better recurrence free survival compared to 





difference in prognosis was observed between tumours with high expression 
of one marker alone and tumours with high expression of both markers, 
suggesting the two homeoproteins work in concert instead of having a 
cumulative effect.    
 Recently, there have been concerns regarding the reliability and 
representativeness of using tissue microarrays to assess biomarker 
expression of tumours as the relatively small amount of tissue is not directly 
comparable to the whole tumours [Pinder et al., 2013]. In this present study, 
three cores of 2mm for each tumour were employed and the highest yielding 
H-score among the three cores was selected, in view of a previous study 
where a high concordance was found between tissue microarray and whole 
sections using the highest H-scores among phyllodes tumours core replicates 
[Ho et al., 2013]. Moreover, use of tissue microarrays have been validated 
even in highly heterogeneous tumours such as ovarian and breast cancer 
[Camp et al., 2000; Rosen et al., 2004]  
 In summary, this section of the study showed that stromal 
cytoplasmic expression of homeoproteins Six1 and Pax3 in phyllodes tumours 
was associated with higher tumour grade, unfavourable clinicopathological 
parameters and poorer prognosis. In addition, the epithelium and stroma 
exhibited different staining patterns, suggesting a distinct behaviour of the 





4.5 Overall conclusions and future studies 
The aim of the study was to investigate and evaluate the prognostic 
importance of clinical and molecular parameters of phyllodes tumours. It is 
demonstrated through the main body of this thesis that a few clinical and 
molecular parameters have contributed in tandem to the course of the 
disease. Histological parameters (atypia, mitoses, stromal overgrowth) and 
surgical margins were significant predictors for recurrence-free survival. High-
level amplifications and homozygous deletions were detected exclusively in 
tumours which recur/ metastasize and expression of biological markers 
CD117, Six1 and Pax3 were found to be associated with unfavourable 
histological parameters and poorer prognoses.  
From these findings, it is shown that the biology of phyllodes tumours 
is complex with multiple factors contributing to malignancy of the tumour, 
with some factors overlapping as evidenced in the superiority of the 
nomogram to a linear total histological score model. The heterogeneity in the 
behaviour of phyllodes tumours extends beyond its histological grade and 
molecular aberrations are not limited to malignant grade tumours, but can be 
discovered also in benign tumours which later recur. The common mutations 
found in carcinoma were not seen in phyllodes tumours, suggesting that 
tumourigenesis and exploitation of oncogenic pathways of phyllodes tumours 
are distinct from that of carcinoma and should be investigated separately as 





homeoproteins Six1 and Pax3 with poorer prognoses suggest that these 
markers may play a role in the biology of phyllodes tumour progression.  
The eventual desired outcome of this work is to improve the 
management of patients with phyllodes tumours. The nomogram developed 
can be used for patient counseling and clinical management of women 
diagnosed with phyllodes tumours albeit requiring further validation from 
external larger cohorts. Although CD117 expression is associated with 
borderline/malignant tumour grade, a lack of activating mutations and 
overexpression suggest that the use of a tyrosine kinase inhibitor in phyllodes 
tumours as a therapeutic option is unlikely to be effective. The inclusion of 
molecular features (genetic aberrations, CD117, Six1 and Pax3) into the 
nomogram was not feasible as the molecular studies were based on a subset 
cohort with insufficient number of events for meaningful statistical 
evaluation. Nonetheless, it will be interesting to incorporate such molecular 
features in the nomogram in the future if there is a sufficient number of 
events. 
Overall strengths of this study are the large study cohort and a 
comprehensive examination of phyllodes tumours ranging from molecular 
investigations to clinical application. The retrospective nature of the study 
and the single cohort of the study population are the overall limitations of 
the study.  Potential future work includes investigation of the mutational 
status of genes not commonly reported in cancer using next generation 





models such as patient derived xenograft mouse model and primary cell 
culture models.  
The understanding of phyllodes tumours in comparison to breast 
carcinoma is significantly lacking, largely due to the rare occurrence of such 
tumours and unavailability of commercial phyllodes tumour cell lines. As such, 
functional investigations on markers or molecules which were observed to be 
associated with malignancy in phyllodes tumours could not be performed 
without availability of cellular models. There is a need for this area to be 
addressed, particularly in this part of the world where phyllodes tumours are 
relatively more frequent compared to the West. It is nonetheless positive 
that at this point in time, in addition to the functional work performed by 
Jones et al. 10 years ago, a group in Taiwan and two groups in China this year 
have published functional studies using primary cell cultures developed in 
their respectively laboratories, to study implication of their hypothesized 
molecules including stem cell markers, microRNAs and cell adhesion 
molecule in phyllodes tumours [Lin et al., 2014; Gong et al., 2014; Ren et al., 
2014]. 
Finally, there are several other questions in the field of phyllodes 
tumours that remain to be addressed. The relationship between epithelium 
and stroma and how these two components affect disease progression is still 
uncertain. Laser capture microdissection could be performed using flash 
frozen materials where quality of DNA is better preserved. Also, whether 
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Supplemental Table 1 Details of chromosomal aberrations observed in 19 phyllodes 
tumours which passed quality control on the OncoScan® FFPE assay. Copy number (CN) gain 
is defined with gain of two copies of chromosomes and above. CN loss is defined with loss of 
one copy while homozygous copy loss is defined with loss of both copies.  
Sample Event Chromosome Region Cytoband Length (bp) 
1 CN Gain chr1 0-1,222,808 1p36.33 1222809 
1 CN Loss chr2 91,813,414-92,196,400 2p11.1 382987 
1 CN Loss chr6 43,695,136-46,893,364 6p21.1 - p12.3 3198229 
1 CN Loss chr6 47,280,591-58,742,393 6p12.3 - p11.1 11461803 
1 CN Loss chr6 61,000,000-65,425,900 6q11.1 - q12 4425901 
1 CN Loss chr6 66,891,799-67,311,468 6q12 419670 
1 CN Loss chr6 69,470,911-70,061,379 6q12 - q13 590469 
1 CN Loss chr6 70,511,448-71,744,348 6q13 1232901 
1 CN Loss chr6 72,354,086-78,485,370 6q13 - q14.1 6131285 
1 CN Loss chr6 80,410,916-84,593,162 6q14.1 - q14.2 4182247 
1 CN Loss chr6 85,152,217-90,311,887 6q14.3 - q15 5159671 
1 CN Loss chr6 91,295,356-91,746,966 6q15 451611 
1 CN Loss chr6 93,213,080-97,358,701 6q16.1 4145622 
1 CN Loss chr6 97,997,670-105,695,999 6q16.1 - q21 7698330 
1 CN Loss chr6 109,938,879-113,818,039 6q21 3879161 
1 CN Loss chr6 114,308,474-116,560,702 6q21 - q22.1 2252229 
1 CN Loss chr6 117,149,837-122,168,871 6q22.1 - q22.31 5019035 
1 CN Loss chr6 123,339,341-125,505,267 6q22.31 2165927 
1 CN Loss chr6 132,876,773-132,941,505 6q23.2 64733 
1 CN Loss chr6 133,228,189-134,141,984 6q23.2 913796 
1 CN Loss chr6 134,498,087-136,280,453 6q23.2 - q23.3 1782367 
1 CN Loss chr6 149,779,031-152,499,603 6q25.1 2720573 
1 CN Loss chr6 152,626,737-154,442,806 6q25.2 1816070 
1 CN Loss chr6 155,085,569-156,832,599 6q25.2 - q25.3 1747031 
1 CN Loss chr6 159,572,985-160,064,613 6q25.3 491629 
1 CN Loss chr6 160,446,357-171,115,067 6q25.3 - q27 10668711 
1 CN Loss chr8 6,788,988-6,911,399 8p23.1 122412 
1 CN Gain chr9 75,699,001-75,774,198 9q21.13 75198 
1 CN Loss chr15 20,161,372-20,192,951 15q11.1 31580 
1 CN Loss chr15 22,796,596-38,019,749 15q11.2 - q14 15223154 
1 CN Loss chr15 44,098,711-48,523,894 15q15.3 - q21.1 4425184 
1 CN Loss chr15 51,291,741-52,238,170 15q21.2 946430 
1 CN Loss chr15 53,028,725-54,518,893 15q21.3 1490169 
1 CN Loss chr15 54,901,706-55,450,209 15q21.3 548504 
1 CN Loss chr15 58,066,967-58,611,769 15q21.3 544803 
1 CN Loss chr15 59,657,100-60,637,187 15q22.2 980088 
1 CN Loss chr15 60,987,346-61,189,584 15q22.2 202239 
1 CN Loss chr16 24,134,820-24,233,073 16p12.2 - p12.1 98254 





1 CN Loss chr17 5,398,280-6,811,774 17p13.2 - p13.1 1413495 
1 CN Gain chr20 45,903,411-45,992,048 20q13.12 88638 
1 CN Loss chr21 45,297,385-47,523,589 21q22.3 2226205 
1 CN Loss chr22 48,870,985-50,030,785 22q13.32 - q13.33 1159801 
2 CN Gain chr10 92,137,961-92,295,085 10q23.31 157125 
2 CN Loss chrX 2,699,968-58,545,809 Xp22.33 - p11.1 55845842 
2 CN Loss chrX 61,944,035-155,270,560 Xq11.1 - q28 93326526 
3 CN Loss chr2 91,813,414-92,196,400 2p11.1 382987 
4 CN Loss chr15 20,161,372-20,192,951 15q11.1 31580 
5 CN Loss chr1 5,004,041-5,919,059 1p36.32 - p36.31 915019 
5 CN Loss chr1 148,915,961-149,761,266 1q21.2 845306 
5 CN Gain chr1 87,785,758-87,818,488 1p22.3 32731 
5 CN Gain chr1 145,419,163-145,527,032 1q21.1 107870 
5 CN Loss chr2 23,526,044-23,617,364 2p24.1 91321 
5 CN Loss chr3 10,440,707-11,019,981 3p25.3 579275 
5 CN Loss chr5 174,176,962-175,576,829 5q35.2 1399868 
5 CN Gain chr5 148,821,669-148,977,145 5q32 155477 
5 CN Gain chr6 25,992,859-26,064,704 6p22.2 71846 
5 CN Gain chr6 26,146,304-26,226,155 6p22.2 79852 
5 CN Gain chr6 27,746,874-27,874,436 6p22.1 127563 
5 CN Loss chr7 56,295,982-57,878,090 7p11.2 1582109 
5 CN Loss chr7 154,873,687-156,025,329 7q36.2 - q36.3 1151643 
5 CN Loss chr7 157,281,738-158,423,097 7q36.3 1141360 
5 CN Gain chr7 94,027,737-94,050,306 7q21.3 22570 
5 CN Gain chr7 134,501,890-134,516,257 7q33 14368 
5 CN Loss chr8 462,508-1,565,363 8p23.3 1102856 
5 CN Loss chr8 139,743,394-141,074,233 8q24.23 - q24.3 1330840 
5 CN Loss chr8 142,358,487-143,987,939 8q24.3 1629453 
5 CN Gain chr8 39,958,745-40,048,822 8p11.21 90078 
5 CN Loss chr9 36,778,731-37,014,719 9p13.2 235989 
5 CN Loss chr9 101,062,838-101,172,425 9q22.33 109588 
5 CN Loss chr10 1,177,416-2,211,229 10p15.3 1033814 
5 CN Loss chr10 26,744,455-26,977,870 10p12.1 233416 
5 CN Loss chr10 87,844,547-88,134,907 10q23.1 - q23.2 290361 
5 CN Loss chr10 132,084,219-135,534,747 10q26.3 3450529 
5 CN Loss chr11 116,180,571-116,525,551 11q23.3 344981 
5 CN Loss chr11 126,356,718-126,958,052 11q24.2 601335 
5 CN Loss chr11 133,115,479-133,701,477 11q25 585999 
5 CN Gain chr11 65,049,910-65,275,146 11q13.1 225237 
5 CN Loss chr12 112,891,067-112,948,019 12q24.13 56953 
5 CN Loss chr12 113,936,155-114,267,840 12q24.13 331686 
5 CN Loss chr12 118,839,701-120,103,511 12q24.23 1263811 
5 CN Loss chr12 128,413,609-130,552,157 12q24.32 - q24.33 2138549 
5 CN Loss chr12 130,801,237-131,293,433 12q24.33 492197 
5 CN Loss chr13 111,867,463-113,134,406 13q34 1266944 





5 CN Loss chr14 24,921,826-25,102,911 14q12 181086 
5 CN Loss chr14 96,171,889-96,442,430 14q32.13 - q32.2 270542 
5 CN Gain chr14 68,366,107-68,774,161 14q24.1 408055 
5 CN Gain chr14 68,831,621-68,886,193 14q24.1 54573 
5 CN Gain chr14 77,482,341-77,515,382 14q24.3 33042 
5 CN Loss chr15 20,161,372-20,192,951 15q11.1 31580 
5 CN Loss chr15 27,890,540-28,332,292 15q12 - q13.1 441753 
5 CN Loss chr15 88,724,961-89,003,474 15q25.3 278514 
5 CN Gain chr15 93,338,187-93,479,204 15q26.1 141018 
5 CN Loss chr16 5,173,205-9,768,469 16p13.3 - p13.2 4595265 
5 CN Loss chr16 23,613,369-24,631,421 16p12.2 - p12.1 1018053 
5 CN Loss chr16 33,828,054-35,219,549 16p11.2 - p11.1 1391496 
5 CN Loss chr16 49,470,113-49,653,214 16q12.1 183102 
5 CN Loss chr16 83,378,232-83,710,981 16q23.3 332750 
5 CN Gain chr16 79,621,593-79,673,887 16q23.2 52295 
5 CN Loss chr17 32,732,800-33,104,907 17q12 372108 
5 CN Loss chr17 35,046,000-35,295,966 17q12 249967 
5 CN Loss chr18 54,709,502-55,207,482 18q21.31 497981 
5 CN Loss chr18 76,061,828-76,627,951 18q23 566124 
5 CN Gain chr18 3,592,059-3,608,238 18p11.31 16180 
5 CN Gain chr18 41,424,543-41,588,101 18q12.3 163559 
5 CN Loss chr19 8,786,085-9,452,179 19p13.2 666095 
5 CN Loss chr19 28,079,145-30,343,191 19q11 - q12 2264047 
5 CN Loss chr19 42,074,179-42,247,949 19q13.2 173771 
5 CN Loss chr19 42,967,112-43,921,371 19q13.2 - q13.31 954260 
5 CN Loss chr19 54,123,228-55,512,121 19q13.42 1388894 
5 CN Loss chr19 57,113,246-57,672,244 19q13.43 558999 
5 CN Loss chr20 23,466,226-24,895,517 20p11.21 1429292 
5 CN Gain chr20 45,892,532-45,992,048 20q13.12 99517 
5 CN Loss chr22 17,299,929-18,163,987 22q11.1 - q11.21 864059 
5 CN Loss chr22 48,856,519-50,140,926 22q13.32 - q13.33 1284408 
6 CN Gain chr7 94,015,482-94,059,477 7q21.3 43996 
6 CN Loss chr15 20,161,372-20,192,951 15q11.1 31580 
6 CN Gain chr17 25,326,941-25,476,780 17q11.1 149840 
7 CN Loss chr9 11,910,201-12,189,666 9p23 279466 
8 CN Loss chr6 94,728,264-95,063,724 6q16.1 335461 
8 CN Gain chr6 26,146,304-26,226,155 6p22.2 79852 
8 CN Gain chr16 68,612,846-68,860,224 16q22.1 247379 
8 CN Loss chrX 110,219,820-110,495,293 Xq23 275474 
9 CN Gain chr1 21,567,243-21,666,377 1p36.12 99135 
9 CN Gain chr1 68,662,447-68,693,759 1p31.3 31313 
9 CN Gain chr1 145,419,163-145,527,032 1q21.1 107870 
9 CN Gain chr1 219,593,792-219,652,927 1q41 59136 
9 CN Gain chr1 234,602,305-234,929,566 1q42.2 - q42.3 327262 
9 CN Gain chr2 189,537,698-189,964,459 2q32.2 426762 





9 CN Gain chr2 238,215,913-238,376,003 2q37.3 160091 
9 CN Loss chr3 10,437,802-10,973,215 3p25.3 535414 
9 CN Loss chr4 177,952,803-178,143,805 4q34.3 191003 
9 CN Loss chr4 188,956,020-191,154,276 4q35.2 2198257 
9 CN Gain chr5 148,776,185-148,977,145 5q32 200961 
9 CN Gain chr6 26,003,552-26,064,704 6p22.2 61153 
9 CN Gain chr6 26,123,254-26,244,409 6p22.2 121156 
9 CN Loss chr7 0-5,719,311 7p22.3 - p22.1 5719312 
9 CN Loss chr7 6,488,745-7,583,246 7p22.1 - p21.3 1094502 
9 CN Loss chr7 7,935,502-11,465,014 7p21.3 3529513 
9 CN Loss chr7 11,777,627-12,386,445 7p21.3 608819 
9 CN Loss chr7 13,284,052-16,483,845 7p21.3 - p21.2 3199794 
9 CN Loss chr7 17,745,173-28,949,939 7p21.1 - p14.3 11204767 
9 CN Loss chr7 29,159,440-36,124,742 7p14.3 - p14.2 6965303 
9 CN Loss chr7 36,437,831-41,988,603 7p14.2 - p14.1 5550773 
9 CN Loss chr7 43,157,773-47,787,860 7p14.1 - p12.3 4630088 
9 CN Loss chr7 47,881,384-55,018,866 7p12.3 - p11.2 7137483 
9 CN Loss chr7 55,192,609-57,878,090 7p11.2 2685482 
9 CN Loss chr7 61,064,518-80,287,194 7q11.1 - q21.11 19222677 
9 CN Loss chr7 82,011,079-90,869,405 7q21.11 - q21.13 8858327 
9 CN Loss chr7 91,254,845-93,810,982 7q21.2 - q21.3 2556138 
9 CN Loss chr7 94,056,185-99,543,334 7q21.3 - q22.1 5487150 
9 CN Loss chr7 100,535,078-129,255,365 7q22.1 - q32.2 28720288 
9 CN Loss chr7 130,860,464-134,239,928 7q32.3 - q33 3379465 
9 CN Loss chr7 134,907,932-142,912,836 7q33 - q34 8004905 
9 CN Loss chr7 143,657,572-159,138,663 7q35 - q36.3 15481092 
9 CN Loss chr8 142,491,110-143,987,939 8q24.3 1496830 
9 CN Gain chr8 17,564,038-17,729,015 8p22 164978 
9 CN Loss chr9 11,793,164-12,189,666 9p23 396503 
9 CN Loss chr10 132,735,673-135,534,747 10q26.3 2799075 
9 CN Gain chr10 33,555,319-33,614,606 10p11.22 59288 
9 CN Gain chr10 95,182,850-95,243,902 10q23.33 61053 
9 CN Gain chr11 64,854,390-65,275,146 11q13.1 420757 
9 CN Gain chr13 48,977,891-48,988,059 13q14.2 10169 
9 CN Gain chr13 110,924,799-111,062,282 13q34 137484 
9 CN Loss chr15 20,161,372-20,192,951 15q11.1 31580 
9 CN Gain chr15 60,654,900-60,696,050 15q22.2 41151 
9 CN Gain chr15 93,367,501-93,479,204 15q26.1 111704 
9 CN Loss chr16 6,752,964-6,834,966 16p13.3 82003 
9 CN Loss chr16 7,174,796-8,791,398 16p13.3 - p13.2 1616603 
9 CN Loss chr16 23,689,373-24,093,371 16p12.2 403999 
9 CN Gain chr16 79,627,608-79,675,910 16q23.2 48303 
9 CN Loss chr17 32,732,800-33,094,213 17q12 361414 
9 CN Loss chr17 45,749,349-45,896,180 17q21.32 146832 
9 CN Gain chr17 57,784,507-57,996,457 17q23.1 211951 





9 CN Gain chr18 41,394,247-41,525,672 18q12.3 131426 
9 CN Gain chr18 52,898,161-53,090,008 18q21.2 191848 
9 CN Loss chr19 8,984,956-9,066,324 19p13.2 81369 
9 CN Loss chr19 28,079,145-30,766,524 19q11 - q12 2687380 
9 CN Loss chr19 54,123,228-55,512,121 19q13.42 1388894 
9 CN Loss chr22 17,299,929-17,721,349 22q11.1 421421 
9 CN Loss chr22 48,686,018-49,860,392 22q13.32 - q13.33 1174375 
9 CN Gain chr22 36,707,127-36,858,770 22q12.3 151644 
9 CN Loss chrX 21,263,462-22,162,506 Xp22.12 - p22.11 899045 
10 CN Loss chr2 91,813,414-92,196,400 2p11.1 382987 
10 CN Loss chr5 100,769,075-161,769,011 5q21.1 - q34 60999937 
10 CN Loss chr8 5,993,004-6,093,800 8p23.2 100797 
10 CN Loss chr15 20,161,372-20,192,951 15q11.1 31580 
12 CN Loss chr2 91,813,414-92,196,400 2p11.1 382987 
12 CN Loss chr5 0-2,882,758 5p15.33 2882759 
12 CN Loss chr5 3,268,942-5,249,875 5p15.33 - p15.32 1980934 
12 CN Loss chr5 5,409,897-5,505,160 5p15.32 95264 
12 CN Loss chr5 5,672,866-9,623,641 5p15.32 - p15.31 3950776 
12 CN Loss chr5 10,050,032-10,236,091 5p15.2 186060 
12 CN Loss chr5 10,333,382-11,792,960 5p15.2 1459579 
12 CN Loss chr5 12,004,786-13,390,161 5p15.2 1385376 
12 CN Loss chr5 13,457,974-14,150,975 5p15.2 693002 
12 CN Loss chr5 14,231,227-14,924,193 5p15.2 692967 
12 CN Loss chr5 15,527,063-23,373,037 5p15.1 - p14.2 7845975 
12 CN Loss chr5 24,053,709-27,316,842 5p14.2 - p14.1 3263134 
12 CN Gain chr5 2,882,758-3,268,942 5p15.33 386185 
12 CN Gain chr5 5,505,160-5,672,866 5p15.32 167707 
12 CN Gain chr5 9,623,641-10,050,032 5p15.31 - p15.2 426392 
12 CN Gain chr5 10,236,091-10,333,382 5p15.2 97292 
12 CN Gain chr5 13,390,161-13,457,974 5p15.2 67814 
12 CN Gain chr5 14,150,975-14,231,227 5p15.2 80253 
12 CN Gain chr5 14,924,193-15,527,063 5p15.2 - p15.1 602871 
12 CN Gain chr5 23,373,037-24,053,709 5p14.2 680673 
12 CN Gain chr5 27,316,842-29,053,732 5p14.1 - p13.3 1736891 
12 CN Gain chr5 29,538,140-34,728,143 5p13.3 - p13.2 5190004 
12 CN Gain chr5 36,710,291-39,402,423 5p13.2 - p13.1 2692133 
12 CN Gain chr5 40,227,613-40,788,044 5p13.1 560432 
12 CN Gain chr7 94,015,482-94,055,161 7q21.3 39680 
12 CN Gain chr8 2,207,062-2,402,151 8p23.2 195090 
12 CN Loss chr9 20,630,484-22,378,924 9p21.3 1748441 
12 CN Loss chr15 20,161,372-20,192,951 15q11.1 31580 
13 CN Loss chr2 91,813,414-92,196,400 2p11.1 382987 
13 CN Loss chr5 0-30,572,608 5p15.33 - p13.3 30572609 
13 CN Loss chr9 20,608,137-21,906,166 9p21.3 1298030 
13 Homozygous 
Copy Loss 





14 CN Loss chr4 52,700,771-191,154,276 4q12 - q35.2 1.38E+08 
14 CN Loss chr15 20,161,372-20,192,951 15q11.1 31580 
15 CN Loss chr2 91,813,414-92,196,400 2p11.1 382987 
16 CN Loss chr1 0-3,038,656 1p36.33 - p36.32 3038657 
16 CN Loss chr2 91,813,414-92,196,400 2p11.1 382987 
16 CN Loss chr2 149,280,179-243,199,373 2q23.1 - q37.3 93919195 
16 CN Gain chr2 144,086,159-144,217,694 2q22.2 - q22.3 131536 
16 CN Loss chr5 62,009,001-68,740,653 5q12.1 - q13.2 6731653 
16 CN Loss chr5 70,744,658-180,915,260 5q13.2 - q35.3 1.1E+08 
16 CN Gain chr5 49,560,859-55,070,314 5q11.1 - q11.2 5509456 
16 CN Gain chr5 56,298,730-59,315,214 5q11.2 - q12.1 3016485 
16 CN Gain chr5 61,198,344-62,009,001 5q12.1 810658 
16 CN Loss chr7 38,525,684-47,748,989 7p14.1 - p12.3 9223306 
16 CN Loss chr7 48,028,854-49,906,334 7p12.3 - p12.2 1877481 
16 CN Loss chr7 50,487,083-50,853,145 7p12.2 - p12.1 366063 
16 CN Loss chr7 51,801,876-52,754,655 7p12.1 952780 
16 CN Loss chr7 61,064,518-94,010,901 7q11.1 - q21.3 32946384 
16 CN Loss chr7 94,054,371-159,138,663 7q21.3 - q36.3 65084293 
16 CN Gain chr7 0-10,298,426 7p22.3 - p21.3 10298427 
16 CN Gain chr7 52,916,459-55,451,949 7p12.1 - p11.2 2535491 
16 CN Loss chr10 130,904,734-131,860,192 10q26.3 955459 
16 CN Gain chr11 19,112,441-22,974,066 11p15.1 - p14.3 3861626 
16 CN Gain chr11 26,185,156-29,969,403 11p14.2 - p14.1 3784248 
16 CN Gain chr11 36,097,891-36,262,802 11p13 164912 
16 CN Loss chr13 19,043,558-115,169,878 13q11 - q34 96126321 
16 CN Loss chr14 20,443,778-107,349,540 14q11.2 - q32.33 86905763 
16 CN Loss chr15 20,161,372-20,192,951 15q11.1 31580 
16 CN Loss chr16 0-32,482,955 16p13.3 - p11.2 32482956 
16 CN Loss chr16 33,828,054-35,219,549 16p11.2 - p11.1 1391496 
16 CN Loss chr16 46,505,821-75,617,935 16q11.2 - q23.1 29112115 
16 CN Loss chr16 76,350,929-79,504,460 16q23.1 - q23.2 3153532 
16 CN Loss chr16 80,084,226-90,354,753 16q23.2 - q24.3 10270528 
16 CN Loss chr17 21,430,743-22,193,626 17p11.2 762884 
16 CN Loss chr17 25,326,941-27,998,913 17q11.1 - q11.2 2671973 
16 CN Gain chr17 5,296,112-9,174,658 17p13.2 - p13.1 3878547 
16 CN Loss chr18 66,094,637-78,077,248 18q22.1 - q23 11982612 
16 CN Gain chr18 40,066,661-40,830,761 18q12.3 764101 
16 CN Gain chr18 41,452,789-45,214,777 18q12.3 - q21.1 3761989 
16 CN Gain chr18 45,372,096-47,778,681 18q21.1 2406586 
16 CN Gain chr18 49,427,917-58,873,990 18q21.2 - q21.32 9446074 
16 CN Gain chr18 62,165,709-64,788,445 18q22.1 2622737 
16 CN Gain chr18 65,234,990-66,094,637 18q22.1 859648 
16 CN Gain chr20 0-981,273 20p13 981274 
16 CN Gain chr20 2,097,839-2,591,738 20p13 493900 
16 CN Gain chr20 3,746,679-5,068,313 20p13 1321635 





16 CN Gain chr20 11,872,003-17,363,946 20p12.2 - p12.1 5491944 
16 CN Gain chr20 19,213,523-20,397,189 20p11.23 1183667 
16 CN Loss chr22 40,039,177-51,304,566 22q13.1 - q13.33 11265390 
17 CN Gain chr1 0-2,314,475 1p36.33 - p36.32 2314476 
17 CN Loss chr2 0-1,420,263 2p25.3 1420264 
17 CN Loss chr2 2,697,484-5,652,163 2p25.3 - p25.2 2954680 
17 CN Loss chr2 29,429,367-29,727,380 2p23.2 298014 
17 CN Loss chr2 70,733,189-70,945,031 2p13.3 211843 
17 CN Loss chr2 120,129,954-120,451,007 2q14.2 321054 
17 CN Gain chr2 197,010,274-197,129,976 2q32.3 119703 
17 CN Loss chr3 12,747,735-14,864,713 3p25.2 - p25.1 2116979 
17 CN Loss chr3 54,238,667-54,612,156 3p21.1 - p14.3 373490 
17 CN Loss chr3 116,328,487-117,124,459 3q13.31 795973 
17 CN Loss chr3 125,013,911-126,285,171 3q21.2 - q21.3 1271261 
17 CN Gain chr3 9,322,373-10,004,672 3p25.3 682300 
17 CN Gain chr3 10,246,327-12,747,735 3p25.3 - p25.2 2501409 
17 CN Gain chr3 14,864,713-15,393,244 3p25.1 528532 
17 CN Loss chr4 0-12,236,950 4p16.3 - p15.33 12236951 
17 CN Loss chr4 36,418,529-37,417,493 4p14 998965 
17 CN Loss chr4 181,900,098-182,825,656 4q34.3 925559 
17 CN Gain chr6 27,746,874-27,889,619 6p22.1 142746 
17 CN Gain chr7 93,918,681-94,054,371 7q21.3 135691 
17 CN Gain chr7 134,462,262-134,627,046 7q33 164785 
17 CN Loss chr10 0-3,783,382 10p15.3 - p15.2 3783383 
17 CN Loss chr10 3,924,266-14,009,283 10p15.1 - p13 10085018 
17 CN Loss chr10 14,095,291-39,075,616 10p13 - p11.1 24980326 
17 CN Loss chr10 87,931,325-88,366,633 10q23.2 435309 
17 CN Loss chr10 117,706,974-118,558,199 10q25.3 851226 
17 CN Loss chr10 124,327,316-124,875,101 10q26.13 547786 
17 CN Loss chr10 130,164,780-135,534,747 10q26.2 - q26.3 5369968 
17 CN Loss chr11 4,167,279-4,731,401 11p15.4 564123 
17 CN Loss chr11 15,295,502-19,135,407 11p15.2 - p15.1 3839906 
17 CN Loss chr11 29,366,931-30,252,668 11p14.1 885738 
17 CN Loss chr11 83,697,258-85,228,552 11q14.1 1531295 
17 CN Loss chr11 112,360,547-112,952,421 11q23.1 - q23.2 591875 
17 CN Loss chr11 114,485,868-115,052,710 11q23.2 - q23.3 566843 
17 CN Loss chr11 117,221,881-117,680,274 11q23.3 458394 
17 CN Loss chr11 120,349,250-120,741,124 11q23.3 391875 
17 CN Loss chr11 126,366,633-128,233,120 11q24.2 - q24.3 1866488 
17 CN Loss chr11 130,724,393-135,006,516 11q24.3 - q25 4282124 
17 CN Loss chr12 109,173,054-115,175,763 12q24.11 - q24.21 6002710 
17 CN Loss chr12 117,383,517-118,006,963 12q24.22 623447 
17 CN Loss chr12 126,531,315-130,884,425 12q24.32 - q24.33 4353111 
17 CN Gain chr13 24,215,307-24,286,444 13q12.12 71138 
17 CN Loss chr14 44,655,207-45,450,045 14q21.2 794839 





17 CN Loss chr14 95,761,768-96,518,919 14q32.13 - q32.2 757152 
17 CN Loss chr14 96,861,107-100,164,568 14q32.2 3303462 
17 CN Loss chr15 20,161,372-20,192,951 15q11.1 31580 
17 CN Loss chr15 22,796,596-27,936,377 15q11.2 - q12 5139782 
17 CN Loss chr15 53,422,076-54,430,253 15q21.3 1008178 
17 CN Loss chr15 59,604,216-60,565,271 15q22.2 961056 
17 CN Loss chr15 69,256,599-70,370,501 15q23 1113903 
17 CN Loss chr15 88,163,141-89,003,474 15q25.3 840334 
17 CN Loss chr15 93,944,364-94,309,537 15q26.1 - q26.2 365174 
17 CN Gain chr15 59,577,752-59,604,216 15q22.2 26465 
17 CN Loss chr16 5,533,187-10,200,494 16p13.3 - p13.2 4667308 
17 CN Loss chr16 12,721,412-13,234,505 16p13.12 513094 
17 CN Loss chr16 16,220,446-24,441,534 16p13.11 - p12.1 8221089 
17 CN Loss chr16 25,870,610-26,944,503 16p12.1 1073894 
17 CN Loss chr16 27,795,877-28,714,254 16p12.1 - p11.2 918378 
17 CN Loss chr16 33,828,054-35,219,549 16p11.2 - p11.1 1391496 
17 CN Loss chr16 68,340,169-68,834,307 16q22.1 494139 
17 CN Loss chr16 73,161,378-73,747,376 16q22.3 585999 
17 CN Loss chr16 79,992,404-80,478,566 16q23.2 486163 
17 CN Loss chr16 82,119,482-83,726,871 16q23.3 1607390 
17 CN Loss chr16 85,944,631-86,589,416 16q24.1 644786 
17 CN Loss chr17 5,423,721-6,488,051 17p13.2 1064331 
17 CN Loss chr17 12,050,896-13,028,504 17p12 977609 
17 CN Loss chr17 25,936,898-26,412,879 17q11.2 475982 
17 CN Loss chr17 31,817,719-33,557,464 17q12 1739746 
17 CN Gain chr17 49,070,647-49,343,480 17q21.33 272834 
17 CN Loss chr18 34,449,292-45,360,061 18q12.2 - q21.1 10910770 
17 CN Loss chr18 47,335,576-48,327,909 18q21.1 - q21.2 992334 
17 CN Loss chr18 74,865,252-76,622,610 18q23 1757359 
17 CN Loss chr19 7,698,752-9,225,812 19p13.2 1527061 
17 CN Loss chr19 12,276,628-13,688,274 19p13.2 1411647 
17 CN Loss chr19 14,422,621-16,074,712 19p13.12 1652092 
17 CN Loss chr19 28,079,145-32,698,583 19q11 - q13.11 4619439 
17 CN Loss chr19 52,574,218-52,809,216 19q13.41 234999 
17 CN Loss chr19 54,072,769-56,799,114 19q13.42 - q13.43 2726346 
17 CN Loss chr21 14,414,872-15,862,900 21q11.2 1448029 
17 CN Loss chr21 20,241,040-23,408,822 21q21.1 3167783 
17 CN Loss chr21 31,262,362-32,351,832 21q21.3 - q22.11 1089471 
17 CN Loss chr21 39,130,486-39,570,730 21q22.13 440245 
17 CN Loss chr21 40,951,501-44,171,368 21q22.2 - q22.3 3219868 
18 CN Gain chr1 19,698,557-19,811,828 1p36.13 113272 
18 CN Gain chr1 174,996,846-175,058,961 1q25.1 62116 
18 CN Gain chr1 201,596,821-205,478,501 1q32.1 3881681 
18 CN Loss chr2 91,813,414-92,196,400 2p11.1 382987 
18 CN Gain chr2 38,319,218-38,451,906 2p22.2 132689 





18 CN Gain chr2 197,006,464-197,043,354 2q32.3 36891 
18 CN Gain chr6 132,293,826-132,553,270 6q23.2 259445 
18 CN Gain chr7 93,918,681-94,056,840 7q21.3 138160 
18 CN Gain chr8 38,046,708-38,874,853 8p11.23 - p11.22 828146 
18 CN Gain chr8 69,958,098-70,136,952 8q13.2 178855 
18 CN Gain chr8 102,569,632-103,077,130 8q22.3 507499 
18 CN Gain chr9 129,657,681-129,990,717 9q33.3 333037 
18 Homozygous 
Copy Loss 
chr9 21,917,917-22,021,617 9p21.3 103701 
18 CN Gain chr11 44,869,678-44,907,690 11p11.2 38013 
18 CN Loss chr16 23,901,688-24,179,253 16p12.2 277566 
18 CN Loss chr17 32,737,405-32,979,825 17q12 242421 
18 CN Gain chr18 6,740,271-6,901,288 18p11.31 161018 
18 CN Gain chr21 39,612,056-39,686,483 21q22.13 74428 
19 CN Loss chr2 91,813,414-92,196,400 2p11.1 382987 
19 CN Loss chr3 0-29,288,635 3p26.3 - p24.1 29288636 
19 CN Loss chr3 29,487,919-37,004,234 3p24.1 - p22.2 7516316 
19 CN Loss chr3 37,083,307-81,295,869 3p22.2 - p12.2 44212563 
19 CN Loss chr3 174,254,000-174,894,768 3q26.31 640769 
19 CN Loss chr8 0-1,503,749 8p23.3 1503750 
19 CN Loss chr8 1,697,226-3,897,423 8p23.3 - p23.2 2200198 
19 CN Loss chr8 4,610,151-6,911,399 8p23.2 - p23.1 2301249 
19 CN Loss chr9 21,033,382-39,184,065 9p21.3 - p13.1 18150684 
19 CN Loss chr11 0-38,971,287 11p15.5 - p12 38971288 
19 CN Loss chr11 44,598,088-49,056,481 11p11.2 - p11.12 4458394 
19 CN Loss chr11 89,150,559-103,748,871 11q14.3 - q22.3 14598313 
19 CN Loss chr11 105,717,448-108,782,298 11q22.3 3064851 
19 CN Loss chr11 109,281,240-113,122,295 11q22.3 - q23.2 3841056 
19 CN Loss chr11 113,164,240-114,176,087 11q23.2 1011848 
19 CN Loss chr11 117,243,797-118,755,045 11q23.3 1511249 
19 CN Loss chr11 126,569,415-131,635,707 11q24.2 - q25 5066293 
19 CN Loss chr11 134,345,105-135,006,516 11q25 661412 
19 CN Gain chr11 43,701,726-44,222,946 11p11.2 521221 
19 CN Gain chr11 44,435,842-44,598,088 11p11.2 162247 
19 CN Gain chr11 116,763,882-117,016,922 11q23.3 253041 
19 CN Loss chr12 40,129,002-65,296,554 12q12 - q14.3 25167553 
19 CN Loss chr12 65,855,703-70,269,536 12q14.3 - q15 4413834 
19 CN Loss chr12 73,797,248-77,636,690 12q21.1 - q21.2 3839443 
19 CN Loss chr12 78,600,338-84,055,732 12q21.2 - q21.31 5455395 
19 CN Loss chr12 85,862,313-91,426,392 12q21.31 - q21.33 5564080 
19 CN Loss chr12 92,181,161-95,649,238 12q21.33 - q22 3468078 
19 CN Loss chr12 96,260,508-96,451,805 12q23.1 191298 
19 CN Loss chr12 97,070,286-97,469,345 12q23.1 399060 
19 CN Loss chr12 98,194,254-133,851,895 12q23.1 - q24.33 35657642 
19 CN Loss chr17 0-22,193,626 17p13.3 - p11.2 22193627 





19 CN Loss chr18 0-15,322,428 18p11.32 - p11.21 15322429 
19 CN Loss chr18 18,535,946-51,759,108 18q11.1 - q21.2 33223163 
19 CN Loss chr18 58,315,573-78,077,248 18q21.32 - q23 19761676 
19 CN Loss chr20 62,600,145-63,025,520 20q13.33 425376 
19 CN Gain chr20 47,030,432-50,242,155 20q13.13 - q13.2 3211724 
19 CN Gain chr20 60,072,489-62,600,145 20q13.33 2527657 
19 Homozygous 
Copy Loss 
chr20 14,799,707-14,836,662 20p12.1 36956 
19 CN Loss chr21 24,593,236-25,385,284 21q21.2 792049 
19 CN Loss chr22 16,267,567-32,170,230 22q11.1 - q12.2 15902664 
19 CN Loss chr22 34,613,912-43,747,390 22q12.3 - q13.2 9133479 
19 CN Loss chr22 45,196,461-48,220,095 22q13.31 3023635 
19 CN Loss chr22 48,415,323-51,304,566 22q13.32 - q13.33 2889244 
20 CN Loss chr2 91,813,414-92,196,400 2p11.1 382987 
20 CN Loss chr15 20,161,372-20,192,951 15q11.1 31580 





Supplemental Table 2  541 somatic mutation assays interrogated on the 
OncoScan™ platform 
1 ABL1_pE255K_c763G_A 
2 ABL1_pE355G_c1064A_G 
3 ABL1_pF311L_c931T_C 
4 ABL1_pF359V_c1075T_G 
5 ABL1_pG250E_c749G_A 
6 ABL1_pH396R_c1187A_G 
7 ABL1_pM351T_c1052T_C 
8 ABL1_pT315I_c944C_T 
9 ABL1_pY253H_c757T_C 
10 ALK_pD1091N_c3271G_A 
11 ALK_pF1174V_c3520T_G 
12 ALK_pF1245C_c3734T_G 
13 ALK_pF1245V_c3733T_G 
14 ALK_pR1275Q_c3824G_A 
15 ALK_pT1211T_c3633C_A 
16 APC_p_c835_minus_8A_G 
17 APC_pE1286X_c3856G_T 
18 
APC_pE1309fs4_c3921_3925d
elAAAAG_allele1 
19 
APC_pE1309fs4_c3927_3931d
elAAAGA_allele1 
20 
APC_pE1309fs6_c3923_3924 
insA_allele1 
21 APC_pE1309X_c3925G_T 
22 APC_pE1322X_c3964G_T 
23 APC_pE1345X_c4033G_T 
24 APC_pE1353X_c4057G_T 
25 APC_pE1379X_c4135G_T 
26 APC_pE1397X_c4189G_T 
27 APC_pE1408X_c4222G_T 
28 APC_pE1451X_c4351G_T 
29 APC_pE1464X_c4390G_T 
30 APC_pE1577X_c4729G_T 
31 APC_pE853X_c2557G_T 
32 APC_pG1499X_c4495G_T 
33 APC_pQ1291X_c3871C_T 
34 APC_pQ1294X_c3880C_T 
35 APC_pQ1328X_c3982C_T 
36 APC_pQ1338X_c4012C_T 
37 APC_pQ1367X_c4099C_T 
38 APC_pQ1378X_c4132C_T 
39 APC_pQ1406X_c4216C_T 
40 APC_pQ1429X_c4285C_T 
41 APC_pQ1447X_c4339C_T 
42 APC_pQ1469X_c4405C_T 
43 APC_pQ789X_c2365C_T 
44 APC_pR1114X_c3340C_T 
45 APC_pR1450X_c4348C_T 
46 APC_pR213X_c637C_T 
47 APC_pR232X_c694C_T 
48 APC_pR283X_c847C_T 
49 APC_pR302X_c904C_T 
50 APC_pR332X_c994C_T 
51 APC_pR564X_c1690C_T 
52 APC_pR876X_c2626C_T 
53 APC_pS1281X_c3842C_A 
54 APC_pS1341R_c4023T_G 
55 
APC_pS1465fs3_c4393_4394 
delAG_allele1 
56 APC_pT1537K_c4610C_A 
57 
APC_pT1556fs3_c4660_4661 
insA_allele1 
58 
APC_pT1556fs3_c4666_4667 
insA_allele1 
59 AR_pA749A_c2247C_T 
60 ATM_pA1309T_c3925G_A 
61 ATM_pF858L_c2572T_C 
62 ATM_pG2867E_c8600G_A 
63 ATM_pI1681V_c5041A_G 
64 ATM_pP604S_c1810C_T 
65 ATM_pQ2442P_c7325A_C 
66 ATM_pR2443Q_c7328G_A 
67 ATM_pR3008C_c9022C_T 
68 ATM_pR3008H_c9023G_A 
69 ATM_pR3047X_c9139C_T 
70 ATM_pR337C_c1009C_T 
71 ATM_pR337S_c1009C_A 
72 ATM_pS707P_c2119T_C 
73 ATM_pT2666A_c7996A_G 
74 ATM_pV410A_c1229T_C 
75 BRAF_pD594G_c1781A_G 
76 BRAF_pF583F_c1749T_C 
77 BRAF_pG464E_c1391G_A 
78 BRAF_pG466E_c1397G_A 
79 BRAF_pG469E_c1406G_A 
80 BRAF_pG469R_c1405G_A 
81 BRAF_pI326T_c977T_C 
82 BRAF_pL618W_c1853T_G 
83 
BRAF_pV600E_c1799T_A_ 
allele1 
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84 
BRAF_pV600K_c1798_1799GT
_AA_allele1 
85 
BRAF_pV600R_c1798_1799GT
_AG_allele1 
86 BRCA1_p_c134_plus_1G_T 
87 BRCA1_p_c5278_minus_1G_T 
88 BRCA1_pE1725X_c5173G_T 
89 BRCA1_pG1077W_c3229G_T 
90 BRCA1_pG778C_c2332G_T 
91 BRCA1_pH448H_c1344C_T 
92 BRCA1_pL30F_c90G_T 
93 BRCA1_pR1751X_c5251C_T 
94 BRCA1_pS1009X_c3026C_A 
95 BRCA1_pS1140G_c3418A_G 
96 BRCA1_pW372X_c1116G_A 
97 BRCA2_pD3095E_c9285C_A 
98 BRCA2_pE1593X_c4777G_T 
99 BRCA2_pE187K_c559G_A 
100 BRCA2_pG1338G_c4014C_T 
101 BRCA2_pH2415N_c7243C_A 
102 BRCA2_pI1017S_c3050T_G 
103 BRCA2_pI3103M_c9309A_G 
104 BRCA2_pP920S_c2758C_T 
105 BRCA2_pQ2934X_c8800C_T 
106 BRCA2_pR18H_c53G_A 
107 BRCA2_pR2678S_c8034G_T 
108 BRCA2_pR2787H_c8360G_A 
109 BRCA2_pR2842C_c8524C_T 
110 BRCA2_pR3128X_c9382C_T 
111 BRCA2_pS1682S_c5046T_C 
112 BRCA2_pT630I_c1889C_T 
113 BRCA2_pV1988I_c5962G_A 
114 CBL_p_c1228_minus_2A_G 
115 CBL_pR420Q_c1259G_A 
116 CBL_pV391I_c1171G_A 
117 CBL_pY371H_c1111T_C 
118 CDC73_pW43X_c128G_A 
119 CDH1_p_c1009_minus_1G_A 
120 CDH1_pI374I_c1122C_T 
121 CDKN2A_p_c1_minus_25C_T 
122 CDKN2A_p_c150_plus_2T_C 
123 CDKN2A_p_c151_minus_1G_A 
124 CDKN2A_p_c457_plus_1G_T 
125 CDKN2A_p_c457_plus_2T_C 
126 CDKN2A_pA30V_c89C_T 
127 CDKN2A_pD108N_c322G_A 
128 CDKN2A_pE120K_c358G_A 
129 CDKN2A_pE26X_c76G_T 
130 CDKN2A_pE61X_c181G_T 
131 CDKN2A_pE69X_c205G_T 
132 CDKN2A_pE88E_c264G_A 
133 CDKN2A_pG35E_c104G_A 
134 CDKN2A_pH83Y_c247C_T 
135 CDKN2A_pP48L_c143C_T 
136 CDKN2A_pR131H_c392G_A 
137 CDKN2A_pR58X_c172C_T 
138 CDKN2A_pR80X_c238C_T 
139 CDKN2A_pS43I_c128G_T 
140 CDKN2A_pW110X_c329G_A 
141 CDKN2A_pW110X_c330G_A 
142 CDKN2A_pW15X_c44G_A 
143 CDKN2A_pY44X_c132C_A 
144 CSF1R_pL301S_c902T_C 
145 CSF1R_pY969C_c2906A_G 
146 CSF1R_pY969H_c2905T_C 
147 CSF1R_pY969X_c2907T_G 
148 CTNNB1_pA13T_c37G_A 
149 
CTNNB1_pA5_A80del_c14_2
41del228_allele1 
150 CTNNB1_pD32N_c94G_A 
151 CTNNB1_pG34E_c101G_A 
152 CTNNB1_pS33Y_c98C_A 
153 CTNNB1_pS45P_c133T_C 
154 CTNNB1_pT41A_c121A_G 
155 CTNNB1_pT41I_c122C_T 
156 EGFR_pA289V_c866C_T 
157 EGFR_pD761Y_c2281G_T 
158 EGFR_pE709A_c2126A_C 
159 EGFR_pE709K_c2125G_A 
160 
EGFR_pE746_A750del_c2235_
2249del15_allele1 
161 
EGFR_pE746_A750del_c2236_
2250del15_allele1 
162 
EGFR_pE746_S752_V_c2237_
2255_T_allele1 
163 EGFR_pG598V_c1793G_T 
164 EGFR_pG719C_c2155G_T 
165 EGFR_pG719S_c2155G_A 
166 EGFR_pG863D_c2588G_A 
167 
EGFR_pL747_A750_P_c2239
_2248TTAAGAGAAG_C_ 
allele1 
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168 
EGFR_pL747_P753_S_c2240
_2257del18_allele1 
169 
EGFR_pL747_T751del_c2240
_2254del15_allele1 
170 EGFR_pL833V_c2497T_G 
171 EGFR_pL858M_c2572C_A 
172 EGFR_pL858R_c2573T_G 
173 
EGFR_pL861Q_c2582T_A_ 
allele1 
174 EGFR_pL861R_c2582T_G 
175 EGFR_pR108K_c323G_A 
176 EGFR_pR677H_c2030G_A 
177 EGFR_pS768I_c2303G_T 
178 EGFR_pT263P_c787A_C 
179 EGFR_pT790M_c2369C_T 
180 EGFR_pV774M_c2320G_A 
181 EGFR_pV819V_c2457G_A 
182 ERBB2_pG776S_c2326G_A 
183 ERBB2_pL755S_c2264T_C 
184 ERBB2_pV777L_c2329G_T 
185 FBXW7_pR224X_c670C_T 
186 FBXW7_pR278X_c832C_T 
187 FBXW7_pR393X_c1177C_T 
188 FBXW7_pR465C_c1393C_T 
189 FBXW7_pR465H_c1394G_A 
190 FBXW7_pR479Q_c1436G_A 
191 FBXW7_pR505C_c1513C_T 
192 FBXW7_pS582L_c1745C_T 
193 FGFR1_pP252T_c754C_A 
194 FGFR1_pS125L_c374C_T 
195 FGFR2_pC382R_c1144T_C 
196 FGFR2_pE475K_c1423G_A 
197 FGFR2_pK310R_c929A_G 
198 FGFR2_pN549K_c1647T_G 
199 FGFR2_pR203C_c607C_T 
200 FGFR2_pY375C_c1124A_G 
201 FGFR3_pA369A_c1107G_T 
202 FGFR3_pA391E_c1172C_A 
203 FGFR3_pG370C_c1108G_T 
204 FGFR3_pG697C_c2089G_T 
205 
FGFR3_pK650M_c1949A_T_
allele1 
206 FGFR3_pK650Q_c1948A_C 
207 FGFR3_pR248C_c742C_T 
208 
FGFR3_pS249C_c746C_G_ 
allele1 
  
209 
FGFR3_pS371C_c1111A_T_ 
allele1 
210 FGFR3_pY373C_c1118A_G 
211 FLT3_pD835E_c2505T_G 
212 FLT3_pD835N_c2503G_A 
213 
FLT3_pD835V_c2504A_T_all
ele1 
214 FLT3_pL561L_c1683A_G 
215 GATA1_pQ17X_c49C_T 
216 GATA1_pV74I_c220G_A 
217 HNF1A_pW206C_c618G_T 
218 HNF1A_pW206L_c617G_T 
219 HRAS_pG12D_c35G_A 
220 HRAS_pG12S_c34G_A 
221 HRAS_pG13D_c38G_A 
222 HRAS_pG13S_c37G_A 
223 HRAS_pQ61H_c183G_T 
224 HRAS_pQ61K_c181C_A 
225 HRAS_pQ61P_c182A_C 
226 IKBKB_pA360S_c1078G_T 
227 INPP4A_pE940D_c2820A_C 
228 IRAK1_pS690G_c2068A_G 
229 JAK2_pK191Q_c571A_C 
230 JAK2_pR683G_c2047A_G 
231 JAK2_pV617F_c1849G_T 
232 JAK2_pY570Y_c1710C_T 
233 KIT_pD52N_c154G_A 
234 KIT_pD816Y_c2446G_T 
235 KIT_pE839K_c2515G_A 
236 KIT_pF584S_c1751T_C 
237 KIT_pI798I_c2394C_T 
238 KIT_pK642E_c1924A_G 
239 KIT_pL576P_c1727T_C 
240 KIT_pN822K_c2466T_G 
241 KIT_pP585P_c1755C_T 
242 KIT_pT670I_c2009C_T 
243 KIT_pV559A_c1676T_C 
244 
KIT_pV560D_c1679T_A_ 
allele1 
245 KIT_pV654A_c1961T_C 
246 KIT_pV825A_c2474T_C 
247 
KIT_pW557_K558del_c1669
_1674delTGGAAG_allele1 
248 KIT_pW557R_c1669T_C 
249 
KIT_pY503_F504insAY_c1509_
1510insGCCTAT_allele1 
250 KIT_pY823D_c2467T_G 
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251 KRAS_pA146T_c436G_A 
252 KRAS_pA59T_c175G_A 
253 KRAS_pG12D_c35G_A 
254 KRAS_pG12S_c34G_A 
255 KRAS_pG13D_c38G_A 
256 KRAS_pG13S_c37G_A 
257 KRAS_pQ61H_c183A_C 
258 KRAS_pQ61K_c181C_A 
259 KRAS_pQ61P_c182A_C 
260 MAP2K4_pR154W_c460C_T 
261 MAP2K4_pS184L_c551C_T 
262 MAP2K4_pS280X_c839C_A 
263 MEN1_p_c654_plus_3A_G 
264 MEN1_pR98X_c292C_T 
265 MEN1_pW471X_c1413G_A 
266 
MET_p982_1028del47_c3082_
plus_1G_T 
267 MET_pM1268T_c3803T_C 
268 MET_pR988C_c2962C_T 
269 MET_pT1010I_c3029C_T 
270 MET_pY1248C_c3743A_G 
271 MET_pY1253D_c3757T_G 
272 MLH1_p_c1732_minus_1G_A 
273 MLH1_p_c790_plus_1G_A 
274 MLH1_pC233R_c697T_C 
275 MLH1_pS556fs14_c1731G_A 
276 MPL_pW515L_c1544G_T 
277 MSH2_p_c1276_plus_1G_A 
278 MSH2_pR680X_c2038C_T 
279 MSH2_pR711X_c2131C_T 
280 MSH6_pP1082P_c3246G_T 
281 
MSH6_pP1087fs3_c3261delC_
allele1 
282 
MSH6_pP1087fs5_c3261_ 
3262insC_allele1 
283 NF1_pK1444E_c4330A_G 
284 NF1_pR1276X_c3826C_T 
285 NF1_pR1362X_c4084C_T 
286 NF1_pR1769X_c5305C_T 
287 NF1_pR1968X_c5902C_T 
288 NF1_pR304X_c910C_T 
289 NF1_pR461X_c1381C_T 
290 NF1_pR816X_c2446C_T 
291 NF2_p_c1340_plus_1G_A 
292 NF2_p_c240_plus_2T_C 
293 NF2_p_c516_plus_1G_A 
294 NF2_p_c675_plus_1G_T 
295 NF2_p_c810_plus_2T_C 
296 NF2_pQ212X_c634C_T 
297 NF2_pQ337X_c1009C_T 
298 NF2_pQ362X_c1084C_T 
299 NF2_pQ400X_c1198C_T 
300 NF2_pQ410X_c1228C_T 
301 NF2_pQ456X_c1366C_T 
302 NF2_pR196X_c586C_T 
303 NF2_pR198X_c592C_T 
304 NF2_pR262X_c784C_T 
305 NF2_pR341X_c1021C_T 
306 NF2_pR466X_c1396C_T 
307 NF2_pR57X_c169C_T 
308 NF2_pV219M_c655G_A 
309 NFKB1_p_c40_minus_1G_A 
310 NOTCH1_pL1575P_c4724T_C 
311 NOTCH1_pL1586P_c4757T_C 
312 NOTCH1_pL1594P_c4781T_C 
313 NOTCH1_pL1601P_c4802T_C 
314 NOTCH1_pL1679P_c5036T_C 
315 NOTCH1_pQ2460X_c7378C_T 
316 
NPM1_pW288fs12_c863_864 
insCATG_allele1 
317 
NPM1_pW288fs12_c863_864 
insCCTG_allele1 
318 
NPM1_pW288fs12_c863_864 
insTCTG_allele1 
319 NRAS_pA18T_c52G_A 
320 NRAS_pG12D_c35G_A 
321 NRAS_pG12S_c34G_A 
322 NRAS_pG13D_c38G_A 
323 NRAS_pQ61H_c183A_C 
324 NRAS_pQ61K_c181C_A 
325 NRAS_pQ61P_c182A_C 
326 PAK7_pT397K_c1190C_A 
327 PDGFRA_pD1071N_c3211G_A 
328 
PDGFRA_pD842V_c2525A_T
_allele1 
329 PDGFRA_pD842Y_c2524G_T 
330 PDGFRA_pD846Y_c2536G_T 
331 PDGFRA_pF808L_c2422T_C 
332 PDGFRA_pN659K_c1977C_A 
333 PDGFRA_pN870S_c2609A_G 
334 PDGFRA_pT674I_c2021C_T 
335 PDGFRA_pV824V_c2472C_T 
336 PIK3CA_pC420R_c1258T_C 
337 PIK3CA_pC901F_c2702G_T 
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338 PIK3CA_pE453K_c1357G_A 
339 PIK3CA_pE542K_c1624G_A 
340 PIK3CA_pE545A_c1634A_C 
341 PIK3CA_pE545K_c1633G_A 
342 PIK3CA_pG1049S_c3145G_A 
343 PIK3CA_pG118D_c353G_A 
344 PIK3CA_pH1047R_c3140A_G 
345 PIK3CA_pH1047Y_c3139C_T 
346 PIK3CA_pH701P_c2102A_C 
347 PIK3CA_pM1043I_c3129G_T 
348 PIK3CA_pM1043V_c3127A_G 
349 PIK3CA_pQ546K_c1636C_A 
350 PIK3CA_pR108H_c323G_A 
351 PIK3CA_pR38H_c113G_A 
352 PIK3CA_pR88Q_c263G_A 
353 PIK3CA_pT1025A_c3073A_G 
354 PIK3CA_pT1025T_c3075C_T 
355 PIK3CA_pY1021C_c3062A_G 
356 PIK3R1_pG376R_c1126G_A 
357 PTCH1_pM561R_c1682T_G 
358 PTCH1_pQ365X_c1093C_T 
359 PTCH1_pQ417X_c1249C_T 
360 PTCH1_pW1018X_c3054G_A 
361 PTEN_p_c1026_plus_1G_T 
362 PTEN_p_c1027_minus_2A_G 
363 PTEN_p_c165_minus_2A_C 
364 PTEN_p_c209_plus_5G_A 
365 PTEN_p_c253_plus_1G_A 
366 PTEN_p_c253_plus_1G_T 
367 PTEN_pA126T_c376G_A 
368 PTEN_pA151T_c451G_A 
369 PTEN_pD107Y_c319G_T 
370 PTEN_pE235X_c703G_T 
371 PTEN_pE299X_c895G_T 
372 PTEN_pE7X_c19G_T 
373 PTEN_pG129R_c385G_A 
374 PTEN_pG165R_c493G_A 
375 PTEN_pG251C_c751G_T 
376 PTEN_pH61R_c182A_G 
377 PTEN_pH93Q_c279T_G 
378 PTEN_pH93Y_c277C_T 
379 PTEN_pI101T_c302T_C 
380 
PTEN_pK267fs9_c800delA_ 
allele1 
381 PTEN_pL23F_c69A_C 
382 PTEN_pL42R_c125T_G 
383 
PTEN_pN323fs2_c968_969 
insA_allele1 
384 
PTEN_pN323fs21_c968delA_
allele1 
385 PTEN_pP246L_c737C_T 
386 PTEN_pP38S_c112C_T 
387 PTEN_pP95L_c284C_T 
388 PTEN_pQ110X_c328C_T 
389 PTEN_pQ171X_c511C_T 
390 PTEN_pQ17X_c49C_T 
391 PTEN_pQ214X_c640C_T 
392 PTEN_pQ219X_c655C_T 
393 PTEN_pQ245X_c733C_T 
394 PTEN_pQ298X_c892C_T 
395 PTEN_pR130Q_c389G_A 
396 PTEN_pR130X_c388C_T 
397 PTEN_pR15I_c44G_T 
398 PTEN_pR173C_c517C_T 
399 PTEN_pR173H_c518G_A 
400 PTEN_pR233X_c697C_T 
401 PTEN_pR335X_c1003C_T 
402 PTEN_pW274X_c822G_A 
403 PTEN_pY155C_c464A_G 
404 PTEN_pY174D_c520T_G 
405 PTEN_pY68H_c202T_C 
406 PTPN11_pA72T_c214G_A 
407 PTPN11_pD61Y_c181G_T 
408 PTPN11_pE76K_c226G_A 
409 PTPN11_pG503V_c1508G_T 
410 PTPN11_pG60V_c179G_T 
411 PTPN11_pS502P_c1504T_C 
412 RB1_p_c1215_plus_1G_A 
413 RB1_p_c1499_minus_1G_T 
414 RB1_p_c1961_minus_1G_A 
415 RB1_p_c2107_minus_2A_G 
416 RB1_p_c2326_minus_2A_C 
417 RB1_p_c380_plus_1G_A 
418 RB1_pE137X_c409G_T 
419 RB1_pE440X_c1318G_T 
420 RB1_pE54X_c160G_T 
421 RB1_pE748X_c2242G_T 
422 RB1_pQ217X_c649C_T 
423 RB1_pQ395X_c1183C_T 
424 RB1_pQ685X_c2053C_T 
425 RB1_pQ702X_c2104C_T 
426 RB1_pR251X_c751C_T 
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427 RB1_pR320X_c958C_T 
428 RB1_pR358X_c1072C_T 
429 RB1_pR445X_c1333C_T 
430 RB1_pR455X_c1363C_T 
431 RB1_pR552X_c1654C_T 
432 RB1_pR556X_c1666C_T 
433 RB1_pR579X_c1735C_T 
434 RB1_pR787X_c2359C_T 
435 RB1_pS82X_c245C_A 
436 RET_pA664D_c1991C_A 
437 RET_pC634R_c1900T_C 
438 RET_pC634Y_c1901G_A 
439 RET_pM918T_c2753T_C 
440 RUNX1_pD198G_c593A_G 
441 RUNX1_pD198N_c592G_A 
442 RUNX1_pI114I_c342C_A 
443 RUNX1_pR107C_c319C_T 
444 RUNX1_pR166X_c496C_T 
445 RUNX1_pR204Q_c611G_A 
446 SMAD4_pD537Y_c1609G_T 
447 SMAD4_pE330A_c989A_C 
448 SMAD4_pG168X_c502G_T 
449 SMAD4_pG358X_c1072G_T 
450 SMAD4_pK507Q_c1519A_C 
451 SMAD4_pQ245X_c733C_T 
452 SMAD4_pR361H_c1082G_A 
453 SMAD4_pR445X_c1333C_T 
454 SMAD4_pR497H_c1490G_A 
455 SMAD4_pY353C_c1058A_G 
456 
SMARCB1_p_c1119_minus_
41G_A 
457 SMARCB1_pE216X_c646G_T 
458 SMARCB1_pR158X_c472C_T 
459 SMARCB1_pR201X_c601C_T 
460 SMARCB1_pR377H_c1130G_A 
461 SMARCB1_pR40X_c118C_T 
462 SMARCB1_pS299S_c897G_A 
463 SMARCB1_pY47X_c141C_A 
464 SMO_pW535L_c1604G_T 
465 SRC_pQ531X_c1591C_T 
466 STK11_pD194Y_c580G_T 
467 STK11_pP281L_c842C_T 
468 STK11_pQ170X_c508C_T 
469 STK11_pQ37X_c109C_T 
470 TGFBR2_pR497X_c1489C_T 
471 TP53_p_c376_minus_1G_A 
472 TP53_p_c672_plus_1G_A 
473 TP53_p_c782_plus_1G_T 
474 TP53_p_c920_minus_1G_A 
475 TP53_pA159V_c476C_T 
476 TP53_pC124R_c370T_C 
477 TP53_pC135F_c404G_T 
478 TP53_pC176F_c527G_T 
479 TP53_pE285K_c853G_A 
480 TP53_pE298X_c892G_T 
481 TP53_pE336X_c1006G_T 
482 TP53_pF113C_c338T_G 
483 TP53_pG245S_c733G_A 
484 TP53_pG266E_c797G_A 
485 TP53_pH179Q_c537T_G 
486 TP53_pH179R_c536A_G 
487 TP53_pH193R_c578A_G 
488 TP53_pK132Q_c394A_C 
489 TP53_pQ331X_c991C_T 
490 TP53_pR158H_c473G_A 
491 TP53_pR175H_c524G_A 
492 TP53_pR196X_c586C_T 
493 TP53_pR213X_c637C_T 
494 TP53_pR248Q_c743G_A 
495 TP53_pR248W_c742C_T 
496 TP53_pR249S_c747G_T 
497 TP53_pR273C_c817C_T 
498 TP53_pR273H_c818G_A 
499 TP53_pR306X_c916C_T 
500 TP53_pR342X_c1024C_T 
501 TP53_pV157F_c469G_T 
502 TP53_pY163C_c488A_G 
503 TP53_pY220C_c659A_G 
504 TP53_pY236C_c707A_G 
505 TSHR_pA623S_c1867G_T 
506 TSHR_pA623V_c1868C_T 
507 TSHR_pI630L_c1888A_C 
508 TSHR_pM453T_c1358T_C 
509 TSHR_pT632I_c1895C_T 
510 VHL_p_c463_plus_1G_T 
511 VHL_p_c463_plus_2T_C 
512 VHL_p_c464_minus_1G_A 
513 VHL_pE160K_c478G_A 
514 VHL_pE189K_c565G_A 
515 VHL_pG114C_c340G_T 
516 VHL_pH115Y_c343C_T 
517 VHL_pI151S_c452T_G 
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518 VHL_pL118P_c353T_C 
519 VHL_pL153P_c458T_C 
520 VHL_pL184P_c551T_C 
521 VHL_pL85P_c254T_C 
522 VHL_pP61P_c183C_T 
523 VHL_pP81S_c241C_T 
524 VHL_pQ132X_c394C_T 
525 VHL_pQ96X_c286C_T 
526 VHL_pR161X_c481C_T 
527 VHL_pR167W_c499C_T 
528 VHL_pS183X_c548C_A 
529 VHL_pS65L_c194C_T 
530 VHL_pS68X_c203C_A 
531 VHL_pW117R_c349T_C 
533 VHL_pW88X_c263G_A 
534 WT1_pF154S_c461T_C 
535 WT1_pG379V_c1136G_T 
536 WT1_pR301X_c901C_T 
537 WT1_pR362X_c1084C_T 
538 WT1_pR390X_c1168C_T 
539 WT1_pR394W_c1180C_T 
540 WT1_pS313X_c938C_A 
541 WT1_pS46X_c137C_A 
 
 
 
 
 
 
